{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.document_loaders import PyPDFLoader\n",
    "from langchain.vectorstores import Chroma\n",
    "from langchain.embeddings.openai import OpenAIEmbeddings\n",
    "from langchain.document_loaders import UnstructuredPDFLoader\n",
    "# from langchain.llms import OpenAI\n",
    "from langchain.chat_models import ChatOpenAI\n",
    "from langchain.chains.question_answering import load_qa_chain\n",
    "\n",
    "from langchain.document_loaders import PyPDFDirectoryLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "\n",
    "from coexpert.params import OPENAI_API_KEY\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Document(page_content='PHYSICIAN’S TECHNICAL MANUAL\\nRESONATE™HFICD,\\nRESONATE™ELICD,\\nPERCIVA™HFICD,\\nPERCIVA™ICD,\\nVIGILANT™ELICD,\\nMOMENTUM™ELICD\\nIMPLANTABLE CARDIOVERTER DEFIBRILLATOR\\nREFD520,D521,D532,D533,D420,D421,D432,D433,D500,D501,D512,D513,D400,D401,\\nD412,D413,D220,D221,D232,D233,D120,D121\\nCAUTION: Federallaw(USA)restricts\\nthisdevicetosalebyoronthe\\norderofaphysician trainedor\\nexperiencedindeviceimplantand\\nfollow-up procedures.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 0}), Document(page_content='', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 1}), Document(page_content='TableofContents\\nTrademarkStatement ..........................................................................................................................1\\nAdditional Information .........................................................................................................................1\\nDeviceDescription ...............................................................................................................................1\\nRelatedInformation .............................................................................................................................4\\nIndications andUsage..........................................................................................................................5\\nContraindications................................................................................................................................5\\nWarnings...........................................................................................................................................6\\nPrecautions........................................................................................................................................8\\nSupplemental Precautionary Information ...............................................................................................20\\nPost-TherapyPulseGeneratorFollowUp......................................................................................20\\nMagneticResonance Imaging(MRI)..............................................................................................21\\nTranscutaneous ElectricalNerveStimulation (TENS).........................................................................24\\nElectrocautery andRadioFrequency (RF)Ablation...........................................................................25\\nIonizingRadiation ....................................................................................................................26\\nElevatedPressures....................................................................................................................27\\nPotentialAdverseEvents....................................................................................................................29\\nMechanical Specifications. ....................................................................................................................31\\nItemsIncludedinPackage..................................................................................................................35\\nSymbolsonPackaging .......................................................................................................................36\\nCharacteristics asShipped...................................................................................................................40\\nX-RayIdentifier.................................................................................................................................42\\nFederalCommunications Commission (FCC)............................................................................................43\\nPulseGenerator Longevity ..................................................................................................................43\\nWarrantyInformation .........................................................................................................................49\\nProductReliability .............................................................................................................................50\\nPatientCounseling Information ............................................................................................................50', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 2}), Document(page_content='PatientHandbook ....................................................................................................................52\\nLeadConnections ..............................................................................................................................52\\nImplanting thePulseGenerator...........................................................................................................55\\nCheckEquipment .....................................................................................................................56\\nInterrogate andCheckthePulseGenerator....................................................................................56\\nImplanttheLeadSystem...........................................................................................................57\\nTakeBaselineMeasurements. .....................................................................................................59\\nFormtheImplantation Pocket......................................................................................................61\\nConnecttheLeadstothePulseGenerator .....................................................................................63\\nEvaluateLeadSignals...............................................................................................................66\\nProgramthePulseGenerator .....................................................................................................69\\nTestforAbilitytoConvertVentricular Fibrillation andInducible\\nArrhythmias ....................................................................................................................71\\nTachyarrhythmia ProgrammingConsiderations. ..............................................................................74\\nImplantthePulseGenerator. ......................................................................................................76\\nComplete andReturntheImplantation Form..................................................................................77\\nBidirectional TorqueWrench.................................................................................................................77\\nFollowUpTesting.............................................................................................................................79\\nExplantation andDisposal....................................................................................................................81', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 3}), Document(page_content='1TRADEMARK STATEMENT\\nThefollowing aretrademarks ofBostonScientificCorporation oritsaffiliates:\\nAcuShock, EASYVIEW ,ENDURALIFE,HeartLogic, IMAGEREADY ,LATITUDE, MOMENTUM, Onset/Stability ,\\nPaceSafe, PERCIVA,QuickConvert, QUICKNOTES, RESONA TE,RHYTHM ID,RHYTHMMA TCH,\\nRYTHMIQ, SafetyCore,SmartBlanking, VENTAK,VIGILANT ,ZIP,ZOOM,ZOOMVIEW.\\nADDITIONAL INFORMATION\\nForadditional referenceinformation, gotowww.bostonscientific -elabeling.com.\\nDEVICEDESCRIPTION\\nThismanualcontainsinformation abouttheRESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT, andMOMENTUM\\nfamiliesofimplantable cardioverterdefibrillators (ICDs),whichcontainthefollowing typesofpulsegenerators (specificmodels\\narelistedin\"Mechanical Specifications\" onpage31):\\n•VR—single-chamber ICDcombining ventricular tachyarrhythmia therapywithventricular pacingandsensing\\n•DR—dual-chamber ICDcombining ventricular tachyarrhythmia therapywithventricular andatrialpacingandsensing\\nNOTE:Thismanualmaycontaininformation formodelnumbersthatarenotcurrentlyapproved forsaleinallgeographies.\\nForacompletelistofmodelnumbersapproved inyourgeography ,consultwithyourlocalsalesrepresentative. Somemodel\\nnumbersmaycontainfewerfeatures;forthosedevices,disregardinformation aboutunavailable features.\\nNOTE:RESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT, andMOMENTUM devicesareconsideredMRConditional.\\nReferto\"Magnetic ResonanceImaging(MRI)\"onpage21andtheImageReady MRConditional Defibrillation SystemMRI\\nTechnicalGuideformoreinformation.\\nTherapies\\nThesepulsegenerators haveasmall,thin,physiologic shapethatminimizespocketsizeandmayminimizedevicemigration.\\nTheyprovideavarietyoftherapies, including:', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 4}), Document(page_content='2•Ventricular tachyarrhythmia therapy,whichisusedtotreatrhythmsassociated withsuddencardiacdeath(SCD)suchas\\nVTandVF\\n•Bradycardiapacing,includingadaptiveratepacing,todetectandtreatbradyarrhythmias andtoprovidecardiacrate\\nsupportafterdefibrillation therapy\\nCardioversion/defibrillation therapiesinclude:\\n•Arangeoflow-andhigh-energy shocksusingabiphasicwaveform\\n•Thechoiceofmultipleshockvectors:\\n–Distalshockelectrode toproximalshockelectrode andpulsegenerator case(TRIADelectrode system)\\n–Distalshockelectrode toproximalshockelectrode (RVCoiltoRACoil)\\n–Distalshockelectrode topulsegenerator case(RVCoiltoCan)\\nLeads\\nThepulsegenerator hasindependently programmable outputsandacceptsoneormoreofthefollowing leads,depending on\\nthemodel:\\n•OneIS-11atriallead\\n•OneDF-1/IS-12cardioversion/defibrillation lead\\n•OneDF4-LLHH orDF4-LLHO3multipolar connector cardioversion/defibrillation lead\\nLeadswitheitheraGDT-LLHH/LLHO orDF4-LLHH/LLHO labelareequivalent andarecompatiblewithadevicecontainingeither\\naGDT-LLHH orDF4-LLHH port.\\nThepulsegenerator andtheleadsconstitute theimplantable portionofthepulsegenerator system.\\n1.IS-1referstotheinternational standardISO5841-3:2013.\\n2.DF-1referstotheinternational standardISO11318:2002.\\n3.DF4referstotheinternational standardISO27186:2010.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 5}), Document(page_content=\"3NOTE:UseofBostonScientificMRConditional leadsisrequiredforanimplanted systemtobeconsideredMRConditional.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnicalGuideformodelnumbersofpulsegenerators,\\nleads,accessories,andothersystemcomponents neededtosatisfytheConditions ofUse.\\nProgramming System\\nThesepulsegenerators canonlybeusedwiththeModel3300LATITUDE ProgrammingSystem.TheLATITUDE Programming\\nSystemistheexternalportionofthepulsegenerator system.\\nNOTE:The2868softwareapplication onthemodel3120LATITUDE programmingsystemisoutdatedandshouldnotbeused\\nwiththepulsegenerators. Forassistance, call+1.651.582.4000 (worldwide) orcontactyourlocalBostonScientificrepresentative.\\nThe3300LATITUDE ProgrammingSystemincludes:\\n•Model3300Programmer\\n•Model3868SoftwareApplication\\n•Model6395AccessoryTelemetry Wand\\nYoucanusetheprogrammingsystemtodothefollowing:\\n•Interrogate thepulsegenerator\\n•Programthepulsegenerator toprovideavarietyoftherapyoptions\\n•Accessthepulsegenerator's diagnostic features\\n•Performnoninvasive diagnostic testing\\n•Accesstherapyhistorydata\\n•Storea12secondtraceoftheECG/EGM displayfromanyscreen\\n•Accessaninteractive Demonstration ModeorPatientDataModewithoutthepresenceofapulsegenerator\\n•Printpatientdataincludingpulsegenerator therapyoptionsandtherapyhistorydata\\n•Savepatientdata\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 6}), Document(page_content=\"4Youcanprogramthepulsegenerator usingtwomethods: automatically usingIndications-Based Programming(IBP)or\\nmanually.\\nRELATEDINFORMATION\\nRefertothelead'sinstruction manualforimplantinformation, generalwarningsandprecautions, indications, contraindications,\\nandtechnicalspecifications. Readthismaterialcarefullyforimplantprocedureinstructions specifictothechosenlead\\nconfigurations.\\nRefertothePRMsystemOperator's ManualorZOOMWirelessTransmitterReferenceGuideforspecificinformation aboutthe\\nPRMorZOOMWirelessTransmitter suchassetup,maintenance, andhandling.\\nRefertothesepulsegenerators’ ReferenceGuideforadditional referenceinformation suchasusingthePRMsoftware,\\ntachyarrhythmia detection andtherapy,pacingtherapy,sensing,anddiagnostics.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnicalGuideforinformation aboutMRIscanning.\\nRefertotheHeartLogic TechnicalGuideforinformation abouttheHeartLogic HeartFailureDiagnostic Service.\\nLATITUDE NXTisaremotemonitoring systemthatprovidespulsegenerator dataforclinicians. Allpulsegenerators described in\\nthismanualaredesignedtobeLATITUDE NXTenabled;availability variesbyregion.\\n•Physicians/Clinicians—LATITUDE NXTenablesyoutoperiodically monitorbothpatientanddevicestatusremotelyand\\nautomatically .TheLATITUDE NXTsystemprovidespatientdatathatcanbeusedaspartoftheclinicalevaluation ofthe\\npatient.\\n•Patients—A keycomponent ofthesystemistheLATITUDE Communicator ,aneasy-to-use, in-homemonitoring device.\\nTheCommunicator automatically readsimplanted devicedatafromacompatible BostonScientificpulsegenerator at\\ntimesscheduled bythephysician. TheCommunicator sendsthisdatatotheLATITUDE NXTsecureserver.TheLATITUDE\\nNXTserverdisplaysthepatientdataontheLATITUDE NXTWebsite,whichisreadilyaccessibleovertheInternetto\\nauthorized physicians andclinicians.\\nRefertotheLATITUDE NXTClinicianManualformoreinformation.\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 7}), Document(page_content='5INTENDED AUDIENCE\\nThisliteratureisintendedforusebyprofessionalstrainedorexperience dindeviceimplantand/orfollow-up procedures.\\nINDICATIONS ANDUSAGE\\nBostonScientificimplantable cardioverter defibrillators (ICDs)areintendedtoprovideventricular antitachycardia pacing(ATP)\\nandventricular defibrillation forautomated treatment oflife-threatenin gventricular arrhythmias.\\nCONTRAINDICATIONS\\nTheseBostonScientificpulsegenerators arecontraindicatedforthefollowing patients:\\n•Patientswhoseventricular tachyarrhythmias mayhavereversiblecause,suchas:\\n•Digitalisintoxication\\n•Electrolyte imbalance\\n•Hypoxia\\n•Sepsis\\n•Patientswhoseventricular tachyarrhythmias haveatransientcause,suchas:\\n•Acutemyocardial infarction (MI)\\n•Electrocution\\n•Drowning\\n•Patientswhohaveaunipolarpacemaker', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 8}), Document(page_content=\"6WARNINGS\\nGeneral\\n•Labelingknowledge. Readthismanualthoroughly beforeimplantation toavoiddamagetothepulsegenerator and/or\\nlead.Suchdamagecanresultinpatientinjuryordeath.\\n•Forsinglepatient/singleprocedureuseonly.Donotreuse,reprocess,orresterilize.Reuse,reprocessing,or\\nresterilization maycompromisethestructuralintegrityofthedeviceand/orleadtodevicefailurewhich,inturn,mayresult\\ninpatientinjury,illness,ordeath.Reuse,reprocessing,orresterilization mayalsocreateariskofcontamination ofthe\\ndeviceand/orcausepatientinfectionorcross-infection, including, butnotlimitedto,thetransmission ofinfectious\\ndisease(s) fromonepatienttoanother.Contamination ofthedevicemayleadtoinjury,illness,ordeathofthepatient.\\n•Backupdefibrillation protection. Alwayshaveexternaldefibrillation equipment availableduringimplantand\\nelectrophysiologic testing.Ifnotterminated inatimelyfashion,aninducedventricular tachyarrhythmia canresultinthe\\npatient'sdeath.\\n•Resuscitation availability .Ensurethatanexternaldefibrillator andmedicalpersonnel skilledinCPRarepresentduring\\npost-implantdevicetestingshouldthepatientrequireexternalrescue.\\n•Separatepulsegenerator. Donotusethispulsegenerator withanotherpulsegenerator.Thiscombination couldcause\\npulsegenerator interaction, resultinginpatientinjuryoralackoftherapydelivery.\\nHandling\\n•Avoidshockduringhandling. Programthepulsegenerator TachyMode(s)toOffduringimplant,explant,orpostmortem\\nprocedurestoavoidinadvertent highvoltageshocks.\\n•Donotkinkleads.Donotkink,twist,orbraidtheleadwithotherleadsasdoingsocouldcauseleadinsulation abrasion\\ndamageorconductordamage.\\n•HandlingtheleadwithoutConnector Tool.ForleadsthatrequiretheuseofaConnector Tool,usecautionhandlingthe\\nleadterminalwhentheConnector Toolisnotpresentonthelead.Donotdirectlycontacttheleadterminalwithany\\nsurgicalinstruments orelectricalconnections suchasPSA(alligator) clips,ECGconnections, forceps,hemostats, and\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 9}), Document(page_content='7clamps.Thiscoulddamagetheleadterminal,possiblycompromisingthesealingintegrityandresultinlossoftherapyor\\ninappropriatetherapy,suchasashortwithintheheader.\\n•Handlingtheterminalwhiletunneling. DonotcontactanyotherportionoftheDF4–LLHH orDF4–LLHO leadterminal,\\notherthantheterminalpin,evenwhentheleadcapisinplace.\\nProgramming andDeviceOperations\\n•Atrialtrackingmodes.Donotuseatrialtrackingmodesinpatientswithchronicrefractoryatrialtachyarrhythmias.\\nTrackingofatrialarrhythmias couldresultinventricular tachyarrhythmias.\\nPost-Implant\\n•Protectedenvironments. Advisepatientstoseekmedicalguidancebeforeenteringenvironments thatcouldadversely\\naffecttheoperation oftheactiveimplantable medicaldevice,includingareasprotected byawarningnoticethatprevents\\nentrybypatientswhohaveapulsegenerator.\\n•MagneticResonance Imaging(MRI)exposure. RESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT and\\nMOMENTUM devicesareconsideredMRConditional. Forthesedevices,unlessalloftheMRIConditions ofUsearemet,\\nMRIscanningofthepatientdoesnotmeetMRConditional requirements fortheimplanted system.Significant harmtoor\\ndeathofthepatientand/ordamagetotheimplanted systemmayresult.Donotexposepatientswithnon-MRConditional\\ndevicestoMRIscanning. Strongmagneticfieldsmaydamagethepulsegenerator and/orleadsystem,possiblyresulting\\nininjurytoordeathofthepatient.\\nForpotentialadverseeventsapplicable whentheConditions ofUsearemetornotmet,refertotheImageReady MR\\nConditional Defibrillation SystemMRITechnicalGuide.Foradditional warnings, precautions, andConditions ofUse,refer\\nto\"Magnetic ResonanceImaging(MRI)\"onpage21.\\n•Diathermy .Donotsubjectapatientwithanimplanted pulsegenerator and/orleadtodiathermy sincediathermy may\\ncausefibrillation, burningofthemyocardium, andirreversible damagetothepulsegenerator becauseofinduced\\ncurrents.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 10}), Document(page_content='8•EnsurePTMisenabled. Ifdesired,ensurethatPatientTriggered Monitorisenabledpriortosendingthepatienthomeby\\nconfirming theMagnetResponse isprogrammedtoStoreEGM.Ifthefeatureisinadvertently leftintheInhibitTherapy\\nsetting,thepatientcouldpotentially disabletachyarrhythmia detection andtherapy.\\n•MagnetResponse settoInhibitTherapy.OncethePatientTriggered Monitorfeaturehasbeentriggeredbythemagnet\\nandanEGMhasbeenstored,orafter60dayshaveelapsedfromthedaythatStoreEGMwasenabled,theMagnet\\nResponse programmingautomatically willbesettoInhibitTherapy.Whenthishappens,thepatientshouldnotapplythe\\nmagnetbecausetachyarrhythmia therapycouldbeinhibited.\\nPRECAUTIONS\\nClinicalConsiderations\\n•Pacemaker-mediated tachycardia (PMT).Programmingminimum PVARPlessthanretrogradeV–Aconduction may\\nincreasethelikelihood ofaPMT.\\n•MVSensormodes.ThesafetyandefficacyoftheMVSensormodeshavenotbeenclinicallyestablished inpatientswith\\nabdominal implantsites.\\n•MVSensormodeperformance. MVSensorperformance maybeadversely affectedundertransientconditions suchas\\npneumothorax, pericardial effusion,orpleuraleffusion.ConsiderprogrammingtheMVSensorOffuntiltheseconditions\\nareresolved.\\n•Adaptive-rate modes.Adaptive-rate modesbasedcompletelyorinpartonMVmightbeinappropriateforpatientswho\\ncanachieverespiratorycyclesshorterthanonesecond(greaterthan60breathsperminute).Higherrespiration rates\\nattenuate theimpedance signal,whichdiminishes theMVrateresponse(i.e.,thepacingratewilldroptowardthe\\nprogrammedLRL).\\nAdaptive-rate modesbasedcompletely orinpartonMVshouldnotbeusedforpatientswith:\\n•Aseparatepacemaker\\n•Aleadotherthanabipolartransvenous lead—MVmeasurement hasonlybeentestedwithabipolartransvenous\\nlead', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 11}), Document(page_content=\"9•Amechanical ventilator—use oftheventilator mightresultinaninappropriate MVSensor-drivenrate\\nSterilization andStorage\\n•Ifpackageisdamaged. Theblistertraysandcontentsaresterilizedwithethyleneoxidegasbeforefinalpackaging.\\nWhenthepulsegenerator and/orleadisreceived,itissterileprovidedthecontainer isintact.Ifthepackaging iswet,\\npunctured,opened,orotherwise damaged, returnthepulsegenerator and/orleadtoBostonScientific.\\n•Ifdeviceisdropped.Donotimplantadevicewhichhasbeendroppedwhileoutsideofitsintactshelfpackage.Donot\\nimplantadevicewhichhasbeendroppedfromaheightofmorethan24inches(61cm)whilewithinitsintactshelf\\npackage.Sterility,integrity,and/orfunctioncannotbeguaranteedundertheseconditions, andthedeviceshouldbe\\nreturnedtoBostonScientificforinspection.\\n•Storagetemperature andequilibration. Recommended storagetemperaturesare0°C–50°C (32°F–122°F). Allowthe\\ndevicetoreachapropertemperatur ebeforeusingtelemetry communication capabilities, programming,orimplanting the\\ndevicebecausetemperatur eextremesmayaffectinitialdevicefunction.\\n•Devicestorage.Storethepulsegenerator inacleanareaawayfrommagnets, kitscontaining magnets, andsourcesof\\nEMItoavoiddevicedamage.\\n•Usebydate.Implantthepulsegenerator and/orleadbeforeorontheUSEBYdateonthepackagelabelbecausethis\\ndatereflectsavalidatedshelflife.Forexample,ifthedateisJanuary1,donotimplantonorafterJanuary2.\\nImplantation\\n•Expectedbenefits. Determine whethertheexpecteddevicebenefitsprovidedbyprogrammable optionsoutweigh the\\npossibility ofmorerapidbatterydepletion.\\n•Evaluatepatientforsurgery.Theremaybeadditional factorsregardingthepatient'soverallhealthandmedical\\nconditionthat,whilenotrelatedtodevicefunctionorpurpose,couldrenderthepatientapoorcandidate forimplantation\\nofthissystem.Cardiachealthadvocacygroupsmayhavepublished guidelines thatmaybehelpfulinconductingthis\\nevaluation.\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 12}), Document(page_content='10•Leadcompatibility .Priortoimplantation, confirmthelead-to-pulse generator compatibility .Usingincompatible leads\\nandpulsegenerators candamagetheconnector and/orresultinpotentialadverseconsequenc es,suchasundersensing of\\ncardiacactivityorfailuretodelivernecessary therapy.\\n•Telemetry wand.Makesureasteriletelemetry wandisavailableshouldlossofZIPtelemetry occur.Verifythatthewand\\ncaneasilybeconnectedtotheprogrammerandiswithinreachofthepulsegenerator.\\n•Line-powered equipment. Exerciseextremecautioniftestingleadsusingline-powere dequipment becauseleakage\\ncurrentexceeding10µAcaninduceventricular fibrillation. Ensurethatanyline-powere dequipment iswithin\\nspecifications.\\n•Replacement device.Implanting areplacement deviceinasubcutaneous pocketthatpreviously housedalargerdevice\\nmayresultinpocketairentrapment, migration, erosion,orinsufficient grounding betweenthedeviceandtissue.Irrigating\\nthepocketwithsterilesalinesolutiondecreases thepossibility ofpocketairentrapment andinsufficient grounding.\\nSuturingthedeviceinplacereducesthepossibility ofmigrationanderosion.\\n•Donotbendtheleadnearthelead-header interface. Inserttheleadterminalstraightintotheleadport.Donotbend\\ntheleadnearthelead-header interface. Improperinsertioncancauseinsulation orconnectordamage.\\n•Absenceofalead.Theabsenceofaleadorpluginaleadportmayaffectdeviceperformance andpotentially leavethe\\npatientwithouteffectivetherapy.Ifaleadisnotused,verifythattheplugandlabeledheaderportmatch(i.e.,IS-1,DF-1,\\norDF4).Fullyinserttheplugintheunusedportandthentightenthesetscrewontotheplug.Verifyappropriat edevice\\nfunctionusingtheprogrammer.\\n•Afunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriate sensingandpacinginall\\nchambers, regardlessofprogrammedconfiguration.ThisincludesdualchamberdevicesprogrammedtoAAI(R).\\n•Lackofafunctional RVleadmayresultinundersensing, and/oroversensing andleavethepatientwithouteffective\\ntherapy.\\n•Electrodeconnections.Donotinsertaleadintothepulsegenerator connector withouttakingthefollowing precautions\\ntoensureproperleadinsertion:', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 13}), Document(page_content='11•Insertthetorquewrenchintothepreslitdepression ofthesealplugbeforeinsertingtheleadintotheport,to\\nreleaseanytrappedfluidorair.\\n•Visuallyverifythatthesetscrewissufficiently retractedtoallowinsertion. Usethetorquewrenchtoloosenthe\\nsetscrewifnecessary.\\n•Fullyinserteachleadintoitsleadportandthentightenthesetscrewontotheterminalpin.\\n•Defibrillation leadimpedance. Iftotalshockingleadimpedance duringimplantislessthan20Ω,verifytheproximalcoil\\nisnotincontactwiththepulsegenerator surface.Ameasurement oflessthan20Ωisanindication ofashortsomewhere\\ninthesystem.Ifrepeatedmeasurements showthetotalshockingleadimpedance islessthan20Ω,theleadand/orpulse\\ngenerator mayneedtobereplaced.\\n•Shuntingenergy.Donotallowanyobjectthatiselectrically conductive tocomeintocontactwiththeleadordevice\\nduringinduction becauseitmayshuntenergy,resultinginlessenergygettingtothepatient,andmaydamagethe\\nimplanted system.\\n•Donotsuturedirectlyoverlead.Donotsuturedirectlyovertheleadbody,asthismaycausestructural damage.Usethe\\nsuturesleevetosecuretheleadproximaltothevenousentrysitetopreventleadmovement.\\n•MVSensor.DonotprogramtheMVSensortoOnuntilafterthepulsegenerator hasbeenimplanted andsystemintegrity\\nhasbeentestedandverified.\\n•Programming MVSensorforrespiratory disorders orabnormal breathing. Forpatientswithrespiratorydisordersor\\nabnormal breathing patterns,thephysician shouldusemedicaljudgment whenprogrammingtheMVSensortoOn.To\\nmitigateinappropriate sensor-drivenrates,thephysician mayevaluatetherateresponseandconsideralowerResponse\\nFactor.\\nDeviceProgramming\\n•Devicecommunication. Useonlythedesignated programm erandsoftwareapplication tocommunicatewiththispulse\\ngenerator.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 14}), Document(page_content='12•STATPACEsettings. Whenapulsegenerator isprogrammedtoSTATPACEsettings,itwillcontinuetopaceatthehigh-\\nenergySTATPACEvaluesifitisnotreprogrammed.TheuseofSTATPACEparameters willlikelydecreasedevicelongevity.\\n•Pacingandsensingmargins.ConsiderleadmaturationinyourchoiceofPacingAmplitude, pacingPulseWidth,and\\nSensitivity settings.\\n•AnacutePacingThreshold greaterthan1.5VorachronicPacingThreshold greaterthan3Vcanresultinlossof\\ncapturebecausethresholds mayincreaseovertime.\\n•AnR-WaveAmplitude lessthan5mVoraP-WaveAmplitude lessthan2mVcanresultinundersensing because\\nthesensedamplitude maydecreaseafterimplantation.\\n•PacingLeadImpedance shouldbegreaterthantheprogrammedLowImpedance Limitandlessthanthe\\nprogrammedHighImpedanceLimit.\\n•Properprogramming oftheshockvector.IftheShockVectorisprogrammedtoRVcoil>>RAcoilandtheleaddoesnot\\nhaveanRAcoil,shockingwillnotoccur.\\n•Programming forsupraventricular tachyarrhythmias (SVTs).Determine ifthedeviceandprogrammable optionsare\\nappropriate forpatientswithSVTsbecauseSVTscaninitiateunwanted devicetherapy.\\n•Adaptive-rate pacing.Rateadaptivepacingshouldbeusedwithcareinpatientswhoareunabletotolerateincreased\\npacingrates.\\n•Ventricular refractory periods(VRPs)inadaptive-rate pacing.Adaptive-rate pacingisnotlimitedbyrefractoryperiods.\\nAlongrefractoryperiodprogrammedincombination withahighMSRcanresultinasynchronous pacingduringrefractory\\nperiodssincethecombination cancauseaverysmallsensingwindowornoneatall.UseDynamicAVDelayorDynamic\\nPVARPtooptimizesensingwindows. IfyouareprogrammingafixedAVDelay,considerthesensingoutcomes.\\n•Shockwaveform polarity.ForIS-1/DF-1leads,neverchangetheshockwaveform polaritybyphysically switching thelead\\nanodesandcathodesinthepulsegenerator header—usetheprogramm ablePolarityfeature.Devicedamageor\\nnonconversion ofthearrhythmia post-operatively mayresultifthepolarityisswitchedphysically.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 15}), Document(page_content=\"13•TachyModetoOff.Topreventinappropriate shocks,ensurethatthepulsegenerator's TachyModeisprogrammedtoOff\\nwhennotinuseandbeforehandlingthedevice.Fortachyarrhythmia detection andtherapy,verifythattheTachyModeis\\nprogrammedtoMonitor+Therapy.\\n•Atrialoversensing. Takecaretoensurethatartifactsfromtheventricles arenotpresentontheatrialchannel,oratrial\\noversensing mayresult.Ifventricular artifactsarepresentintheatrialchannel,theatrialleadmayneedtoberepositioned\\ntominimizeitsinteraction.\\n•ATRentrycount.ExercisecarewhenprogrammingtheEntryCounttolowvaluesinconjunction withashortATR\\nDuration.Thiscombinationallowsmodeswitching withveryfewfastatrialbeats.Forexample,iftheEntryCountwas\\nprogrammedto2andtheATRDurationto0,ATRmodeswitching couldoccuron2fastatrialintervals.Intheseinstances,\\nashortseriesofprematureatrialeventscouldcausethedevicetomodeswitch.\\n•ATRexitcount.ExercisecarewhenprogrammingtheExitCounttolowvalues.Forexample,iftheExitCountwas\\nprogrammedto2,afewcyclesofatrialundersensing couldcausetermination ofmodeswitching.\\n•Properprogramming withoutanatriallead.Ifanatrialleadisnotimplanted (portispluggedinstead),oranatriallead\\nisabandoned butremainsconnected totheheader,deviceprogrammingshouldbeconsistent withthenumberandtype\\nofleadsactuallyinuse.\\n•Atrialsensingprogrammed toOff.WhenatrialsensingisprogrammedtoOffinaDDI(R)orDDD(R)mode,anyatrial\\npacingthatoccurswillbeasynchronous .Additionally ,featuresthatrequireatrialsensingmaynotfunctionasexpected.\\n•Cross-chamber artifacts. Sensitivity adjustments associated withSmartBlankingmaynotbesufficienttoinhibitdetection\\nofcross-chamber artifactsifthecross-chamber artifactsaretoolarge.Considerotherfactorsthatimpactthesize/\\namplitude ofcross-chamber artifactsincludinglead-placement, pacingoutput,programmedSensitivity settings,shock\\noutput,andtimesincelastdeliveredshock.\\n•SignalArtifactMonitorProgramming Considerations. Formaximum sensitivity indetecting andpreventing potential\\nsignalartifact-generatedoversensing, itisrecommended thattheSignalArtifactMonitor(SAM)isprogrammedOnany\\ntimetheMV/Respir atorySensorisprogrammedtoOnorPassive.TurningtheSignalArtifactMonitorOffmayputthe\\npatientatincreased riskofoversensing, unlesstheMV/Respiratory SensorisalsoprogrammedOff.\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 16}), Document(page_content='14•TurningtheSignalArtifactMonitorOff.TurningtheSignalArtifactMonitorOffmayputthepatientatincreased riskof\\noversensing, unlesstheMV/Respiratory Sensorisalsoprogramm edtoOff.\\n•MVRecalibration. ToobtainanaccurateMVbaselinefollowing anysurgicalprocedureinvolvingthepulsegenerator or\\nleads,anew,manualcalibration shouldbeperformed. Leadmaturation, airentrapmen tinthepocket,pulsegenerator\\nmotionduetoinadequate suturing,externaldefibrillation orcardioversion, orotherpatientcomplications (e.g.,\\npneumothorax) requireanewMVbaselineforappropriate MVbehavior.\\n•Sensingadjustment. Following anysensingrangeadjustment oranymodification ofthesensinglead,alwaysverify\\nappropriate sensing.ProgrammingSensitivity tothehighestvalue(lowestsensitivity) mayresultindelayeddetection or\\nundersensing ofcardiacactivity.Likewise,programmingtothelowestvalue(highestsensitivity) mayresultinoversensing\\nofnon-cardiac signals.\\n•Patientsheartonescomingfromtheirdevice.Patientsshouldbeadvisedtocontacttheirphysician immediately ifthey\\nheartonescomingfromtheirdevice.\\n•UseofPatientTriggered Monitor.UsecarewhenusingPatientTriggered Monitor,becausethefollowing conditionswill\\nexistwhileitisenabled:\\n•Allothermagnetfeatures,includinginhibiting therapy,aredisabled.TheMagnet/Beeper featurewillnotindicate\\nmagnetposition.\\n•Devicelongevityisimpacted. Tohelpreducethelongevityimpact,PTMonlyallowsstorageofoneepisode,and\\nPTMisautomatically disabledafter60daysifdatastoragewasnevertriggered.\\n•OncetheEGMisstored(or60dayselapses),PTMisdisabledandthedeviceMagnetResponse automatically willbe\\nsettoInhibitTherapy.However,thepulsegenerator willnotinhibittherapyuntilthemagnetisremovedfor3\\nsecondsandplacedonthedeviceagain.\\nEnvironmental andMedicalTherapyHazards\\n•Avoidelectromagnetic interference (EMI).AdvisepatientstoavoidsourcesofEMIbecauseEMImaycausethepulse\\ngenerator todeliverinappropriate therapyorinhibitappropriate therapy.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 17}), Document(page_content='15MovingawayfromthesourceoftheEMIorturningoffthesourceusuallyallowsthepulsegenerator toreturntonormal\\noperation.\\nExamples ofpotentialEMIsourcesare:\\n•Electricalpowersources,arcweldingorresistanceweldingequipment, androboticjacks\\n•Highvoltagepowerdistribution lines\\n•Electricalsmeltingfurnaces\\n•LargeRFtransmitterssuchasradar\\n•Radiotransmitters,includingthoseusedtocontroltoys\\n•Electronic surveillance (antitheft) devices\\n•Analternator onacarthatisrunning\\n•Medicaltreatments anddiagnostic testsinwhichanelectricalcurrentispassedthroughthebody,suchasTENS,\\nelectrocautery ,electrolysis/thermolysis, electrodiagnostic testing,electromyogr aphy,ornerveconduction studies\\n•Anyexternally applieddevicethatusesanautomatic leaddetection alarmsystem(e.g.,anEKGmachine)\\n•WirelessECG.WirelessECGissusceptibletoRFinterferenc e,andmayhaveanintermittent orlostsignal.Ifinterferenc eis\\npresent,especially duringdiagnostic testing,considerusingasurfaceECGinstead.\\nHospitalandMedicalEnvironments\\n•Mechanical ventilators. ProgramtheMV/Respir atorySensortoOffduringmechanical ventilation. Otherwise, the\\nfollowing mayoccur:\\n•Inappropriate MVSensor-drivenrate\\n•Misleading respiration-based trending', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 18}), Document(page_content='16•Conducted electricalcurrent.Anymedicalequipment, treatment, therapy,ordiagnostic testthatintroduceselectrical\\ncurrentintothepatienthasthepotentialtointerferewithpulsegenerator function.\\n•Externalpatientmonitors(e.g.,respiratorymonitors, surfaceECGmonitors, hemodynamic monitors) maycause:\\n–Inappropriate MVSensor-driven rate(uptomaximum sensor-drivenrate)\\n–Misleading respiration-based trending\\n•Medicaltherapies, treatments, anddiagnostic teststhatuseconducted electricalcurrent(e.g.,TENS,electrocautery ,\\nelectrolysis/thermolysis, electrodiagn ostictesting,electromyogr aphy,ornerveconductionstudies)mayinterfere\\nwithordamagethepulsegenerator.ProgramthedevicetoElectrocautery Protection Modepriortothetreatment,\\nandmonitordeviceperformance duringthetreatment. Afterthetreatment, verifypulsegenerator function(\"Post-\\nTherapyPulseGeneratorFollowUp\"onpage20).\\nToresolvesuspected interactions withRespiratory Sensor-baseddiagnostics, deactivate thepulsegenerator\\' sRespiratory\\nSensorbyprogrammingittoOff.\\n•Internaldefibrillation. Donotuseinternaldefibrillation paddlesorcathetersunlessthepulsegenerator isdisconnect ed\\nfromtheleadsbecausetheleadsmayshuntenergy.Thiscouldresultininjurytothepatientanddamagetothe\\nimplanted system.\\n•Externaldefibrillation. Itcantakeupto15secondsforsensingtorecoverafteranexternalshockisdelivered. Innon-\\nemergency situations, forpacemakerdependent patients,considerprogrammingthepulsegenerator toanasynchronous\\npacingmodeandprogrammingtheMV/Respiratory SensortoOffpriortoperforming externalcardioversion or\\ndefibrillation.\\nAvoidplacingapad(orpaddle)directlyoveranysubcutaneous leads.\\nExternaldefibrillation orcardioversioncandamagethepulsegenerator.Tohelppreventdamagetothepulsegenerator,\\nconsiderthefollowing:\\n•Avoidplacingapad(orpaddle)directlyoverthepulsegenerator.Positionthepads(orpaddles)asfarfromthe\\npulsegenerator aspossible.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 19}), Document(page_content='17•Positionthepads(orpaddles)inaposterior-anteriororientation whenthedeviceisimplanted intherightpectoral\\nregionorananterior-apexorientation whenthedeviceisimplanted intheleftpectoralregion.\\n•Setenergyoutputofexternaldefibrillation equipment aslowasclinicallyacceptable.\\nFollowing externalcardioversion ordefibrillation, verifypulsegenerator function(\"Post-TherapyPulseGeneratorFollow\\nUp\"onpage20).\\n•Lithotripsy .Extracorporealshockwavelithotripsy (ESWL)maycauseelectromagnetic interferenc ewithordamagetothe\\npulsegenerator.IfESWLismedically necessary,considerthefollowing tominimizethepotentialforencountering\\ninteraction:\\n•FocustheESWLbeamatleast15cm(6in)awayfromthepulsegenerator.\\n•Depending onthepacingneedsofthepatient,programtheBradyModetoOfforanon-rate-r esponsive VVImode.\\n•ProgramtheTachyModetoOfftopreventinappropriate shocks.\\n•Ultrasound energy.Therapeutic ultrasound (e.g.,lithotripsy) energymaydamagethepulsegenerator.Iftherapeutic\\nultrasoundenergymustbeused,avoidfocusingnearthepulsegenerator site.Diagnostic ultrasound(e.g.,\\nechocardiography)isnotknowntobeharmfultothepulsegenerator.\\n•Electricalinterference. Electricalinterferenceor“noise”fromdevicessuchaselectrocautery andmonitoring equipment\\nmayinterferewithestablishing ormaintaining telemetry forinterrogating orprogrammingthedevice.Inthepresenceof\\nsuchinterferenc e,movetheprogrammerawayfromelectricaldevices,andensurethatthewandcordandcablesarenot\\ncrossingoneanother.Iftelemetry iscancelledasaresultofinterferenc e,thedeviceshouldbere-interrogatedpriorto\\nevaluating information frompulsegenerator memory.\\n•Radiofrequency (RF)interference. RFsignalsfromdevicesthatoperateatfrequencies nearthatofthepulsegenerator\\nmayinterruptZIPtelemetry whileinterrogating orprogrammingthepulsegenerator.ThisRFinterferenc ecanbereduced\\nbyincreasing thedistancebetweentheinterfering deviceandthePRMandpulsegenerator.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 20}), Document(page_content='18•Centrallineguidewire insertion. Usecautionwheninsertingguidewires forplacement ofothertypesofcentralvenous\\ncathetersystemssuchasPIClinesorHickmancathetersinlocationswherepulsegenerator leadsmaybeencounter ed.\\nInsertionofsuchguidewiresintoveinscontaining leadscouldresultintheleadsbeingdamaged ordislodged.\\nHomeandOccupationalEnvironments\\n•Homeappliances. Homeappliancesthatareingoodworkingorderandproperlygrounded donotusuallyproduce\\nenoughEMItointerferewithpulsegenerator operation. Therehavebeenreportsofpulsegenerator disturbances caused\\nbyelectrichandtoolsorelectricrazorsuseddirectlyoverthepulsegenerator implantsite.\\n•Magneticfields.Advisepatientsthatextendedexposuretostrong(greaterthan10gaussor1mTesla)magnetic fields\\nmaytriggerthemagnetfeature.Examples ofmagneticsourcesinclude:\\n•Industrial transformers andmotors\\n•MRIscanners\\nNOTE:ThemagnetfeatureisdisabledwhenthedeviceisinMRIProtection Mode.Referto\"Magnetic Resonance\\nImaging(MRI)\"onpage21andtheImageReady MRConditional Defibrillation SystemMRITechnicalGuideformore\\ninformation.\\n•Largestereospeakers\\n•Telephone receiversifheldwithin1.27cm(0.5inches)ofthepulsegenerator\\n•MagneticwandssuchasthoseusedforairportsecurityandintheBingogame\\n•ElectronicArticleSurveillance (EAS)andsecuritysystems. Advisepatientshowtoavoidimpacttocardiacdevice\\nfunctionduetoantitheftandsecuritygates,tagdeactivators, ortagreadersthatincluderadiofrequency identification\\n(RFID)equipment. Thesesystemsmaybefoundattheentrancesandexitsofstores,atcheckoutcounters,inpublic\\nlibraries,andinpoint-of-entryaccesscontrolsystems.Patientsshouldavoidlingeringnearorleaningagainstantitheft\\nandsecuritygatesandtagreaders.Inaddition,patientsshouldavoidleaningagainstcheckoutcounter-mounted and\\nhandheld tagdeactivation systems.Anti-theft gates,securitygates,andentrycontrolsystemsareunlikelytoaffectcardiac\\ndevicefunctionwhenpatientswalkthroughthematanormalpace.Ifthepatientisnearanelectronic antitheft,security,', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 21}), Document(page_content=\"19orentrycontrolsystemandexperience ssymptoms, theyshouldpromptlymoveawayfromnearbyequipment andinform\\ntheirdoctor.\\n•Cellularphones.Advisepatientstoholdcellularphonestotheearoppositethesideoftheimplanted device.Patients\\nshouldnotcarryacellularphonethatisturnedoninabreastpocketoronabeltwithin15cm(6inches)oftheimplanted\\ndevicesincesomecellularphonesmaycausethepulsegenerator todeliverinappropriate therapyorinhibitappropriate\\ntherapy.\\nFollow-up Testing\\n•Conversion testing.SuccessfulVForVTconversion duringarrhythmia conversion testingisnoassurancethatconversion\\nwilloccurpost-operatively .Beawarethatchangesinthepatient'scondition,drugregimen,andotherfactorsmaychange\\ntheDFT,whichmayresultinnonconversion ofthearrhythmia post-operatively .\\n•Pacingthreshold testing.Ifthepatient'scondition ordrugregimenhaschangedordeviceparametershavebeen\\nreprogrammed,considerperforming apacingthreshold testtoconfirmadequate marginsforpacecapture.\\n•Follow-up considerations forpatientsleavingthecountry.Pulsegenerator follow-up considerationsshouldbemade\\ninadvanceforpatientswhoplantotravelorrelocatepost-implanttoacountryotherthanthecountryinwhichtheir\\ndevicewasimplanted. Regulatory approvalstatusfordevicesandassociated programmersoftwareconfigurationsvaries\\nbycountry;certaincountriesmaynothaveapprovalorcapability tofollowspecificproducts.\\nContactBostonScientific, usingtheinformation onthebackcover,forhelpindetermining feasibility ofdevicefollow-up in\\nthepatient'sdestination country.\\nExplantandDisposal\\n•Incineration. Besurethatthepulsegenerator isremovedbeforecremation. Cremation andincineration temperatur es\\nmightcausethepulsegenerator toexplode.\\n•Devicehandling. Beforeexplanting, cleaning,orshippingthedevice,completethefollowing actionstoprevent\\nunwanted shocks,overwriting ofimportant therapyhistorydata,andaudibletones:\\n•Programthepulsegenerator TachyandBradyModestoOff.\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 22}), Document(page_content='20•ProgramtheMagnetResponse featuretoOff.\\n•ProgramtheBeepwhenExplantisIndicatedfeaturetoOff.\\n•ProgramtheBeepWhenOut-of-Range featuretoOff.\\n•Handlingattimeofdisposal. Cleananddisinfectthedeviceusingstandardbiohazard handlingtechniques sinceall\\nexplanted components areconsideredbiohazardous.\\nSUPPLEMENTAL PRECAUTIONARY INFORMATION\\nPost-TherapyPulseGenerator FollowUp\\nFollowing anysurgeryormedicalprocedurewiththepotentialtoaffectpulsegenerator function,youshouldperforma\\nthoroughfollow-up, whichmayincludethefollowing:\\n•Interrogating thepulsegenerator withaprogrammer\\n•Reviewing clinicaleventsandfaultcodes\\n•Reviewing theArrhythmia Logbook, includingstoredelectrograms(EGMs)\\n•Reviewing real-timeEGMs\\n•Testingtheleads(threshold,amplitude, andimpedance)\\n•Performing amanualcapacitorre-formation\\n•Reviewing MVSensor-baseddiagnostics, MVSensorperformance, andperforming amanualMVSensorcalibration if\\ndesired\\n•Reviewing RespiratorySensor-baseddiagnostics\\n•Verifyingbatterystatus\\n•Programminganypermanent bradyparametertoanewvalueandthenreprogrammingitbacktothedesiredvalue\\n•ProgrammingtheTachyModetoanewvalueandthenreprogramming itbacktothedesiredvalue', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 23}), Document(page_content='21•Savingallpatientdata\\n•Verifyingtheappropriate finalprogrammingpriortoallowingthepatienttoleavetheclinic\\nMagneticResonance Imaging(MRI)\\nMRIProtection ModeisavailableinRESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT, andMOMENTUM devices.\\nThefollowing Warnings andPrecautions, andConditions ofUseareapplicable toMRIscanningofpatientsimplanted withan\\nImageReady MRConditional Defibrillation System.RefertotheImageReady MRConditional Defibrillation SystemMRITechnical\\nGuideatwww.bostonscientific -elabeling.com foracomprehensivelistofWarnings andPrecautions, andConditions ofUsethat\\nareapplicable toMRIscanningofpatientsimplanted withanImageReady MRConditional Defibrillation System.\\nMRConditional Defibrillation SystemWarnings andPrecautions\\nWARNING: RESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT andMOMENTUM devicesareconsideredMR\\nConditional. Forthesedevices,unlessalloftheMRIConditions ofUsearemet,MRIscanningofthepatientdoesnotmeetMR\\nConditional requirementsfortheimplanted system.Significant harmtoordeathofthepatientand/ordamagetotheimplanted\\nsystemmayresult.Donotexposepatientswithnon-MRConditional devicestoMRIscanning. Strongmagneticfieldsmay\\ndamagethepulsegenerator and/orleadsystem,possiblyresultingininjurytoordeathofthepatient.\\nForpotentialadverseeventsapplicable whentheConditions ofUsearemetornotmet,refertotheImageReady MRConditional\\nDefibrillation SystemMRITechnicalGuide.Foradditional warnings, precautions, andConditions ofUse,referto\"Magnetic\\nResonance Imaging(MRI)\"onpage21.\\nWARNING: MRIscanningafterExplantstatushasbeenreachedmayleadtopremature batterydepletion, ashortened device\\nreplacementwindow,orsuddenlossoftherapy.Afterperforming anMRIscanonadevicethathasreachedExplantstatus,\\nverifypulsegenerator function(\"Post-TherapyPulseGenerator FollowUp\"onpage20)andscheduledevicereplacement.\\nWARNING: Determine thebeepertypebeforeanMRIscan.TheArmature Beepermaynolongerbeusablefollowing anMRI\\nscan.Comingincontactwiththestrongmagnetic fieldofanMRIscannermaycauseapermanent lossoftheArmature Beeper\\nvolume.Thiscannotberecovered,evenafterleavingtheMRIscanenvironment andexitingMRIProtection Mode.Forthe\\nArmature Beeper,beforeanMRIscanisperformed, aphysician andpatientshouldweighthebenefitoftheMRIscanagainst', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 24}), Document(page_content='22theriskoflosingtheBeeper;aftertheMRIscan,performBeeperevaluation testtodetermine iftheBeeperisusable.Ifthe\\nBeeperisnotusable,itisstronglyrecommended thatpatientsarefollowedonLATITUDE NXTafteranMRIscaniftheyarenot\\nalready.Otherwise, anin-clinicfollow-up scheduleofeverythreemonthsisstronglyrecommended tomonitordevice\\nperformance.\\nWARNING: DuringMRIProtection Mode,thepatientwillnotreceiveTachycardiatherapy(including ATPanddefibrillation),\\nand,ifBradyModeisprogrammedtoOff,willnotreceiveBradycardiapacing(including backuppacing)andCardiac\\nResynchronization Therapy.Thereforethepatientmustbecontinuously monitored fortheentiredurationinwhichthesystemis\\ninMRIProtection Mode,includingduringthescan.\\nWARNING: IftheMRIProtection Time-outvalueisprogrammedtoOff,thepatientwillnotreceiveTachycardia therapy,and\\nthepacingoptionsarelimitedtoOfforAsynchronous untilthepulsegenerator isprogrammedoutofMRIProtection Modeand\\nbacktonormaloperation.\\nWARNING: DuringMRIProtection Mode,Tachycardiatherapyissuspended. Thesystemwillnotdetectventricular\\narrhythmias andthepatientwillnotreceiveATPorshockdefibrillation therapyuntilthepulsegenerator isprogrammedbackto\\nnormaloperation. Onlyscanthepatientifjudgedtobeclinicallycapableoftolerating noTachycardiaprotection fortheentire\\ndurationinwhichthepulsegenerator isinMRIProtection Mode.\\nWARNING: Theriskofarrhythmia maybeincreased withasynchronous pacing(AOO,VOO,DOO).Whenprogramming\\nasynchronou spacingduringMRIProtection Mode,selectapacingratethatavoidscompetitive pacingandminimizethetimein\\nMRIProtection Mode.\\nWARNING: Intherareeventthatnon-recoverableorrepeatfaultconditions occurwhilethedeviceisprogramm edinMRI\\nProtectionMode,thesubsequent devicebehaviorwillbedetermined bytheMRIProtection BradyModesetting.\\n•IfMRIBradyModeissettoOff,thedevicewillenterSafetyMode(permanent VVIunipolarpacingandtachycardia\\ntherapyenabled).\\n•IfMRIBradyModeissettoasynchronous pacing(AOO,VOO,DOO),bothbradycardiatherapyandtachycardiatherapy\\nwillbepermanently disabled.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 25}), Document(page_content='23WARNING: TheProgrammerisMRUnsafeandmustremainoutsidetheMRIsiteZoneIII(andhigher)asdefinedbythe\\nAmerican CollegeofRadiology Guidance Document onMRSafePractices4.Undernocircumstanc esshouldtheProgrammerbe\\nbroughtintotheMRIscannerroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nWARNING: Implantofthesystemcannotbeperformed inanMRIsiteZoneIII(andhigher)asdefinedbytheAmerican\\nCollegeofRadiology Guidance Document onMRSafePractices4.Someoftheaccessoriespackaged withpulsegenerators and\\nleads,includingthetorquewrenchandstyletwires,arenotMRConditional andshouldnotbebroughtintotheMRIscanner\\nroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nCAUTION: Thephysician choosingMRIProtectionModeparameter valueswillneedtoexerciseprofessionaljudgment to\\ndetermine anindividual patient’sabilitytotoleratethedevicesettingsrequiredforMRConditional scanning, inconjunction with\\nthephysicalconditions requiredduringascan(forexample,prolonged timeinasupineposition).\\nCAUTION: Thepresenceoftheimplanted defibrillation systemmaycauseMRIimageartifacts.\\nNOTE:Otherimplanted devicesorpatientconditions maycauseapatienttobeineligibleforanMRIscan,independent ofthe\\nstatusofthepatient’sImageReady MRConditional Defibrillation System.\\nMRConditions ofUse\\nThefollowing subsetoftheMRIConditions ofUsepertainstoimplantation andmustbemetinorderforapatientwithan\\nImageReady Defibrillation SystemtoundergoanMRIscan.AdherencetotheConditions ofUsemustbeverifiedpriortoeach\\nscantoensurethatthemostuptodateinformation hasbeenusedtoassessthepatient’seligibilityandreadiness foranMR\\nConditional scan.RefertotheImageReady MRConditional Defibrillation SystemMRITechnicalGuideatwww.bostonscientific -\\nelabeling.com foracomprehensive listofWarnings andPrecautions, andConditions ofUsethatareapplicable toMRIscanning\\nofpatientsimplanted withanImageReady MRConditional Defibrillation System.\\nCardiology\\n1.Patientisimplanted withanImageReady MRConditional Defibrillation System\\n4.KanalE,Barkovich AJ,BellC,etal.ACRguidancedocument onMRsafepractices:2013.J.Magn.Reson.Imaging2013;37:501-530.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 26}), Document(page_content='242.Nootheractiveorabandoned implanted devices,components, oraccessoriespresentsuchasleadadaptors, extenders,\\nleads,orpulsegenerators\\n3.PatientisjudgedtobeclinicallycapableoftoleratingnoTachycardia protectionfortheentiredurationinwhichthepulse\\ngenerator isinMRIProtection Mode\\n4.Pulsegenerator implantlocationrestricted toleftorrightpectoralregion\\n5.Atleastsix(6)weekshaveelapsedsinceimplantation and/oranyleadrevisionorsurgicalmodification oftheMR\\nConditional Defibrillation System\\n6.Noevidenceofafracturedleadorcompromisedpulsegenerator-leadsystemintegrity\\nTranscutaneous ElectricalNerveStimulation (TENS)\\nCAUTION: TENSinvolvespassingelectricalcurrentthroughthebody,andmayinterferewithpulsegenerator function.IfTENS\\nismedically necessary,evaluatetheTENStherapysettingsforcompatibility withthepulsegenerator.Thefollowing guidelines\\nmayreducethelikelihood ofinteraction:\\n•PlacetheTENSelectrodes asclosetogetherandasfarawayfromthepulsegenerator andleadsaspossible.\\n•Usethelowestclinically-appropriate TENSenergyoutput.\\n•Considercardiacmonitoring duringTENSuse,especially forpacemaker-dependent patients.\\nAdditional stepscanbetakentohelpreduceinterferenc eduringin-clinicuseofTENS:\\n•Ifinterferenceissuspected duringin-clinicuse,turnofftheTENSunit.\\n•DonotchangeTENSsettingsuntilyouhaveverifiedthatthenewsettingsdonotinterferewithpulsegenerator function.\\nIfTENSismedically necessary outsidetheclinicalsetting(at-homeuse),providepatientswiththefollowing instructions:\\n•DonotchangetheTENSsettingsorelectrodepositionsunlessinstructed todoso.\\n•EndeachTENSsessionbyturningofftheunitbeforeremoving theelectrodes.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 27}), Document(page_content='25•IfthepatientreceivesashockduringTENSuse,oriftheyexperiencesymptoms oflightheadedness, dizziness, orlossof\\nconsciousness, theyshouldturnofftheTENSunitandcontacttheirphysician.\\nFollowthesestepstousethePRMtoevaluatepulsegenerator functionduringTENSuse:\\n1.Programthepulsegenerator TachyModetoMonitorOnly.\\n2.Observereal-timeEGMsatprescribed TENSoutputsettings,notingwhenappropriate sensingorinterferenc eoccurs.\\nNOTE:Patienttriggeredmonitoring maybeusedasanadditional methodtoconfirmdevicefunctionduringTENSuse.\\n3.Whenfinished,turnofftheTENSunitandreprogramtheTachyModetoMonitor+Therapy.\\nYoushouldalsoperformathorough follow-up evaluation ofthepulsegenerator following TENS,toensurethatdevicefunction\\nhasnotbeencompromised(\"Post-TherapyPulseGenerator FollowUp\"onpage20).\\nForadditional information, contactBostonScientificusingtheinformation onthebackcover.\\nElectrocauteryandRadioFrequency (RF)Ablation\\nCAUTION: Electrocautery andRFablationmayinduceventricular arrhythmias and/orfibrillation, andmaycauseasynchronous\\npacing,inhibition ofpacing,inappropriate shocks,and/orareduction inpulsegenerator pacingoutputpossiblyleadingtoloss\\nofcapture.RFablationmayalsocauseventricular pacinguptotheMTRand/orchangesinpacingthresholds.Additionally ,\\nexercisecautionwhenperforming anyothertypeofcardiacablationprocedureinpatientswithimplanted devices.\\nIfelectrocautery orRFablationismedically necessary,observethefollowing tominimizerisktothepatientanddevice:\\n•Depending onthepacingneedsofthepatient,programtheTachyModetoElectrocautery Protection ModeorOff.\\n•Havetemporary pacingandexternaldefibrillation equipment available.\\n•Avoiddirectcontactbetweentheelectrocautery equipment orablationcathetersandthepulsegenerator andleads.RF\\nablationclosetotheleadelectrode maydamagethelead-tissue interface.\\n•Keepthepathoftheelectricalcurrentasfarawayaspossiblefromthepulsegenerator andleads.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 28}), Document(page_content=\"26•IfRFablationand/orelectrocautery isperformed ontissuenearthedeviceorleads,monitorpre-andpost-\\nmeasurements forsensingandpacingthresholds andimpedances todetermine theintegrityandstabilityofthesystem.\\n•Forelectrocautery ,useabipolarelectrocautery systemwherepossibleanduseshort,intermittent, andirregularburstsat\\nthelowestfeasibleenergylevels.\\n•RFablationequipment maycausetelemetry interferenc ebetweenthepulsegenerator andPRM.Ifdeviceprogramming\\nchangesarenecessary duringanRFablationprocedure,turnofftheRFablationequipment beforeinterrogation.\\nWhentheprocedureisfinished,canceltheElectrocautery Protection ModeorprogramTachyModetoMonitor+Therapyin\\nordertoreactivate thepreviously programmedtherapymodes.\\nIonizingRadiation\\nCAUTION: Itisnotpossibletospecifyasaferadiationdosageorguaranteeproperpulsegenerator functionfollowing\\nexposuretoionizingradiation. Multiplefactorscollectivelydetermine theimpactofradiationtherapyonanimplanted pulse\\ngenerator,includingproximity ofthepulsegenerator totheradiationbeam,typeandenergyleveloftheradiationbeam,dose\\nrate,totaldosedeliveredoverthelifeofthepulsegenerator,andshieldingofthepulsegenerator.Theimpactofionizing\\nradiationwillalsovaryfromonepulsegenerator toanotherandmayrangefromnochangesinfunctiontoalossofpacingand\\ndefibrillation therapy.\\nSourcesofionizingradiationvarysignificantly intheirpotentialimpactonanimplanted pulsegenerator.Severaltherapeutic\\nradiationsourcesarecapableofinterfering withordamaging animplanted pulsegenerator,includingthoseusedforthe\\ntreatmentofcancer,suchasradioactive cobalt,linearaccelerators,radioactive seeds,andbetatrons.\\nPriortoacourseoftherapeutic radiationtreatment, thepatient'sradiationoncologist andcardiologist orelectrophysiologist\\nshouldconsiderallpatientmanagement options,includingincreased follow-up anddevicereplacement.Otherconsiderations\\ninclude:\\n•Maximizing shieldingofthepulsegenerator withinthetreatment field\\n•Determining theappropriate levelofpatientmonitoring duringtreatment\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 29}), Document(page_content='27Evaluatepulsegenerator operation duringandfollowing thecourseofradiationtreatment toexerciseasmuchdevice\\nfunctionality aspossible(\"Post-TherapyPulseGenerator FollowUp\"onpage20).Theextent,timing,andfrequency ofthis\\nevaluation relativetotheradiationtherapyregimenaredependent uponcurrentpatienthealth,andthereforeshouldbe\\ndetermined bytheattending cardiologist orelectrophysiologist.\\nManypulsegenerator diagnostics areperformed automatically onceperhour,sopulsegenerator evaluation shouldnotbe\\nconcluded untilpulsegenerator diagnostics havebeenupdatedandreviewed(atleastonehourafterradiationexposure).The\\neffectsofradiationexposureontheimplanted pulsegenerator mayremainundetected untilsometimefollowing exposure.For\\nthisreason,continuetomonitorpulsegenerator functioncloselyandusecautionwhenprogrammingafeatureintheweeksor\\nmonthsfollowing radiationtherapy.\\nElevatedPressures\\nTheInternational Standards Organization (ISO)hasnotapproved astandardize dpressuretestforimplantable pulsegenerators\\nthatexperiencehyperbaric oxygentherapy(HBOT)orSCUBAdiving.However,BostonScientificdeveloped atestprotocolto\\nevaluatedeviceperformance uponexposuretoelevatedatmospheric pressures.Thefollowing summary ofpressuretesting\\nshouldnotbeviewedasandisnotanendorsement ofHBOTorSCUBAdiving.\\nCAUTION: ElevatedpressuresduetoHBOTorSCUBAdivingmaydamagethepulsegenerator.Duringlaboratory testing,all\\npulsegenerators inthetestsamplefunctioned asdesigned whenexposedtomorethan1000cyclesatapressureupto5.0\\nATA.Laboratory testingdidnotcharacteriz etheimpactofelevatedpressureonpulsegenerator performance orphysiological\\nresponsewhileimplanted inahumanbody.\\nPressureforeachtestcyclebeganatambient/r oompressure,increased toahighpressurelevel,andthenreturnedtoambient\\npressure.Although dwelltime(theamountoftimeunderelevatedpressure)mayhaveanimpactonhumanphysiology ,testing\\nindicateditdidnotimpactpulsegenerator performance. Pressurevalueequivalencies areprovidedbelow(Table1Pressure\\nValueEquivalencies onpage28).', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 30}), Document(page_content='28Table1.PressureValueEquivalencies\\nPressurevalueequivalencies\\nAtmospheres Absolute 5.0ATA\\nSeawaterdeptha40m(130ft)\\nPressure,absolute 72.8psia\\nPressure,gaugeb58.1psig\\nBar 5.0\\nkPaAbsolute 500\\na.Allpressureswerederivedassuming seawaterdensityof1030kg/m3.\\nb.Pressureasreadonagaugeordial(psia=psig+14.7psi).\\nPriortoSCUBAdivingorstartinganHBOTprogram,thepatient\\'sattending cardiologist orelectrophysiologist shouldbe\\nconsultedtofullyunderstand thepotentialconsequenc esrelativetothepatient\\'sspecifichealthcondition. ADiveMedicine\\nSpecialist mayalsobeconsulted priortoSCUBAdiving.\\nMorefrequentdevicefollow-up maybewarranted inconjunctionwithHBOTorSCUBAdiving.Evaluatepulsegenerator\\noperationfollowing highpressureexposure(\"Post-TherapyPulseGeneratorFollowUp\"onpage20).Theextent,timing,and\\nfrequencyofthisevaluation relativetothehighpressureexposurearedependent uponcurrentpatienthealth,andshouldbe\\ndetermined bytheattending cardiologist orelectrophysiologist.\\nIfyouhaveadditional questions, orwouldlikemoredetailregardingthetestprotocolortestresultsspecifictoHBOTorSCUBA\\ndiving,contactBostonScientificusingtheinformation onthebackcover.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 31}), Document(page_content='29POTENTIALADVERSEEVENTS\\nBasedontheliteratureandonpulsegenerator and/orleadimplantexperience ,thefollowing alphabetical listincludesthe\\npossibleadverseeventsassociated withimplantation ofproductsdescribed inthisliterature:\\n•Airembolism\\n•Allergicreaction\\n•Bleeding\\n•Bradycardia\\n•Cardiactamponade\\n•Chronicnervedamage\\n•Component failure\\n•Conductor coilfracture\\n•Death\\n•Elevatedthresholds\\n•Erosion\\n•Excessive fibrotictissuegrowth\\n•Extracardiacstimulation (muscle/nerve stimulation)\\n•Failuretoconvertaninducedarrhythmia\\n•Fluidaccumulation\\n•Foreignbodyrejectionphenomena\\n•Formation ofhematomas orseromas\\n•Heartblock\\n•Heartfailurefollowing chronicRVapicalpacing\\n•Inabilitytodefibrillate orpace', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 32}), Document(page_content='30•Inappropriate therapy(e.g.,shocksandantitachycardia pacing[ATP]whereapplicable, pacing)\\n•Incisional pain\\n•Incomplete leadconnection withpulsegenerator\\n•Infectionincludingendocarditis\\n•Insulating myocardium duringdefibrillation withinternalorexternalpaddles\\n•Leaddislodgment\\n•Leadfracture\\n•Leadinsulation breakage orabrasion\\n•Leadperforation\\n•Leadtipdeformation and/orbreakage\\n•Localtissuereaction\\n•Lossofcapture\\n•Myocardial infarction (MI)\\n•Myocardial necrosis\\n•Myocardial trauma(e.g.,tissuedamage,valvedamage)\\n•Myopotential sensing\\n•Oversensing/undersensing\\n•Pacemaker-mediated tachycardia (PMT)(Appliestodual-chamber devicesonly.)\\n•Pericardial rub,effusion\\n•Pneumothorax\\n•Pulsegenerator migration\\n•Shuntingcurrentduringdefibrillation withinternalorexternalpaddles\\n•Syncope', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 33}), Document(page_content='31•Tachyarrhythmias, whichincludeaccelerationofarrhythmias andearly,recurrentatrialfibrillation\\n•Thrombosis/thr omboemboli\\n•Valvedamage\\n•Vasovagal response\\n•Venousocclusion\\n•Venoustrauma(e.g.,perforation, dissection, erosion)\\n•Worsening heartfailure\\nForalistofpotentialadverseeventsassociated withMRIscanning, refertotheImageReady MRConditional Defibrillation\\nSystemMRITechnicalGuide.\\nPatientsmaydeveloppsychological intolerancetoapulsegenerator systemandmayexperience thefollowing:\\n•Dependency\\n•Depression\\n•Fearofprematurebatterydepletion\\n•Fearofshockingwhileconscious\\n•Fearthatshockingcapability maybelost\\n•Imagined shocking\\n•Fearofdevicemalfunction\\nMECHANICAL SPECIFICATIONS\\nAllRESONATE HFICDandExtended Longevity (EL)ICDmodelshaveacaseelectrodesurfaceareaof6192mm².Usablebattery\\ncapacityis1.8AhandresidualusablebatterycapacityatExplantis0.12Ahforsinglechamberdevicesand0.12Ahfordual\\nchamberdevices.Mechanical specifications specifictoeachmodelarelistedbelow.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 34}), Document(page_content='32AllPERCIVAHFICDandPERCIVAICDmodelshaveacaseelectrode surfaceareaof5487mm².Usablebatterycapacityis1.1Ah\\nandresidualusablebatterycapacityatExplantis0.12Ahforsinglechamberdevicesand0.13Ahfordualchamberdevices.\\nMechanical specifications specifictoeachmodelarelistedbelow.\\nTable2.Mechanical Specifications -RESONATE HFICDs\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nD520(VR) 5.37x7.79x0.99 70.7 31.5 RV:IS-1/DF–1 Yes\\nD521(DR) 5.37x7.79x0.99 71.0 31.5 RA:IS-1;RV:IS-\\n1/DF–1Yes\\nD532(VR) 5.37x7.36x0.99 68.9 29.5 RV:DF4 Yes\\nD533(DR) 5.37x7.68x0.99 71.4 31.0 RA:IS-1;RV:DF4 Yes\\nTable3.Mechanical Specifications -RESONATE Extended Longevity (EL)ICDs\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nD420(VR) 5.37x7.79x0.99 70.7 31.5 RV:IS-1/DF–1 Yes\\nD421(DR) 5.37x7.79x0.99 71.0 31.5 RA:IS-1;RV:IS-\\n1/DF–1Yes', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 35}), Document(page_content='33Table3.Mechanical Specifications -RESONATE Extended Longevity (EL)ICDs(continued)\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nD432(VR) 5.37x7.36x0.99 68.9 29.5 RV:DF4 Yes\\nD433(DR) 5.37x7.68x0.99 71.4 31.0 RA:IS-1;RV:DF4 Yes\\nTable4.Mechanical Specifications -PERCIVAHFICDs\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nD500(VR) 5.23x7.14x0.99 61.9 28.5 RV:IS-1/DF–1 Yes\\nD501(DR) 5.23x7.14x0.99 62.3 28.5 RA:IS-1;RV:IS-\\n1/DF–1Yes\\nD512(VR) 5.23x6.71x0.99 60.0 26.5 RV:DF4 Yes\\nD513(DR) 5.23x7.03x0.99 62.5 28.0 RA:IS-1;RV:DF4 Yes', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 36}), Document(page_content='34Table5.Mechanical Specifications -PERCIVAICDs\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nD400(VR) 5.23x7.14x0.99 61.9 28.5 RV:IS-1/DF–1 Yes\\nD401(DR) 5.23x7.14x0.99 62.3 28.5 RA:IS-1;RV:IS-\\n1/DF–1Yes\\nD412(VR) 5.23x6.71x0.99 60.0 26.5 RV:DF4 Yes\\nD413(DR) 5.23x7.03x0.99 62.5 28.0 RA:IS-1;RV:DF4 Yes\\nTable6.Mechanical Specifications -VIGILANTExtended Longevity (EL)ICDs\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nD220(VR) 5.37x7.79x0.99 70.7 31.5 RV:IS-1/DF–1 Yes\\nD221(DR) 5.37x7.79x0.99 71.0 31.5 RA:IS-1;RV:IS-\\n1/DF–1Yes\\nD232(VR) 5.37x7.36x0.99 68.9 29.5 RV:DF4 Yes\\nD233(DR) 5.37x7.68x0.99 71.4 31.0 RA:IS-1;RV:DF4 Yes', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 37}), Document(page_content='35Table7.Mechanical Specifications -MOMENTUM Extended Longevity (EL)ICDs\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume(cm3)Connector TypeMRConditional\\nD120(VR) 5.37x7.79x0.99 70.7 31.5 RV:IS-1/DF–1 Yes\\nD121(DR) 5.37x7.79x0.99 71.0 31.5 RA:IS-1;RV:IS-\\n1/DF–1Yes\\nMaterialspecifications areshownbelow:\\n•Case:hermetically sealedtitanium\\n•Header:implantation-grade polymer\\n•PowerSupply(RESONATE HFandEL):lithium-manganese dioxidecell;BostonScientificENDURALIFE; 401988\\n•PowerSupply(PERCIVAHFandPERCIVA): lithium-manganese dioxidecell;BostonScientific; 400010\\nITEMSINCLUDED INPACKAGE\\nThefollowing itemsareincludedwiththepulsegenerator:\\n•Onetorquewrench\\n•Productliterature\\nNOTE:Accessories(e.g.,wrenches) areintendedforone-timeuseonly.Theyshouldnotberesterilizedorreused.\\nWARNING: Implantofthesystemcannotbeperformed inanMRIsiteZoneIII(andhigher)asdefinedbytheAmerican\\nCollegeofRadiology Guidance Document onMRSafePractices5.Someoftheaccessoriespackaged withpulsegenerators and\\n5.KanalE,Barkovich AJ,BellC,etal.ACRguidancedocument onMRsafepractices:2013.J.Magn.Reson.Imaging2013;37:501-530.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 38}), Document(page_content='36leads,includingthetorquewrenchandstyletwires,arenotMRConditional andshouldnotbebroughtintotheMRIscanner\\nroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nSYMBOLSONPACKAGING\\nThefollowing symbolsmaybeusedonpackaging andlabeling:\\nTable8.Symbolsonpackaging\\nSymbol Description\\nReferenceNumber\\nContents\\nPulsegenerator\\nTorquewrench\\nLiteratureenclosed\\nSerialNumber', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 39}), Document(page_content='37Table8.Symbolsonpackaging (continued)\\nSymbol Description\\nUseBy\\nLotNumber\\nDateofManufacture\\nNon-Ionizing Electromagnetic Radiation\\nSterilizedusingethyleneoxide.\\nSTERILIZE2\\nDoNotResterilize\\nSingleuse.Donotre-use.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 40}), Document(page_content='38Table8.Symbolsonpackaging (continued)\\nSymbol Description\\nDonotuseifpackageisdamaged.\\nDangerous Voltage\\nConsultinstructions foruseonthiswebsite:www.\\nbostonscientific -elabeling.com\\nTemperatur elimitation.\\nPlacetelemetry wandhere', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 41}), Document(page_content='39Table8.Symbolsonpackaging (continued)\\nSymbol Description\\n,\\nOpenHere\\nManufacturer\\nMRConditional\\nCRT-DRA,RV,LV\\nICDRA,RV\\nICDRV\\nUncoated device', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 42}), Document(page_content='40Table8.Symbolsonpackaging (continued)\\nSymbol Description\\nRFTelemetry\\nDoublesterilebarriersystem\\nCHARACTERISTICS ASSHIPPED\\nRefertothetableforpulsegenerator settingsatshipment (Table9Characteristics asshippedonpage40).\\nTable9.Characteristics asshipped\\nParameter Setting\\nTachyMode Storage\\nTachyTherapyavailable ATP,Shock\\nPacingMode Storage\\nPacingTherapyavailable DDDR(DRmodels)VVIR(VRmodels)\\nSensor Accelerometer', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 43}), Document(page_content='41Table9.Characteristics asshipped(continued)\\nParameter Setting\\nSensor Blend(AccelandMV)(MOMENTUM, RESONATE HFandPERCIVAHF\\nmodels)\\nPace/Sense Configuration RA:BI/BI(DRmodels)\\nPace/Sense Configuration RV:BI/BI\\nThepulsegenerator isshippedinapower-savingStoragemodetoextenditsshelflife.InStoragemode,allfeaturesare\\ninactiveexcept:\\n•Telemetry support,whichallowsinterrogation andprogramming\\n•Real-time clock\\n•Commanded capacitorre-formation\\n•STATSHOCKandSTATPACEcommands\\nThedeviceleavesStoragemodewhenoneofthefollowing actionsoccurs;however,programmingotherparameters willnot\\naffecttheStoragemode:\\n•STATSHOCKorSTATPACEiscommanded\\n•TachyModeisprogramm edto:\\n•Off\\n•MonitorOnly\\n•Monitor+Therapy', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 44}), Document(page_content=\"42Onceyouhaveprogramm edthepulsegenerator outofStoragemode,thedevicecannotbereprogrammedtothatmode.\\nX-RAYIDENTIFIER\\nThepulsegenerator hasanidentifierthatisvisibleonanx-rayorfluoroscopicimage.Thisidentifierprovidesnoninvasive\\nconfirmationofthemanufacturer andconsistsofthefollowing:\\n•Theletters,BSC,toidentifyBostonScientificasthemanufacturer .\\n•Thenumber,140,toidentifythepulsegenerators.\\nThex-rayidentifierisembedded intheheaderofthedevice.Foraleftsidepectoralimplant,theidentifierwillbevisiblebyx-\\nrayorfluorographyattheapproximate locationshown(Figure1X-rayidentifieronpage42).\\n1\\n2\\n3\\n[1]X-RayIdentifier[2]Header[3]PulseGeneratorCase\\nFigure1.X-rayidentifier\\nForinformation onidentifying thedeviceviatheProgrammer,refertotheProgrammerOperator's Manual.\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 45}), Document(page_content=\"43Thepulsegenerator modelnumberandserialnumberareaccessiblefromtheProgrammerSummary screenoncethepulse\\ngenerator isinterrogated. Additional information suchasdateofmanufacture canbeobtainedbycontactingBostonScientific\\nandproviding themodelnumberandserialnumber.\\nFEDERALCOMMUNICATIONS COMMISSION (FCC)\\nThisdevicecomplieswithTitle47,Part15oftheFCCrules.Operationissubjecttothefollowing twoconditions:\\n•Thisdevicemaynotcauseharmfulinterferenc e,and\\n•Thisdevicemustacceptanyinterferenc ereceived,includinginterferenc ethatmaycauseundesired operation.\\nForpulsegenerators operating withatransmitfrequency of402to405MHz:thistransmitter isauthorizedbyruleunderthe\\nMedicalDeviceRadiocommunication Service(inpart95oftheFCCRules)andmustnotcauseharmfulinterferenc etostations\\noperating inthe400.150–406.000 MHzbandintheMeteorological Aids(i.e.,transmitters andreceiversusedtocommunicate\\nweatherdata),theMeteorological Satellite,ortheEarthExploration SatelliteServicesandmustacceptinterferenc ethatmaybe\\ncausedbysuchstations,includinginterferenc ethatmaycauseundesired operation. Thistransmitter shallbeusedonlyin\\naccordancewiththeFCCRulesgoverning theMedicalDeviceRadiocomm unicationService.Analoganddigitalvoice\\ncommunications areprohibited. Although thistransmitterhasbeenapproved bytheFederalCommunications Commission,\\nthereisnoguarantee thatitwillnotreceiveinterferenc eorthatanyparticular transmission fromthistransmitter willbefree\\nfrominterference.\\nCAUTION: Changesormodifications notexpresslyapproved byBostonScientificcouldvoidtheuser'sauthoritytooperatethe\\nequipment.\\nRESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT, andMOMENTUM devicesoperateinthe402–405MHzbandusing\\nFSKmodulation withradiatedpowerconforming totheapplicable 25μWlimit.TheFCCIDisESCCRMG17912. Wandedtelemetry\\noperatesat57kHzandusesQPSKmodulation.\\nPULSEGENERATOR LONGEVITY\\nBasedonsimulated studies,itisanticipated thatthesepulsegenerators haveaveragelongevitytoexplantasshownbelow.\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 46}), Document(page_content='44RefertothePRMSummary andBatteryDetailSummary screensforanestimateofpulsegenerator longevityspecifictothe\\nimplanted device.\\nThelongevityexpectations, whichaccountfortheenergyusedduringmanufacture andstorage,applyattheconditions shown\\ninthetablesalongwiththefollowing:\\n•Assumes60ppmLRL,0.4mspacingpulsewidth;sensorsOn,HeartFailureSensorSuiteOn.\\nThefollowing longevity tablesandconditions ofuseapplytoRESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT,\\nandMOMENTUM devices.\\nProjectedlongevityiscalculated assuming 2maximum energychargingcyclesperyear,includingautomatic capacitorre-forms\\nandtherapeutic shocks.Thesecalculations alsoassume3-channel EGMOnsetisonandthatthepulsegenerator spends3\\nmonthsinStoragemodeduringshippingandstorage.\\nPaceSafeOnforRAATandRVATprovidesanoutputof2Xthethreshold withaminimum outputof2.0V.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 47}), Document(page_content='45Table10.RESONATE HFandExtended Longevity (EL)ICDpulsegenerator lifeexpectancy estimation (implantto\\nexplant)withENDURALIFE battery\\nAllModelsa\\nPacing\\nAmpli-\\ntudePacingLongevity (years)\\n500Ωwith\\nLATITUDEb700Ωwith\\nLATITUDEb900Ωwith\\nLATITUDEb700ΩNoLATITUDE,\\nMV/RS,orHFSSc\\nVR DR VR DR VR DR VR DR\\n2.0V 0% 15.4 14.2 15.4 14.2 15.4 14.2 17.5 16.0\\n2.0V15% 15.2 13.8 15.2 13.9 15.3 14.0 17.2 15.6\\n2.0V50% 14.6 13.0 14.8 13.2 14.9 13.4 16.7 14.8\\n2.0V100% 13.9 11.9 14.3 12.4 14.5 12.7 16.0 13.7\\n2.5V15% 15.0 13.6 15.1 13.7 15.2 13.8 17.1 15.4\\n2.5V50% 14.2 12.3 14.5 12.7 14.7 13.0 16.3 14.1\\n2.5V100% 13.2 10.9 13.7 11.5 14.0 12.0 15.3 12.7\\na.AssumesZIPtelemetry usefor1houratimplantandfor40minutesannuallyforin-clinicfollow-up checks.\\nb.AssumesstandarduseoftheLATITUDE Communicator asfollows:DailyDeviceCheckon,quarterlyscheduled remotefollowups,andother\\ntypicalinterrogations.\\nc.AssumesLATITUDE Communicator isnotused,MinuteVentilation (MV)/Respiratory SensorisOff,andHeartFailureSensorSuiteisOff.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 48}), Document(page_content='46Table11.PERCIVAICDpulsegenerator lifeexpectancy estimation (implanttoexplant)\\nAllModelsa\\nPacing\\nAmpli-\\ntudePacingLongevity (years)\\n500Ωwith\\nLATITUDEb700Ωwith\\nLATITUDEb900Ωwith\\nLATITUDEb700ΩNoLATITUDE,\\nRS,orHFSSc\\nVR DR VR DR VR DR VR DR\\n2.0V 0% 8.2 7.5 8.2 7.5 8.2 7.6 9.3 8.5\\n2.0V15% 8.1 7.3 8.1 7.4 8.1 7.4 9.1 8.3\\n2.0V50% 7.8 6.9 7.9 7.0 7.9 7.1 8.9 7.8\\n2.0V100% 7.4 6.3 7.6 6.6 7.7 6.7 8.5 7.3\\n2.5V15% 8.0 7.2 8.0 7.3 8.1 7.3 9.1 8.1\\n2.5V50% 7.5 6.5 7.7 6.8 7.8 6.9 8.7 7.5\\n2.5V100% 7.0 5.7 7.3 6.1 7.4 6.3 8.1 6.7\\na.AssumesZIPtelemetry usefor1houratimplantandfor40minutesannuallyforin-clinicfollow-up checks.\\nb.AssumesstandarduseoftheLATITUDE Communicator asfollows:DailyDeviceCheckon,quarterlyscheduled remotefollowups,andother\\ntypicalinterrogations.\\nc.AssumesLATITUDE Communicator isnotused,MinuteVentilation (MV)/Respiratory SensorisOff,andHeartFailureSensorSuiteisOff.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 49}), Document(page_content='47NOTE:Theenergyconsumptioninthelongevitytableisbasedupontheoretical electricalprinciples andverifiedviabench\\ntestingonly.\\nThepulsegenerator longevitymayincreasewithadecreaseinanyofthefollowing:\\n•Pacingrate\\n•Pacingpulseamplitude(s)\\n•Pacingpulsewidth(s)\\n•Percentageofpacedtosensedevents\\n•Chargingfrequency\\nForRESONATE HFandExtended Longevity (EL)devices,longevityisalsoaffectedinthefollowing circumstanc es:6\\n•Adecreaseinpacingimpedance mayreducelongevity.\\n•WhentheMV/Respiratory SensorisprogrammedOffforthelifeofthedevice,longevityisincreased byapproximately 6\\nmonths.\\n•WhenPatientTriggered MonitorisprogrammedtoOnfor60days,longevityisreducedbyapproximately 5days.\\n•WhentheLATITUDE Communicator isnotusedforthelifeofthedevice,longevityisincreasedbyapproximately 7\\nmonths.\\n•Onehourofadditional ZIPwandless telemetry reduceslongevitybyapproximately 11days.\\n•Fivepatient-initiatedLATITUDE Communicator interrogations perweekforayearreduceslongevitybyapproximately 52\\ndays.\\n•Anadditional maximum-energy shockreduceslongevitybyapproximate ly24days.\\n•SixhoursinMRIProtection Modereduceslongevitybyapproximately 4days.\\n•Anadditional 6monthsinStoragemodepriortoimplantwillreducelongevityby67days.\\n6.Assumesimplanted settingsof60ppmLRL;2.5VpacingpulseAmplitude and0.4mspacingPulseWidth;500ΩpacingImpedance; 50%\\npacing.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 50}), Document(page_content='48•WhentheHeartFailureSensorSuiteisprogrammedtoOffforthelifeofthedevice,longevityisincreasedby\\napproximately 1month.\\n•AHeartLogic subscription withdailyalertchecksandweeklyinterrogations willdecreaselongevitybyapproximately 3\\nmonthswhenusedforthelifeofthedevice.\\n•Dailyinterrogations torefreshHeartLogic following analertfor30dayseachyearwilldecreaselongevitybyanadditional\\n2months.\\n•ForDRdevices,whentheSignalArtifactMonitorisprogrammedOnforthelifeofthedevice,longevityisreducedby\\napproximately 4months.7\\n•ForVRdevices,whentheSignalArtifactMonitorisprogrammedOnforthelifeofthedevice,longevityisreducedby\\napproximately 6months.7\\nForPERCIVAdevices,longevityisalsoaffectedinthefollowing circumstanc es:8\\n•Adecreaseinpacingimpedancemayreducelongevity.\\n•WhentheMV/Respiratory SensorisprogrammedOffforthelifeofthedevice,longevityisincreased byapproximately 3\\nmonths.\\n•WhenPatientTriggeredMonitorisprogrammedtoOnfor60days,longevityisreducedbyapproximately 5days.\\n•WhentheLATITUDE Communicator isnotusedforthelifeofthedevice,longevityisincreased byapproximately4\\nmonths.\\n•Onehourofadditional ZIPwandless telemetry reduceslongevitybyapproximately 11days.\\n•Fivepatient-initiatedLATITUDE Communicator interrogations perweekforayearreduceslongevitybyapproximately 47\\ndays.\\n•Anadditional maximum-energy shockreduceslongevitybyapproximately 26days.\\n7.Assumessettingsof60min-1LRL;2.0VpacingpulseAmplitude and0.4mspacingPulseWidth;500ΩpacingImpedance; 0%pacing.\\n8.Assumesimplanted settingsof60ppmLRL;2.5VpacingpulseAmplitude and0.4mspacingPulseWidth;500ΩpacingImpedance; 50%\\npacing.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 51}), Document(page_content='49•SixhoursinMRIProtection Modereduceslongevitybyapproximately 4days.\\n•Anadditional 6monthsinStoragemodepriortoimplantwillreducelongevityby66days.\\n•WhentheHeartFailureSensorSuiteisprogrammedtoOffforthelifeofthedevice,longevityisincreased by\\napproximately 1month.\\n•AHeartLogic subscription withdailyalertchecksandweeklyinterrogations willdecreaselongevitybyapproximately2\\nmonthswhenusedforthelifeofthedevice.\\n•Dailyinterrogations torefreshHeartLogic following analertfor30dayseachyearwilldecreaselongevitybyanadditional\\n1month.\\n•ForDRdevices,whentheSignalArtifactMonitorisprogrammedOnforthelifeofthedevice,longevityisreducedby\\napproximately 2months.9\\n•ForVRdevices,whentheSignalArtifactMonitorisprogrammedOnforthelifeofthedevice,longevityisreducedby\\napproximately 3months.9\\nDevicelongevitymayalsobeaffectedby:\\n•Tolerancesofelectronic components\\n•Variations inprogrammedparameters\\n•Variations inusageasaresultofpatientcondition\\nWARRANTY INFORMATION\\nAlimitedwarrantycertificate forthepulsegenerator isavailableatwww.bostonscientific.com. Foracopy,contactBoston\\nScientificusingtheinformation onthebackcover.\\n9.Assumessettingsof60min-1LRL;2.0VpacingpulseAmplitude and0.4mspacingPulseWidth;500ΩpacingImpedance; 0%pacing.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 52}), Document(page_content=\"50PRODUCTRELIABILITY\\nItisBostonScientific's intenttoprovideimplantable devicesofhighqualityandreliability.However,thesedevicesmayexhibit\\nmalfunctions thatmayresultinlostorcompromisedabilitytodelivertherapy.Thesemalfunctions mayincludethefollowing:\\n•Prematurebatterydepletion\\n•Sensingorpacingissues\\n•Inabilitytoshock\\n•Errorcodes\\n•Lossoftelemetry\\nRefertoBostonScientific's CRMProductPerformance Reportonwww.bostonscientific.com formoreinformation aboutdevice\\nperformance, includingthetypesandratesofmalfunctions thatthesedeviceshaveexperiencedhistorically .Whilehistorical\\ndatamaynotbepredictive offuturedeviceperformance, suchdatacanprovideimportant contextforunderstanding theoverall\\nreliabilityofthesetypesofproducts.\\nSometimes devicemalfunctions resultintheissuanceofproductadvisories. BostonScientificdetermines theneedtoissue\\nproductadvisories basedontheestimated malfunction rateandtheclinicalimplication ofthemalfunction. WhenBoston\\nScientificcommunicates productadvisoryinformation, thedecisionwhethertoreplaceadeviceshouldtakeintoaccountthe\\nrisksofthemalfunction, therisksofthereplacementprocedure,andtheperformance todateofthereplacement device.\\nPATIENTCOUNSELING INFORMATION\\nThefollowing topicsshouldbediscussed withthepatientpriortodischarge:\\n•Externaldefibrillation—the patientshouldcontacttheirphysician tohavetheirpulsegenerator systemevaluated ifthey\\nreceiveexternaldefibrillation\\n•Beepingtones—the patientshouldcontacttheirphysician immediately iftheyheartonescomingfromtheirpulse\\ngenerator\\n•Signsandsymptoms ofinfection\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 53}), Document(page_content='51•Symptoms thatshouldbereported(e.g.,sustained high-rate pacingrequiringreprogramming)\\n•Protected environments—the patientshouldseekmedicalguidancebeforeenteringareasprotected byawarningnotice\\nthatpreventsentrybypatientswhohaveapulsegenerator\\n•MRIscanning—the physician following thepatient\\'sdevicemustbeconsultedtodetermine eligibilityforanMRIscan.\\nBeforeanMRIprocedureisperformed, aphysician andpatientshouldweighthebenefitoftheMRprocedureagainstthe\\nriskoflosingtheBeeper.\\nWARNING: Determine thebeepertypebeforeanMRIscan.TheArmature Beepermaynolongerbeusablefollowing anMRI\\nscan.Comingincontactwiththestrongmagnetic fieldofanMRIscannermaycauseapermanent lossoftheArmature Beeper\\nvolume.Thiscannotberecovered,evenafterleavingtheMRIscanenvironment andexitingMRIProtection Mode.Forthe\\nArmature Beeper,beforeanMRIscanisperformed, aphysician andpatientshouldweighthebenefitoftheMRIscanagainst\\ntheriskoflosingtheBeeper;aftertheMRIscan,performBeeperevaluation testtodetermine iftheBeeperisusable.Ifthe\\nBeeperisnotusable,itisstronglyrecommended thatpatientsarefollowedonLATITUDE NXTafteranMRIscaniftheyarenot\\nalready.Otherwise, anin-clinicfollow-up scheduleofeverythreemonthsisstronglyrecommended tomonitordevice\\nperformance.\\n•AvoidingpotentialsourcesofEMIinhome,work,andmedicalenvironments\\n•Personsadministering CPR—thepresenceofvoltage(tingling)onthepatient\\'sbodysurfacemaybeexperience dwhen\\nthepulsegenerator deliversashock\\n•Reliability oftheirpulsegenerator (\"ProductReliability\" onpage50)\\n•Activityrestrictions (ifapplicable)\\n•Minimum heartrate(lowerratelimitofthepulsegenerator)\\n•Frequency offollowup\\n•Travelorrelocation—follow-up arrangements shouldbemadeinadvanceifthepatientisleavingthecountryofimplant\\n•PatientIDcard—thepatientshouldbeadvisedtocarrytheirpatientIDcardatalltimes(atemporary patientIDcardis\\nprovidedwiththedevice,andapermanent IDcardwillbesenttothepatient4to6weeksaftertheimplantformis\\nreceivedbyBostonScientific)', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 54}), Document(page_content='52NOTE:PatientsshouldpresenttheirpatientIDcardbeforeenteringprotected environments suchasforMRI\\nscanning.\\nPatientHandbook\\nThePatientHandbook isprovidedforeachdevice.\\nItisrecommended thatyoudiscusstheinformation inthePatientHandbook withconcernedindividuals bothbeforeandafter\\nimplantation sotheyarefullyfamiliarwithpulsegenerator operation.\\nInaddition,forpatientswithanImageReady MRConditional Defibrillation System,anImageReady MRConditional Defibrillation\\nSystemMRIPatientGuideisavailable.\\nForadditional copies,contactBostonScientificusingtheinformation onthebackcover.\\nLEADCONNECTIONS\\nLeadconnections areillustrated below.\\nCAUTION: Priortoimplantation, confirmthelead-to-pulse generator compatibility.Usingincompatible leadsandpulse\\ngenerators candamagetheconnector and/orresultinpotentialadverseconsequenc es,suchasundersensing ofcardiacactivity\\norfailuretodelivernecessary therapy.\\nWhendeactivating alead,ensuretheleadisfullyinsulatedandelectricalnonactivebyusingleadcaps.Whendeactivating a\\nleadport,verifythattheplugandlabeledheaderportmatch.Verifywithaprogrammertheappropriate devicefunctionand\\nnewlyestablished configuration.Theabsenceofaleadorportplugmayaffectdeviceperformance andpotentially leavethe\\npatientwithouteffectivetherapy.\\nNOTE:UseofBostonScientificMRConditional leadsisrequiredforanimplanted systemtobeconsideredMRConditional.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnicalGuideformodelnumbersofpulsegenerators,\\nleads,accessories,andothersystemcomponentsneededtosatisfytheConditions ofUse.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 55}), Document(page_content='53\\n4\\n3\\n5DF4-LLHH\\nIS-1 \\nB\\nI\\nR\\nV\\nRA\\n1\\n2[1]RA:White[2]RV:Red[3]RA(-)[4]SutureHoles[5]RV(-)\\nFigure2.Leadconnections andsetscrewlocations, RA:IS-1,RV:DF4-LLHH\\n3\\n2\\nDF4-LLHH\\nRV\\n1\\n[1]RV:Red[2]RV(-)[3]SutureHoles\\nFigure3.Leadconnections andsetscrewlocations, RV:DF4-LLHH', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 56}), Document(page_content='54\\n9\\n5\\n6\\n7\\n8\\nIS-1 \\nBI\\nRV\\n–\\n+\\nR\\nA\\nDF-1\\nDF-1\\nIS-1 \\nBI\\n1\\n2\\n43[1]Defib(-):Red[2]Defib(+):Blue[3]RA:White[4]RV:White[5]Defib(+)[6]Defib(-)[7]RA(-)[8]RV(-)[9]SutureHole\\nFigure4.Leadconnections andsetscrewlocations, RA:IS-1,RV:IS-1/DF-1', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 57}), Document(page_content='55\\n7\\n4\\n5\\n6\\nIS-1 \\nBI\\nR\\nV\\n–\\n+\\nDF-1\\nDF-1\\n1\\n2\\n3[1]Defib(-):Red[2]Defib(+):Blue[3]RV:White[4]Defib(+)[5]Defib(-)[6]RV(-)[7]SutureHole\\nFigure5.Leadconnections andsetscrewlocations, RV:IS-1/DF-1\\nNOTE:Thepulsegenerator caseisusedasadefibrillating electrodeunlessthepulsegenerator hasbeenprogrammedtothe\\nDistalCoiltoProximalCoil(or“ColdCan”)ShockVector.\\nIMPLANTING THEPULSEGENERATOR\\nImplantthepulsegenerator byperforming thefollowing stepsinthesequence provided. Somepatientsmayrequirepacing\\ntherapies immediately uponconnecting theleadstothepulsegenerator.Insuchcases,considerprogrammingthepulse\\ngenerator beforeorinparallelwithimplanting theleadsystemandformingtheimplantation pocket.\\nWARNING: Implantofthesystemcannotbeperformed inanMRIsiteZoneIII(andhigher)asdefinedbytheAmerican\\nCollegeofRadiology Guidance Document onMRSafePractices10.Someoftheaccessoriespackaged withpulsegenerators and\\n10.KanalE,Barkovich AJ,BellC,etal.ACRguidancedocument onMRsafepractices:2013.J.Magn.Reson.Imaging2013;37:501-530.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 58}), Document(page_content='56leads,includingthetorquewrenchandstyletwires,arenotMRConditional andshouldnotbebroughtintotheMRIscanner\\nroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nStepA:CheckEquipment\\nItisrecommended thatinstrumentation forcardiacmonitoring, defibrillation, andleadsignalmeasurement shouldbeavailable\\nduringtheimplantprocedure.ThisincludesthePRMsystemwithitsrelatedaccessoriesandthesoftwareapplication. Before\\nbeginning theimplantation procedure,becomecompletely familiarwiththeoperation ofalltheequipment andtheinformation\\nintherespective operator\\'s anduser\\'smanuals.Verifytheoperational statusofallequipment thatmaybeusedduringthe\\nprocedure.Incaseofaccidental damageorcontamination, thefollowing shouldbeavailable:\\n•Sterileduplicates ofallimplantable items\\n•Sterilewand\\n•SterilePSAcables\\n•Torqueandnon-torque wrenches\\nDuringtheimplantation procedure,alwayshaveastandardexternaldefibrillator withexternalpadsorpaddlesavailableforuse\\nduringdefibrillation threshold testing.\\nStepB:InterrogateandCheckthePulseGenerator\\nThePRMcommunicates withthepulsegenerator usingatelemetry wand.Afterinitiatingcommunication withthewand,the\\nPRMcanusewandless ZIPtelemetry (two-way RFcommunication) tointerfacewithRFcapablepulsegenerators. Telemetry is\\nrequiredtodirectcommands fromthePRMsystem,modifydeviceparametersettingsandconductdiagnostics tests.\\nForadditional technicalspecifications regardingtelemetry function,referto\"FederalCommunications Commission (FCC)\"on\\npage43.\\nTomaintainsterility,testthepulsegenerator asdescribed belowbeforeopeningthesterileblistertray.Thepulsegenerator\\nshouldbeatroomtemperatur etoensureaccuratelymeasured parameters.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 59}), Document(page_content=\"571.Interrogate thepulsegenerator usingthePRM.Verifythatthepulsegenerator's TachyModeisprogrammedtoStorage.\\nIfotherwise, contactBostonScientificusingtheinformation onthebackcover.\\nTobeginaZIPtelemetry session,verifythattheZOOMWirelessTransmitter isconnectedtothePRMviatheUSBcable\\nandthatthegreenlightontopofthetransmitter isilluminated. Toinitiatecommunication withalldevices,positionthe\\nwandoverthePGandusethePRMtoInterrogate thepulsegenerator.Keepthetelemetry wandinpositionuntileithera\\nmessageappears,indicating thatthetelemetry wandmayberemovedfromproximity ofthepulsegenerator,ortheZIP\\ntelemetry lightilluminates onthePRMsystem.SelecttheEndSessionbuttontoquitatelemetry sessionandreturnto\\nthestartupscreen.Radiofrequency interferencemaytemporarily disruptZIPtelemetry communication. Increasing the\\ndistancefromthesourceofinterfering signalsorrepositioning theZOOMWirelessTransmitter mayimproveZIP\\ntelemetry performance. IfZIPtelemetry performance isnotsatisfactory ,theoptionofusingwandedtelemetry is\\navailable.\\n2.Performamanualcapacitorre-formation.\\n3.Reviewthepulsegenerator's currentbatterystatus.Countersshouldbeatzero.Ifthepulsegenerator batterystatusis\\nnotatfullcapacity,donotimplantthepulsegenerator.ContactBostonScientificusingtheinformation onthebackcover.\\nStepC:ImplanttheLeadSystem\\nThepulsegenerator requiresaleadsystemforsensing,pacing,anddelivering shocks.Thepulsegenerator canuseitscaseasa\\ndefibrillating electrode.\\nAfunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriat esensingandpacinginallchambers,\\nregardlessofprogrammedconfiguration,inconjunction withalltherapyrequiredleads.\\nSelectionofleadconfigurationandspecificsurgicalproceduresisamatterofprofessional judgment. Thefollowing leadsare\\navailableforusewiththepulsegenerator depending onthedevicemodel.\\n•Bipolarendocardial cardioversion/defibrillation andpacingleadsystem\\n•Ventricular endocardial bipolarlead\\n•Atrialbipolarlead\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 60}), Document(page_content='58•Superiorvenacavaleadcoupledwithaventricular patchlead\\n•Two-patch epicardial leadsconfiguration\\nNOTE:UseofBostonScientificMRConditional leadsisrequiredforanimplanted systemtobeconsideredMRConditional.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnicalGuideformodelnumbersofpulsegenerators,\\nleads,accessories,andothersystemcomponentsneededtosatisfytheConditions ofUse,andforwarningsandprecautions\\nregardingMRIscanning.\\nCAUTION: Theabsenceofaleadorpluginaleadportmayaffectdeviceperformance andpotentially leavethepatient\\nwithouteffectivetherapy.Ifaleadisnotused,verifythattheplugandlabeledheaderportmatch(i.e.,IS-1,DF-1,orDF4).Fully\\ninserttheplugintheunusedportandthentightenthesetscrewontotheplug.Verifyappropriate devicefunctionusingthe\\nprogrammer.\\n•Afunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriate sensingandpacinginall\\nchambers, regardlessofprogrammedconfiguration.ThisincludesdualchamberdevicesprogrammedtoAAI(R).\\n•Lackofafunctional RVleadmayresultinundersensing, and/oroversensing andleavethepatientwithouteffective\\ntherapy.\\nCAUTION: Donotsuturedirectlyovertheleadbody,asthismaycausestructural damage.Usethesuturesleevetosecure\\ntheleadproximaltothevenousentrysitetopreventleadmovement.\\nWhichever leadconfigurationisusedforbothpacing/sensing anddefibrillating, severalconsiderationsandcautionsshouldbe\\nheeded.Factorssuchascardiomegaly ordrugtherapymaynecessitate repositioning ofthedefibrillating leadsorsubstituting\\noneleadforanothertofacilitatearrhythmia conversion. Insomeinstances, noleadconfigurationmaybefoundthatprovides\\nreliablearrhythmia termination atenergylevelsavailablefromthepulsegenerator.Implantation ofthepulsegenerator isnot\\nrecommended inthesecases.\\nImplanttheleadsviathesurgicalapproach chosen.\\nNOTE:Shouldleadperformance changesoccurwhichcannotberesolvedwithprogramming,theleadmayneedtobe\\nreplacedifnoadapterisavailable.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 61}), Document(page_content='59NOTE:Useofadaptersisinconsistent withtheConditions ofUserequiredforMRConditional status.RefertotheImageReady\\nMRConditional Defibrillation SystemMRITechnicalGuideforwarnings, precautions, andotherinformation aboutMRIscanning.\\nStepD:TakeBaselineMeasurements\\nOncetheleadsareimplanted, takebaselinemeasurements. Evaluatetheleadsignals.Ifperforming apulsegenerator\\nreplacementprocedure,existingleadsshouldbereevaluated, (e.g.,signalamplitudes, pacingthresholds, andimpedance). The\\nuseofradiographymayhelpensureleadpositionandintegrity.Iftestingresultsareunsatisfactory ,leadsystemrepositioning or\\nreplacementmayberequired.\\n•Connectthepace/sense lead(s)toapacingsystemanalyzer(PSA).\\nWARNING: ForleadsthatrequiretheuseofaConnector Tool,usecautionhandlingtheleadterminalwhentheConnector\\nToolisnotpresentonthelead.Donotdirectlycontacttheleadterminalwithanysurgicalinstruments orelectricalconnections\\nsuchasPSA(alligator) clips,ECGconnections, forceps,hemostats, andclamps.Thiscoulddamagetheleadterminal,possibly\\ncompromisingthesealingintegrityandresultinlossoftherapyorinappropriatetherapy,suchasashortwithintheheader.\\n•Pace/sense leadmeasurements,measured approximately 10minutesafterinitialplacement (acute)orduringa\\nreplacementprocedure(chronic),arelistedbelow.Valuesotherthanwhataresuggested inthetablemaybeclinically\\nacceptableifappropriate sensingcanbedocumented withthecurrentlyprogrammedvalues.Considerreprogramming\\nthesensitivity parameter ifinappropriate sensingisobserved. Notethatthepulsegenerator measurements maynot\\nexactlycorrelatetothePSAmeasurements duetosignalfiltering.\\nTable12.Leadmeasurements\\nPace/senselead(acute) Pace/senselead(chronic)Shockinglead(acuteand\\nchronic)\\nR-WaveAmplitudeab>5mV >5mV >1.0mV\\nP-WaveAmplitudeab>1.5mV >1.5mV', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 62}), Document(page_content='60Table12.Leadmeasurements (continued)\\nPace/senselead(acute) Pace/senselead(chronic)Shockinglead(acuteand\\nchronic)\\nR-WaveDurationbcd<100ms <100ms\\nPacingThreshold (right\\nventricle)<1.5Vendocardial\\n<2.0Vepicardial<3.0Vendocardial\\n<3.5Vepicardial\\nPacingThreshold (atrium) <1.5Vendocardial <3.0Vendocardial\\nLeadimpedance (at5.0V\\nand0.5msatrium)e>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg\\nLeadimpedance (at5.0V\\nand0.5msrightventricle)e>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>20Ω\\n<programmedHigh\\nImpedance Limit(125–200\\nΩ)\\na.Amplitudes lessthan2mVcauseinaccurate ratecountinginthechronicstate,andresultininabilitytosenseatachyarrhythmia orthe\\nmisinterpretation ofanormalrhythmasabnormal.\\nb.LowerR-waveamplitudes andlongerdurationmaybeassociated withplacement inischemicorscarredtissues.Sincesignalqualitymay', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 63}), Document(page_content=\"61Table12.Leadmeasurements (continued)\\ndeteriorate chronically ,effortsshouldbemadetomeettheabovecriteriabyrepositioning theleadstoobtainsignalswiththelargestpossible\\namplitude andshortestduration.\\nc.Durations longerthan135ms(thepulsegenerator's refractoryperiod)mayresultininaccuratecardiacratedetermination, inabilitytosensea\\ntachyarrhythmia, orinthemisinterpretation ofanormalrhythmasabnormal.\\nd.Thismeasurement isnotinclusiveofcurrentofinjury.\\ne.Changesinthedefibrillation electrode surfacearea,suchaschangingfromatriadconfigurationtoasinglecoilconfiguration,canaffectthe\\nimpedance measurements. Baselinedefibrillation impedance measurements shouldfallwithintherecommended valuesindicatedinthetable.\\nf.TheLowImpedance Limitisprogrammable between200–500Ω.\\ng.TheHighImpedance Limitisprogrammable between2000–3000 Ω.\\nIftheleadintegrityisinquestion, standardleadtroubleshooting testsshouldbeusedtoassesstheleadsystemintegrity.\\nTroubleshooting testsinclude,butarenotlimitedto,thefollowing:\\n•Electrogramanalysiswithpocketmanipulation\\n•X-rayorfluoroscopicimagereview\\n•Additional maximum-energy shocks\\n•ProgrammingtheShockLeadVector\\n•WirelessECG\\n•Invasivevisualinspection\\nStepE:FormtheImplantation Pocket\\nUsingstandardoperating procedurestoprepareanimplantation pocket,choosethepositionofthepocketbasedonthe\\nimplanted leadconfigurationandthepatient'sbodyhabitus.Givingconsiderationtopatientanatomyandpulsegenerator size\\nandmotion,gentlycoilanyexcessleadandplaceadjacenttothepulsegenerator.Itisimportant toplacetheleadintothe\\npocketinamannerthatminimizes leadtension,twisting,sharpangles,and/orpressure.Pulsegenerators aretypically\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 64}), Document(page_content='62implanted subcutaneously inordertominimizetissuetraumaandfacilitateexplant.However,deeperimplantation (e.g.,\\nsubpectora l)mayhelpavoiderosionorextrusioninsomepatients.\\nIfanabdominal implantissuitable,itisrecommended thatimplantation occurontheleftabdominal side.\\nNOTE:Anabdominal implantsiteisinconsistentwiththeConditions ofUseforMRConditional MRIscanning. Refertothe\\nImageReady MRConditional Defibrillation SystemMRITechnicalGuideforwarnings, precautions andotherinformation about\\nMRIscanning.\\nIfitisnecessarytotunnelthelead,considerthefollowing:\\nWARNING: ForleadsthatrequiretheuseofaConnector Tool,usecautionhandlingtheleadterminalwhentheConnector\\nToolisnotpresentonthelead.Donotdirectlycontacttheleadterminalwithanysurgicalinstruments orelectricalconnections\\nsuchasPSA(alligator) clips,ECGconnections,forceps,hemostats, andclamps.Thiscoulddamagetheleadterminal,possibly\\ncompromisingthesealingintegrityandresultinlossoftherapyorinappropriate therapy,suchasashortwithintheheader.\\nWARNING: DonotcontactanyotherportionoftheDF4–LLHH orDF4–LLHO leadterminal,otherthantheterminalpin,even\\nwhentheleadcapisinplace.\\n•Ifacompatibletunnelerisnotused,captheleadterminalpins.APenrosedrain,largechesttube,ortunneling toolmay\\nbeusedtotunneltheleads.\\n•ForDF4-LLHH orDF4-LLHO leads,ifacompatible tunneling tipand/ortunnelerkitisnotused,captheleadterminaland\\ngriponlytheterminalpinwithahemostat orequivalent.\\n•Gentlytunneltheleadssubcutaneously totheimplantation pocket,ifnecessary.\\n•Reevaluate allleadsignalstodetermine ifanyoftheleadshavebeendamaged duringthetunneling procedure.\\nIftheleadsarenotconnected toapulsegenerator atthetimeofleadimplantation, theymustbecappedbeforeclosingthe\\nincision.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 65}), Document(page_content='63StepF:ConnecttheLeadstothePulseGenerator\\nToconnectleadstothepulsegenerator,useonlythetoolsprovidedinthepulsegenerator steriletrayoraccessorykit.Failure\\ntousethesuppliedtorquewrenchmayresultindamagetothesetscrews, sealplugs,orconnector threads.Donotimplantthe\\npulsegenerator ifthesealplugsappeartobedamaged. Retainthetoolsuntilalltestingproceduresarecompleteandthepulse\\ngenerator isimplanted.\\nNOTE:Somepatientsmayrequirepacingtherapies immediately uponconnecting theleadstothepulsegenerator.Insuch\\ncases,considerprogrammingthepulsegenerator beforecontinuing.\\nLeadsshouldbeconnected tothepulsegenerator inthefollowing sequence (forpulsegenerator headerandsetscrewlocation\\nillustrations, referto\"LeadConnections\" onpage52):\\n1.Rightventricle. ConnecttheRVleadfirstbecauseitisrequiredtoestablishRV-based timingcyclesthatyield\\nappropriate sensingandpacinginallchambers, regardless oftheprogrammedconfiguration.\\n•InmodelswithanIS-1RVleadport,insertandsecuretheterminalpinofanIS-1RVpace/sense lead.\\n•InmodelswithaDF4-LLHH RVleadport,insertandsecuretheterminalpinofaDF4-LLHH orDF4-LLHO lead.\\n2.Rightatrium.\\n•InmodelswithanIS-1RAleadport,insertandsecuretheterminalpinofanIS-1atrialpace/sense lead.\\n3.Defibrillation lead.\\n•InmodelswithDF-1leadports,firstinsertandsecurethedefibrillation leadanode(+,proximal) intothe(+)DF-1\\nleadport.Theninsertandsecuretheleadcathode(–,distal)intothe(–)DF-1leadport.\\nCAUTION: ForIS-1/DF-1leads,neverchangetheshockwaveform polaritybyphysically switching theleadanodesand\\ncathodesinthepulsegenerator header—use theprogrammable Polarityfeature.Devicedamageornonconversion ofthe\\narrhythmia post-operatively mayresultifthepolarityisswitchedphysically.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 66}), Document(page_content='64Connecteachleadtothepulsegenerator byfollowing thesesteps(foradditional information aboutthetorquewrench,referto\\n\"BidirectionalTorqueWrench\"onpage77):\\n1.Checkforthepresenceofanybloodorotherbodyfluidsintheleadportsonthepulsegenerator header.Iffluid\\ninadvertently enterstheports,cleanthemthoroughly withsterilewater.\\n2.Ifapplicable, removeanddiscardthetipprotection beforeusingthetorquewrench.\\n3.Gentlyinsertthetorquewrenchbladeintothesetscrewbypassingitthroughthepreslit,centerdepression oftheseal\\nplugata90°angle(Figure6Insertingthetorquewrenchonpage65).Thiswillopenupthesealplug,relievingany\\npotentialpressurebuild-upfromtheleadportbyproviding apathwaytoreleasetrappedfluidorair.\\nNOTE:Failuretoproperlyinsertthetorquewrenchinthepreslitdepression ofthesealplugmayresultindamageto\\nthepluganditssealingproperties.\\nCAUTION: Donotinsertaleadintothepulsegenerator connector withouttakingthefollowing precautionstoensure\\nproperleadinsertion:\\n•Insertthetorquewrenchintothepreslitdepression ofthesealplugbeforeinsertingtheleadintotheport,to\\nreleaseanytrappedfluidorair.\\n•Visuallyverifythatthesetscrewissufficiently retractedtoallowinsertion. Usethetorquewrenchtoloosenthe\\nsetscrewifnecessary.\\n•Fullyinserteachleadintoitsleadportandthentightenthesetscrewontotheterminalpin.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 67}), Document(page_content='65\\nFigure6.Insertingthetorquewrench\\n4.Withthetorquewrenchinplace,fullyinserttheleadterminalintotheleadport.Theleadterminalpinshouldbeclearly\\nvisiblebeyondtheconnector blockwhenviewedthroughthesideofthepulsegenerator header.Placepressureonthe\\nleadtomaintainitspositionandensurethatitremainsfullyinsertedintheleadport.\\nCAUTION: Inserttheleadterminalstraightintotheleadport.Donotbendtheleadnearthelead-header interface.\\nImproperinsertioncancauseinsulation orconnectordamage.\\nNOTE:Ifnecessary,lubricatetheentireleadterminal(areashowninFigure7DF4LeadTerminalonpage65)sparingly\\nwithsterilewaterorsterilemineraloiltomakeinsertioneasier.\\nFigure7.DF4LeadTerminal\\nNOTE:ForIS-1leads,becertainthattheterminalpinvisiblyextendsbeyondtheconnector blockatleast1mm.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 68}), Document(page_content='66NOTE:ForDF4-LLHH orDF4-LLHO leads,theterminalpinmustbeinsertedbeyondthesetscrewblocktoenablea\\nproperconnection. Visualization oftheterminalpininsertionindicatorbeyondthesetscrewblockmaybeusedtoconfirm\\nthattheterminalpinisfullyinsertedintotheleadport.\\n5.Applygentledownward pressureonthetorquewrenchuntilthebladeisfullyengagedwithinthesetscrewcavity,taking\\ncaretoavoiddamagetothesealplug.Tightenthesetscrewbyslowlyturningthetorquewrenchclockwise, untilit\\nratchetsonce.Thetorquewrenchispresettoapplytheproperamountofforcetothecaptivesetscrew; additional\\nrotationandforceisunnecessary .\\n6.Removethetorquewrench.\\n7.Applygentletractiontotheleadtoensureasecureconnection.\\n8.Iftheleadterminalisnotsecure,attempttoreseatthesetscrew.Reinsertthetorquewrenchasdescribed above,and\\nloosenthesetscrewbyslowlyturningthewrenchcounterclockwise, untiltheleadisloose.Thenrepeatthesequence\\nabove.\\n9.Ifaleadportisnotused,insertaplugintotheunusedportandtightenthesetscrew.\\nCAUTION: Theabsenceofaleadorpluginaleadportmayaffectdeviceperformance andpotentially leavethe\\npatientwithouteffectivetherapy.Ifaleadisnotused,verifythattheplugandlabeledheaderportmatch(i.e.,IS-1,DF-1,\\norDF4).Fullyinserttheplugintheunusedportandthentightenthesetscrewontotheplug.Verifyappropriate device\\nfunctionusingtheprogrammer.\\n•Afunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriat esensingandpacingin\\nallchambers, regardlessofprogrammedconfiguration.ThisincludesdualchamberdevicesprogrammedtoAAI(R).\\n•Lackofafunctional RVleadmayresultinundersensing, and/oroversensing andleavethepatientwithout\\neffectivetherapy.\\nStepG:EvaluateLeadSignals\\n1.Takethepulsegenerator outofpower-savingStoragemodebyprogrammingtheTachyModetoOff.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 69}), Document(page_content=\"67CAUTION: Topreventinappropriate shocks,ensurethatthepulsegenerator's TachyModeisprogrammedtoOffwhennot\\ninuseandbeforehandlingthedevice.Fortachyarrhythmia detection andtherapy,verifythattheTachyModeisprogrammedto\\nMonitor+Therapy.\\n2.Insertthepulsegenerator intotheimplantation pocket.\\n3.Evaluatethepace/senseanddefibrillation leadsignalsbyviewingthereal-timeEGMsandmarkers.Thesignalfromthe\\nimplanted defibrillation leadsshouldbecontinuous andwithoutartifact,similartoabody-surface ECG.Adiscontinuous\\nsignalmayindicateapoorconnection, leadfractureorotherwise damaged lead,oraninsulation breakthatwould\\nnecessitate leadreplacement.Inadequate signalsmayresultinfailureofthepulsegenerator systemtodetectan\\narrhythmia, inabilitytodeliverprogrammedtherapy,orunnecessary deliveryoftherapy.Leadmeasurements should\\nreflectthoseabove(Table12Leadmeasurements onpage59).\\nCAUTION: Takecaretoensurethatartifactsfromtheventricles arenotpresentontheatrialchannel,oratrialoversensing\\nmayresult.Ifventricular artifactsarepresentintheatrialchannel,theatrialleadmayneedtoberepositioned tominimizeits\\ninteraction.\\n4.Evaluateallleadimpedances.\\nCAUTION: Iftotalshockingleadimpedance duringimplantislessthan20Ω,verifytheproximalcoilisnotincontactwith\\nthepulsegenerator surface.Ameasurement oflessthan20Ωisanindication ofashortsomewhere inthesystem.Ifrepeated\\nmeasurements showthetotalshockingleadimpedance islessthan20Ω,theleadand/orpulsegenerator mayneedtobe\\nreplaced.\\nTheHighImpedance Limitisnominally setto2000Ω,andisprogrammable between2000and3000Ωin250Ωincrements.\\nTheLowImpedanceLimitisnominally setto200Ω,andisprogrammable between200and500Ωin50Ωincrements.\\nConsiderthefollowing factorswhenchoosingavaluefortheimpedance limits:\\n•Forchronicleads,historicalimpedance measurements forthelead,aswellasotherelectricalperformance indicators such\\nasstabilityovertime\\n•Fornewlyimplanted leads,thestartingmeasured impedance value\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 70}), Document(page_content=\"68NOTE:Depending onleadmaturation effects,duringfollow-up testingthephysician maychoosetoreprogramthe\\nimpedancelimits.\\n•Pacingdependenc eofthepatient\\n•Recommended impedancerangeforthelead(s)beingused,ifavailable\\nTheShockLowImpedance Limitisfixedat20Ω.TheShockHighImpedance Limitisnominally setto125Ω,andis\\nprogrammable between125and200Ωin25Ωincrements. Considerthefollowing factorswhenchoosingavaluefortheHigh\\nImpedanceLimits:\\n•Forchronicleads,historicalimpedance measurements forthelead,aswellasotherelectricalperformance indicators such\\nasstabilityovertime\\n•Fornewlyimplanted leads,thestartingmeasured impedance value\\nNOTE:Depending onleadmaturation effects,duringfollow-up testingthephysician maychoosetoreprogramtheHigh\\nImpedanceLimits.\\n•Recommended impedancerangeforthelead(s)beingused,ifavailable\\n•Theimpedance valueofahighormaximum energyshockimpedance test\\nShockingleadimpedance readingsbetween20ΩandtheprogrammedHighImpedance Limitareconsideredin-range.Ifabrupt\\norlargeimpedance fluctuations orout-of-range conditions areobserved, considerthefollowing:\\n•Verifytheconfiguration—ensure theprogrammedShockVectormatchestheconfigurationoftheimplanted lead(e.g.,\\nuseRVCoiltoCanwithasingle-coil lead).\\n•Verifytheconnection—ensur etheshockinglead'sterminalpinsareplacedinthecorrectleadportsandverifyasecure\\nleadconnection.\\n•Verifythecontact—ensur ethedeviceisinsideawetimplantpocketsincethepulsegenerator caseservesasanactive\\nelectrode intheV-TRIADconfiguration.Avoidpocketmanipulation duringthetest.\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 71}), Document(page_content='69•Turnoffsourcesofexternalnoise(e.g.,electrocautery equipment, monitors).\\n•Useothertroubleshooting tools,asneeded,tofurtherassessleadsystemintegrity,includingelectrogramanalysis,X-ray\\norfluoroscopicimagereview,orinternalvisualinspection.\\nNOTE:Becausethisdeviceusesasubthreshold testpulsetoconductshockleadimpedance measurements, itcanbedifficult\\ntomeasureresponses totestsignalswhenelectricalinterferenc eor“noise”(e.g.,electrocautery orexternalmonitoring\\nequipment attacheddirectlytothepatient)ispresentduringthetest.Thismayresultinimpedance measurement variations,\\nparticularly atimplant.Intheabsenceofsuchelectricalinterferenc e,shockleadimpedance readingswillbemorestable.\\nStepH:ProgramthePulseGenerator\\n1.ChecktheProgrammerClockandsetandsynchroniz ethepulsegenerator asnecessary sothatthepropertimeappears\\nonprintedreportsandPRMstripchartrecordings.\\n2.ItmaybeusefultoprogramtheBeepDuringCapacitorChargefeaturetoOnduringconversion testingandimplantation\\ntohelprecognizewhenthepulsegenerator ischargingtodeliverashock.\\n3.Performamanualcapacitorre-formation ifnotalreadyperformed.\\n4.Programthepulsegenerator appropriately ifaleadport(s)isnotused.\\n5.Programthepulsegenerator todesiredparametersappropriat eforthepatientforconversion testing.\\nConsiderthefollowing whenprogrammingthepulsegenerator:\\n•Theminimum 2Xvoltageor3Xpulsewidthsafetymarginisrecommended foreachchamberbasedonthecapture\\nthresholds, whichshouldprovideanadequate safetymarginandhelppreservebatterylongevity.\\n•WhenSmartBlankingisused,itispossiblethatpolarization artifactsfollowing atrialpacingmaybedetectedasR-waves\\nandinhibitventricular pacing(aftertachytherapyorhigh-output ventricular pacing).Ifthepatientispacemaker-\\ndependent, testforpropersensingaftershocktherapy.Ifoversensing isoccurringpost-shock,bepreparedtousethe\\nSTATPACEcommand.\\n•Programmingalongerblankingperiodmayincreasethelikelihood ofundersensing R-waves.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 72}), Document(page_content='70•Programmingashorterblankingperiodmayincreasethelikelihood forventricular oversensing ofanatrialpacedevent.\\n•Toreducetheriskofventricular undersensing duetoV-BlankafterA-Pace(whenadual-chamber pacingmodewithRate\\nSmoothing orRateAdaptivePacingisnecessary):\\n–ReducetheLRL\\n–ShortentheAVDelayoruseDynamicAVDelayandreducetheminimum DynamicAVDelaysetting\\n–ReducetheSearchAVDelayforAVSearch+\\n–IncreasetheDownRateSmoothing percentagetothelargestpossiblevalue\\n–DecreasetheRecoveryTimeforRateAdaptivePacingmodes\\n–ReducetheMTRorMPRifDownRateSmoothing ison\\n–ReducetheMSRifthepacingmodeisrateadaptive\\n•Whenreprogramming theRhythmMatch Threshold value,considerthefollowing:\\n–Reviewthemeasured RhythmMatch valuesforpreviousepisodesofVTandSVT(inducedorspontaneous)\\n–Toincreasethelikelihood ofappropriate treatment ofVT,theRhythmMatch Threshold shouldbeprogrammed\\nabovethemeasured RhythmMatch valuesofanyVTs\\n–Toincreasethelikelihood ofappropriate inhibition oftherapyforSVT,theRhythmMatch Threshold shouldbe\\nprogrammedbelowthemeasured RhythmMatch valuesofanySVTs\\n–Ingeneral,thesensitivity ofVTdetection declineswithlowerprogrammedRhythmMatch Threshold values,\\nthereforeformaximum sensitivity toVT,thehighestappropriate RhythmMatch Threshold valueshouldbe\\nprogrammed.\\n–Measured RhythmMatch valuesmayalsobeusefulforprogrammingotherRhythmIDparametersincludingAtrial\\nTachyarrhythmia Discrimination, AFibRateThreshold, andStability', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 73}), Document(page_content=\"71•WhenprogrammingMTR,considerthepatient’scondition, age,generalhealth,sinusnodefunction,andthatahighMTR\\nmaybeinappropriateforpatientswhoexperience anginaorothersymptoms ofmyocardial ischemiaathigherrates.\\n•WhenprogrammingMSR,considerthepatient’scondition, age,generalhealthandthatadaptive-rat epacingathigher\\nratesmaybeinappropriate forpatientswhoexperienceanginaorothersymptoms ofmyocardial ischemiaatthese\\nhigherrates.Anappropriate MSRshouldbeselectedbasedonanassessment ofthehighestpacingratethatthepatient\\ncantoleratewell.\\n•ProgramminglongAtrialRefractory periodsincombination withcertainAVDelayperiodscancause2:1blocktooccur\\nabruptlyattheprogrammedMTR.\\n•PriortoprogrammingRVATon,considerperforming aCommanded Ventricular Automatic Threshold Measurement to\\nverifythatthefeaturefunctionsasexpected.\\n•Inpacemaker-dependent patients,usecarewhenconsidering settingNoiseResponse toInhibitPacingaspacingwillnot\\noccurinthepresenceofnoise.\\n•Toresolvesuspected impedance-basedinteractions withtheMV/Respiratory Sensor,programthesensortoOff.\\nCAUTION: Topreventinappropriate shocks,ensurethatthepulsegenerator's TachyModeisprogrammedtoOffwhennot\\ninuseandbeforehandlingthedevice.Fortachyarrhythmia detection andtherapy,verifythattheTachyModeisprogrammedto\\nMonitor+Therapy.\\nStepI:TestforAbilitytoConvertVentricular Fibrillation andInducibleArrhythmias\\nAfterobtaining acceptablesignalsfromtheimplanted leads,thephysician maychoosetoperformVTandVFconversion testing\\ntodetermine (1)iftheconfigurationandpositionoftheimplanted leadsareappropriate forthepatientand(2)ifthepulse\\ngenerator’s programmedshockenergyormaximum-shock energywillbesufficienttoconvertarrhythmias reliablyand(3)if\\nAGCanddetection enhancements areprogrammedappropriately todetectVF/VT.Aconversion testconsistsofinducingthe\\narrhythmia andthenattempting toconvertthearrhythmia withapreselected energylevel.\\nDemonstrating conversion ofventricular fibrillation issuggested beforeimplanting apulsegenerator becauseashockdelivered\\nduringventricular tachycardia hasthepotentialtoacceleratethearrhythmia. Intraopera tivetestingmaybeminimized by\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 74}), Document(page_content=\"72performing onlyVFtestingattimeofimplantandperforming VTtestingpost-operatively intheelectrophysiology labpriorto\\nthepatient’sdischarge.\\nIftheconversion isunsuccessful,thepatientshouldberescuedusinganappropriate externaldefibrillator .Aspartoftheoverall\\nclinicalevaluation duringconversion testingandevaluation ofspontaneous episodesduringfollowup,ensurethereisnodelay\\norinterruption intachyarrhythmia detection andtherapydelivery.Performadditional evaluation ifanydiversionofcharging\\ncyclesorshockdeliveryisobserved.\\nIfconversion testingisperformed, thepermanently programmedparameters maybethesameasthoseusedduringtesting,or\\ntheymaybemodifiedtodifferentvalues.Thedevicecanbeprogrammedwiththeintendedfinalparameter settingsforallVT/\\nVF(multiplezones),orwithasinglezoneVFsettingwitharatethreshold belowthatofanyknownarrhythmia. Whenno\\nconversiontestingisperformed inpatientswithprimaryprevention indications, aphysician shouldconsiderthathighdetection\\nratescanlimittheabilityofthedevicetoaccuratelydetectandtreatpolymorphic tachyarrhythmias. Itisimportant toevaluate\\nthedevice'sstoreddiagnostic dataandEGMs,includingtheintervalplot,afterconversion testing(referto“Tachyarrhythmia\\nProgramming Considerations”below).Programmingfinalratethresholds forVT/VFtohighervalues,orlesssensitiveAGC\\nsettings,thanthetestedparameters mayresultinunder-detection oflaterspontaneous tachyarrhythmias.\\nWARNING: Alwayshaveexternaldefibrillation equipment availableduringimplantandelectrophysiologic testing.Ifnot\\nterminated inatimelyfashion,aninducedventricular tachyarrhythmia canresultinthepatient'sdeath.\\nNOTE:Ifopenchestsurgeryisperformed andachestretractorisused,removeitbeforeconversion testingtobestsimulate\\ntheambulatory conditionsinwhichthepulsegenerator willoperateandtoavoidpotentialshuntingofenergy.\\nInducethePatient’sArrhythmia\\nAnarrhythmia canbeinducedbyusingtheinduction featuresofthepulsegenerator.\\nAllowthepatient’sbloodpressureandelectrophysiologic statustoreturntobaselinebetweenarrhythmia inductions, whether\\nsuccessfulorunsuccessful.Theminimum timebetweenconversion testsshouldbebasedontheclinical(hemodynamic and\\nmetabolic) stabilityofthepatientandthephysician’s discretion.\\nDuringeacharrhythmia induction, notetheheartratetodetermine theappropriate ratethreshold values.Ventricular cycle\\nlengthsthatoccurclosetobutbelowthelowestprogrammedratethresholdvaluemaybedetectedasnormalsinusrhythm.To\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 75}), Document(page_content='73providesufficientopportunity fordetection, theratethreshold value(s)shouldbeprogramm edatleast10bpmbelowtherate\\nofthearrhythmia(s) intendedtobetreated.\\nPerformtheInduction\\n1.Verifythepulsegenerator isintheimplantation pocket.Temporarily closethepocketenoughtoensurethatthepulse\\ngenerator willremaininpositionduringconversion testing.Makesurethepulsegenerator hasgoodcontactwith\\nsurrounding tissue;flushthepocketwithsalinesolution,ifnecessary,toavoidadrypocket.\\nCAUTION: Donotallowanyobjectthatiselectrically conductive tocomeintocontactwiththeleadordeviceduring\\ninduction becauseitmayshuntenergy,resultinginlessenergygettingtothepatient,andmaydamagetheimplanted system.\\n2.Verifymagnetfunctionandtelemetry toensurethepulsegenerator iswithinacceptablerange.\\n3.Programtheappropriate parameters andchangethepulsegenerator TachyModetoMonitor+Therapy.\\n4.Performtheinduction usingtheprogrammer.\\nTestingEnergyRequirements andThresholds forSuccessfulDefibrillation\\nDefibrillation energyrequirementsandthreshold testingforsuccessfuldefibrillation shouldbeperformed atimplant.\\nShocksintendedforVForpolymorphic VTtherapyshouldbeprogrammedwitha10Jsafetymarginabovetheshockenergy\\nlevelthatthephysician determines isrequiredforsuccessfulVFconversion. Insomesituations, analternative safetymargin\\n(abovetheshockenergylevelrequiredforsuccessfulVFconversion) maybedetermined bythephysician tobeadequate.\\nDifferenttestmethodsfordetermining defibrillation thresholds aredescribed inclinicalliteratureandinclude,butarenot\\nlimitedto:\\n•Steppingdowntofailuredefibrillation threshold testingtodetermine theDFTandverifyingthelastsuccessfulenergy\\neitheronce[1x(DFT+)]ortwice[2x(DFT++)].\\n•Selectingthedefibrillation energyrequirement testingbysubtracting theacceptedsafetymarginfromthedevice\\nmaximum output.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 76}), Document(page_content='74Defininganimplantation safetymarginandtherelationship totheprobabilityforsuccessisdescribed inclinicalliterature.Any\\nresultfromasingletestmethodmaybeanexampleofstatistical variation, andaone-timeconversion ofarhythmdisturbance\\nataparticular energyleveldoesnotguaranteeorensurethattheenergylevelisreliableforconversion.\\nAsasafetymarginwitha41Jsystem,itisrecommended thattheconversion testbeperformed attheDFTleveltwotimesif\\ntheDFTorselectedenergylevelis31J,oronetimeiftheDFTorselectedenergylevelis21Jwithnofailurestoconvert.\\nAlwayshaveastandardexternaldefibrillator withexternalpadsorpaddlesavailableforuseduringdefibrillation threshold\\ntesting.\\nIfimplantation safetymarginandinitialconversion at31Jisunsuccessful,consideracombination ofdifferentmethodsto\\noptimizethedefibrillation fieldandefficacy.Possibilities include,butarenotlimitedto:\\n•Optimizetheleadposition—placetheleadasapicalandseptalaspossibletodirectmostoftheenergytotheleft\\nventricular massasdescribed inclinicalliterature.\\n•Reversepolarity—useelectronic deviceprogrammingoptionstochangepolarity.Donotphysically switchthelead\\nanodesandcathodesinthepulsegenerator header.\\n•ReprogramtheShockLeadVectorconfigurationinthedevice(e.g.,removetheproximalcoilfromaTRIADconfiguration\\ntoasingleshockvectorsuchastheRVCoiltoCanconfiguration).\\n•Addadditional defibrillation coilsorleadstoincreasethedefibrillation surfacearea.\\nNOTE:RefertoTable12Leadmeasurements onpage59foracceptableleadmeasurements afterleadrepositioning or\\nreprogramming.\\nStepJ:Tachyarrhythmia Programming Considerations\\nDetection Zones\\nSelecttheappropriate numberoftherapyzones(VT-1,VT,VF)totreattheexpectedventricular tachyarrhythmias basedonthe\\ntachyarrhythmia hemodynamic stability,patientindications, andtheindividual patientclinicalcharacteris tics.Toprovide', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 77}), Document(page_content='75sufficientopportunity fordetection, theratethreshold value(s)shouldbeprogrammedatleast10bpmbelowtherateofknown\\narrhythmia(s) intendedtobetreated.\\nNOTE:Thedevicedetection andsubsequent therapymaybedifferentforthesameunderlying tachyarrhythmia depending on\\nthenumberofzonesandprogrammedparameters suchasratethreshold, detection time,anddetection enhancements (if\\napplied).\\nEpisodeStorageReview\\nDevicediagnostics arestoredinthepulsegenerator andareviewableviathePRMorLATITUDE NXT.Diagnostics enablea\\nreviewofdevicedetection andresponsetoinducedandspontaneous tachyarrhythmias. Storedelectrogramsincludeaninterval\\nplot.Evaluating theintervalplothelpstoidentifydetectedbeatsincludingthosebelowtheratethreshold. Beatsbelowthe\\nprogrammedratethreshold maydelayorinhibitdevicedetection ofatachyarrhythmia, andconsiderationshouldbegivento\\nreprogramtheratestoimprovedetection. Inspection ofthestoredelectrograms,withuseoftheon-screen calipersforEGM\\namplitude andtimingmeasurement, permitsthephysician tointerpretwhetherthereareventricular beatswhicharenot\\ndetected. Ifthereareunmarked beats,thenanassessment shouldoccurtodetermine ifprogrammingslowerratezoneswould\\nimprovedetection.\\nDetection andAutomatic GainControl(AGC)\\nTherightventricular AGCissettoanominalvalueof0.6mVandcanbeadjustedusingthePRM.Adjustment oftheAGCmay\\nbeconsideredforcaseswithlowamplitude EGMs,delayintimetotherapy,orperthephysician’s discretion inindividual cases.\\nAnyadjustment oftheAGCmustbeevaluated incombination withtheprogrammeddetection ratethresholds/z onestoensure\\nappropriate ratedetection oftheexpectedtachyarrhythmia. TheAGCmaynotreachitsprogrammedfloorwhen\\ntachyarrhythmia detection ratesarerapidandthearrhythmia ispolymorphic. Alwaysevaluatetherateofthedetection zones\\nandtheAGCsettingincombinationusingtheepisodestorageinformation. Ifaphysician examines theEGMsandbelievesthe\\ndeviceisnotdetecting ventricular beat(s)intheappropriat ezone,thenreprogrammingdetection ratethresholds toslowerrates\\nmayfacilitatetheoveralldetection behavior.Adjusting theAGCwithconversion testingmaybeconsidered.Changesinthe\\npatient’smetabolic state,alongwithprescription drugs,mayaffectthesizeofthewaveform ontheEGM.AGCreprogramming\\nmaynotbenecessary whenmarkersindicatedevicesensingisappropriate, butthesensedintervalsarebelowtheratecriteria.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 78}), Document(page_content='76Markers\\nMarkerssuchasVT-1,VT,andVF,includingthemeasured cyclelength,arerecordedandassociated withtheprogrammed\\ndetection zones.Thepresenceofmarkersindicatesthatthedevicehasdetectedacertainbeat.Fluctuating tachycardiarates\\nthatarecloseto,orjustbelow,thelowestratethreshold maybemarkedasVS(ventricular sense).Reviewoftheintervalplot\\nprovidesanoverviewoftheprogrammedratethresholds andintervaldistribution duringtheepisodes. Thisinformation enables\\nclinicaladjustment ofdetection parameters perthephysician’s discretion.\\nStepK:ImplantthePulseGenerator\\n1.ProgramtheTachyModetoOff.\\n2.Verifymagnetfunctionandwandedtelemetry toensurethepulsegenerator iswithinacceptablerangetoinitiate\\ninterrogation.\\n3.Ensurethatthepulsegenerator hasgoodcontactwithsurrounding tissueoftheimplantation pocket,andthensutureit\\ninplacetominimizedevicemigration(forsutureholelocationillustrations,referto\"LeadConnections\" onpage52).\\nGentlycoilexcessleadandplaceadjacenttothepulsegenerator.Flushthepocketwithsalinesolution,ifnecessary,to\\navoidadrypocket.\\nWARNING: Donotkink,twist,orbraidtheleadwithotherleadsasdoingsocouldcauseleadinsulation abrasion\\ndamageorconductor damage.\\n4.Closetheimplantation pocket.Considerationshouldbegiventoplacetheleadsinamannertopreventcontactwith\\nsuturematerials. Itisrecommended thatabsorbable suturesbeusedforclosureoftissuelayers.\\n5.Complete anyelectrocautery proceduresbeforereactivating thepulsegenerator.\\n6.ProgramtheTachyModetothedesiredsettingandconfirmfinalprogrammedparameters.\\nCAUTION: Following anysensingrangeadjustment oranymodification ofthesensinglead,alwaysverifyappropriate\\nsensing.Programming Sensitivity tothehighestvalue(lowestsensitivity) mayresultindelayeddetection or\\nundersensing ofcardiacactivity.Likewise,programmingtothelowestvalue(highestsensitivity) mayresultin\\noversensing ofnon-cardiac signals.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 79}), Document(page_content=\"777.UsethePRMtoprintoutparameter reportsandsaveallpatientdata.\\nStepL:Complete andReturntheImplantation Form\\nWithintendaysofimplantation, completetheWarrantyValidation andLeadRegistration formandreturntheoriginaltoBoston\\nScientificalongwithacopyofthepatientdatasavedfromthePRM.Thisinformation enablesBostonScientifictoregistereach\\nimplanted pulsegenerator andsetofleads,andprovideclinicaldataontheperformance oftheimplanted system.Keepacopy\\noftheWarrantyValidation andLeadRegistration formandprogrammerprintouts, andtheoriginalpatientdataforthepatient's\\nfile.\\nComplete thetemporary patientidentification cardandgiveittothepatient.Afterreceivingthevalidation form,Boston\\nScientificsendsthepatientapermanent identification card.\\nBIDIRECTIONAL TORQUEWRENCH\\nAtorquewrench(model6628)isincludedinthesteriletraywiththepulsegenerator,andisdesignedfortightening and\\nloosening #2-56setscrews, capturedsetscrews,andsetscrews onthisandotherBostonScientificpulsegenerators andlead\\naccessoriesthathavesetscrews thatspinfreelywhenfullyretracted(thesesetscrews typicallyhavewhitesealplugs).\\nThetorquewrenchisbidirectional, ispresettoapplyadequate torquetothesetscrew,andwillratchetwhenthesetscrewis\\nsecure.Theratchetreleasemechanism preventsovertightening thatcouldresultindevicedamage.Tofacilitatetheloosening of\\ntightextended setscrews,thiswrenchappliesmoretorqueinthecounterclockwise directionthanintheclockwise direction.\\nNOTE:Asanadditional safeguard, thetipofthetorquewrenchisdesignedtobreakoffifusedtoovertighten beyondpreset\\ntorquelevels.Ifthisoccurs,thebrokentipmustbeextractedfromthesetscrewusingforceps.\\nThistorquewrenchmayalsobeusedforloosening setscrews onotherBostonScientificpulsegenerators andleadaccessories\\nthathavesetscrews thattightenagainstastopwhenfullyretracted(thesesetscrews typicallyhaveclearsealplugs).However,\\nwhenretractingthesesetscrews,stopturningthetorquewrenchwhenthesetscrewhascomeincontactwiththestop.The\\nadditional counterclockwise torqueofthiswrenchmaycausethesesetscrews tobecomestuckiftightened againstthestop.\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 80}), Document(page_content='78Loosening StuckSetscrews\\nFollowthesestepstoloosenstucksetscrews:\\n1.Fromaperpendicular position,tiltthetorquewrenchtotheside20ºto30ºfromtheverticalcenteraxisofthesetscrew\\n(Figure8Rotatingthetorquewrenchtoloosenastucksetscrewonpage79).\\n2.Rotatethewrenchclockwise (forretractedsetscrew) orcounterclockwise (forextendedsetscrew) aroundtheaxisthree\\ntimes,suchthatthehandleofthewrenchorbitsthecenterline ofthescrew(Figure8Rotatingthetorquewrenchto\\nloosenastucksetscrewonpage79).Thetorquewrenchhandleshouldnotturnortwistduringthisrotation.\\n3.Asneeded,youmayattemptthisuptofourtimeswithslightlymoreangleeachtime.Ifyoucannotfullyloosenthe\\nsetscrew,usethe#2torquewrenchfromWrenchKitModel6501.\\n4.Oncethesetscrewhasbeenfreed,itmaybeextended orretractedasappropriate.\\n5.Discardthetorquewrenchuponcompletion ofthisprocedure.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 81}), Document(page_content='79\\n20°–30°[1]Clockwise rotationtofreesetscrews stuckintheretractedposition[2]Counterclockwise rotationtofreesetscrews stuckinthe\\nextended position\\nFigure8.Rotatingthetorquewrenchtoloosenastucksetscrew\\nFOLLOWUPTESTING\\nItisrecommended thatdevicefunctionsbeevaluated withperiodicfollow-up testingbytrainedpersonnel. Followupguidance\\nbelowwillenablethorough reviewofdeviceperformance andassociated patienthealthstatusthroughout thelifeofthedevice\\n(refertotheinformation withinthe“ProgramthePulseGenerator”stepin\"Implanting thePulseGenerator\" onpage55).\\nWARNING: Ensurethatanexternaldefibrillator andmedicalpersonnel skilledinCPRarepresentduringpost-implantdevice\\ntestingshouldthepatientrequireexternalrescue.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 82}), Document(page_content='80Predischar geFollowUp\\nThefollowing proceduresaretypicallyperformed duringthepredischar gefollowuptestusingPRMtelemetry:\\n1.Interrogate thepulsegenerator andreviewtheSummary screen.\\n2.Verifypacingthresholds,leadimpedance, andamplitude ofintrinsicsignals.\\n3.Reviewcountersandhistograms.\\n4.Whenalltestingiscomplete, performafinalinterrogation andsaveallthepatientdata.\\n5.PrinttheQuickNotesandPatientDatareportstoretaininyourfilesforfuturereference.\\n6.Clearthecountersandhistograms sothatthemostrecentdatawillbedisplayed atthenextfollowupsession.Counters\\nandhistograms canbeclearedbypressingResetontheHistogram screen,TachyCountersscreen,orBradyCounters\\nscreen.\\nRoutineFollowUp\\nYoushouldconductroutinefollowupexaminations onemonthafterthepredischar gecheckandeverythreemonthsthereafter\\ntoevaluatedeviceprogramming,therapyeffectiveness, leadstatus,andbatterystatus.Officevisitsmaybesupplemented by\\nremotemonitoring whereavailable.\\nNOTE:Becausethedurationofthedevicereplacementtimeristhreemonths(startingwhenExplantstatusisreached),three\\nmonthfollowupfrequency isparticularly important aftertheOneYearRemaining statusisreached.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 83}), Document(page_content='81Considerperforming thefollowing proceduresduringaroutinefollow-up test:\\n1.Interrogate thepulsegenerator andreviewtheSummary screen.\\n2.Verifypacingthresholds, leadimpedance, andamplitude ofintrinsicsignals.\\n3.PrinttheQuickNotesandPatientDatareportstoretaininyourfilesforfuturereference.\\n4.ReviewtheArrhythmia Logbookscreenandforepisodesofinterest,printepisodedetailsandstoredelectrogram\\ninformation.\\n5.Clearthecountersandhistograms sothatthemostrecentepisodedatawillbedisplayed atthenextfollow-up session.\\n6.Verifythatimportant programmedparameter values(e.g.,LowerRateLimit,AVDelay,RateAdaptivePacing,output\\nAmplitude, PulseWidth,Sensitivity ,Ventricular Zones,Detection Rate)areoptimalforcurrentpatientstatus.Refertothe\\nstepsabove(“TestforAbilitytoConvertVentricular Fibrillation andInducibleArrhythmias” and“Tachyarrhythmia\\nProgrammingConsiderations”) foradditional information onprogrammingtachyarrhythmia detection andtherapy\\n(\"Implanting thePulseGenerator\" onpage55).\\nNOTE:Echo-Doppler studiesmaybeusedtonon-invasively evaluateAVDelayandotherprogrammingoptionspost-implant.\\nCAUTION: SuccessfulVForVTconversion duringarrhythmia conversion testingisnoassurancethatconversion willoccur\\npost-operatively .Beawarethatchangesinthepatient\\'scondition, drugregimen,andotherfactorsmaychangetheDFT,which\\nmayresultinnonconversion ofthearrhythmia post-operatively .\\nEXPLANTATION ANDDISPOSAL\\nWARNING: Donotreuse,reprocess,orresterilize.Reuse,reprocessing,orresterilization maycompromisethestructural\\nintegrityofthedeviceand/orleadtodevicefailurewhich,inturn,mayresultinpatientinjury,illness,ordeath.Reuse,\\nreprocessing,orresterilization mayalsocreateariskofcontamination ofthedeviceand/orcausepatientinfectionorcross-\\ninfection, including, butnotlimitedto,thetransmission ofinfectious disease(s) fromonepatienttoanother.Contamination of\\nthedevicemayleadtoinjury,illness,ordeathofthepatient.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 84}), Document(page_content=\"82NOTE:Returnallexplanted devicestoBostonScientificregardlessofcondition. Examination ofexplanted devicescanprovide\\ninformation forcontinued improvement insystemreliabilityandwarrantyconsiderations.ForaReturnedProductKit,contact\\nBostonScientificusingtheinformation onthebackcover.\\nContactBostonScientificwhenanyofthefollowing occur:\\n•Whenaproductisremovedfromservice.\\n•Intheeventofpatientdeath(regardlessofcause),alongwithanautopsyreport,ifperformed.\\n•Forotherobservation orcomplication reasons.\\nConsiderthefollowing itemswhenexplanting andreturning devices:\\n•Interrogate thepulsegenerator andprintacomprehensivereport.\\n•Deactivate thepulsegenerator beforeexplantation.\\n•Disconnect theleadsfromthepulsegenerator.\\n•Ifleadsareexplanted,attempttoremovethemintact,andreturnthemregardless ofcondition. Donotremoveleads\\nwithhemostats oranyotherclampingtoolthatmaydamagetheleads.Resorttotoolsonlyifmanualmanipulation\\ncannotfreethelead.\\n•Wash,butdonotsubmerge, thedevicestoremovebodyfluidsanddebrisusingadisinfectant solution.Donotallow\\nfluidstoenterthepulsegenerator's headerport(s).\\n•UseaBostonScientificReturnedProductKittoproperlypackagethedevices,andsendittoBostonScientific.\\nCAUTION: Cleananddisinfectthedeviceusingstandardbiohazard handlingtechniques sinceallexplantedcomponents are\\nconsideredbiohazardous.\\nNOTE:Discolorationofthepulsegenerator mayhaveoccurredduetoanormalprocessofanodization, andhasnoeffecton\\nthepulsegenerator function.\\nCAUTION: Besurethatthepulsegenerator isremovedbeforecremation. Cremationandincineration temperatur esmight\\ncausethepulsegenerator toexplode.\", metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 85}), Document(page_content='83CAUTION: Beforeexplanting, cleaning,orshippingthedevice,completethefollowing actionstopreventunwanted shocks,\\noverwriting ofimportant therapyhistorydata,andaudibletones:\\n•Programthepulsegenerator TachyandBradyModestoOff.\\n•ProgramtheMagnetResponse featuretoOff.\\n•ProgramtheBeepwhenExplantisIndicatedfeaturetoOff.\\n•ProgramtheBeepWhenOut-of-Range featuretoOff.\\nAllitemsusedduringexplantation, suchasaccessories,consumables, andsharps,maybecontaminated withinfectious\\nsubstances. Considerthefollowing tominimizetheriskofinfection, microbialhazards,orphysicalharm:\\n•Biohazardous wasteshouldbedisposedinabiohazard containerthatislabeledwiththebiological hazardsymboland\\ntakentoadesignated facilityforbiohazardous wasteforpropertreatment inaccordancewithhospital,administrative,\\nand/orlocalgovernment policy.\\n•Biohazardous wasteshouldbetreatedwithanappropriate thermalorchemicalprocess.\\n•Sharpsshouldbedisposedofinasharpsdisposalcontainer.\\nNOTE:Disposalofexplanted devicesissubjecttoapplicable lawsandregulations.\\nNOTE:Untreatedbiohazardous wasteshouldnotbedisposedofinamunicipal wastesystem.', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 86}), Document(page_content='', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 87}), Document(page_content='', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 88}), Document(page_content='Foradditional referenceinformation, gotowww.\\nbostonscientific -elabeling.com.\\nBostonScientificCorporation\\n4100HamlineAvenueNorth\\nSt.Paul,MN55112–5798 USA\\nwww.bostonscientific.com\\n1.800.CARDIAC (227.3422)\\n+1.651.582.4000\\n©2021BostonScientificCorporation oritsaffiliates.\\nAllrightsreserved.\\n51114084-001 ENUS2021-08\\n*51114084-001*', metadata={'source': 'raw_data/_51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 89}), Document(page_content='PHYSICIAN’S TECHNICAL MANUAL\\nRESONATE™HFCRT-D,\\nRESONATE™CRT-D,\\nRESONATE™X4CRT-D,\\nVIGILANT™CRT-D,\\nVIGILANT™X4CRT-D,\\nMOMENTUM™CRT-D,\\nMOMENTUM™X4CRT-D\\nCARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR\\nREFG524,G525,G526,G528,G537,G547,G548,G424,G425,G426,G428,G437,G447,G448,\\nG224,G225,G228,G237,G247,G248,G124,G125,G126,G128,G138\\nCAUTION: Federallaw(USA)restricts\\nthisdevicetosalebyoronthe\\norderofaphysician trainedor\\nexperiencedindeviceimplantand\\nfollow-up procedures.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 0}), Document(page_content='', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 1}), Document(page_content='TableofContents\\nTrademarkStatement ..........................................................................................................................1\\nAdditional Information .........................................................................................................................1\\nDeviceDescription ...............................................................................................................................1\\nRelatedInformation .............................................................................................................................4\\nIndications andUsage..........................................................................................................................5\\nContraindications................................................................................................................................5\\nWarnings...........................................................................................................................................5\\nPrecautions ........................................................................................................................................8\\nSupplemental Precautionary Information ................................................................................................21\\nPost-TherapyPulseGeneratorFollowUp.......................................................................................21\\nMagnetic Resonance Imaging(MRI).............................................................................................22\\nTranscutaneous ElectricalNerveStimulation (TENS).........................................................................25\\nElectrocautery andRadioFrequency (RF)Ablation...........................................................................26\\nIonizingRadiation .....................................................................................................................27\\nElevatedPressures...................................................................................................................28\\nPotentialAdverseEvents....................................................................................................................30\\nMechanical Specifications. ...................................................................................................................33\\nItemsIncludedinPackage...................................................................................................................37\\nSymbolsonPackaging .......................................................................................................................38\\nCharacteristics asShipped...................................................................................................................42\\nX-RayIdentifier.................................................................................................................................44\\nFederalCommunications Commission (FCC)............................................................................................45\\nPulseGenerator Longevity ..................................................................................................................45\\nWarrantyInformation .........................................................................................................................50\\nProductReliability .............................................................................................................................50\\nPatientCounseling Information .............................................................................................................51', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 2}), Document(page_content='PatientHandbook ....................................................................................................................52\\nLeadConnections ..............................................................................................................................53\\nImplanting thePulseGenerator...........................................................................................................58\\nCheckEquipment .....................................................................................................................59\\nInterrogate andCheckthePulseGenerator....................................................................................59\\nImplanttheLeadSystem...........................................................................................................60\\nTakeBaselineMeasurements. .....................................................................................................62\\nFormtheImplantation Pocket.....................................................................................................65\\nConnecttheLeadstothePulseGenerator .....................................................................................66\\nEvaluateLeadSignals................................................................................................................71\\nProgramthePulseGenerator ......................................................................................................73\\nTestforAbilitytoConvertVentricular Fibrillation andInducible\\nArrhythmias ...................................................................................................................76\\nTachyarrhythmia ProgrammingConsiderations. ..............................................................................79\\nImplantthePulseGenerator. ......................................................................................................80\\nComplete andReturntheImplantation Form..................................................................................81\\nBidirectional TorqueWrench................................................................................................................82\\nFollowUpTesting.............................................................................................................................84\\nExplantation andDisposal...................................................................................................................85', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 3}), Document(page_content='1TRADEMARK STATEMENT\\nThefollowing aretrademarks ofBostonScientificCorporation oritsaffiliates:\\nAcuShock,AVT,CONTAK,CONTAKRENEWAL,EASYVIEW,ENDURALIFE,HeartLogic, IMAGEREADY ,\\nLATITUDE,MOMENTUM, Onset/Stability ,PaceSafe,QuickCapture,QuickConvert,QUICKNOTES,\\nRESONATE,RHYTHMID,RHYTHMMATCH,SafetyCore,SmartBlanking,SmartDelay,VectorGuide,\\nVIGILANT,ZIP,ZOOM,ZOOMVIEW.\\nADDITIONAL INFORMATION\\nForadditional referenceinformation, gotowww.bostonscientific -elabeling.com.\\nDEVICEDESCRIPTION\\nThismanualcontainsinformation abouttheRESONATE HF,RESONATE, VIGILANT, andMOMENTUM familiesofcardiac\\nresynchronization therapydefibrillators (CRT-Ds)(specificmodelsarelistedin\"Mechanical Specifications\" onpage33):\\nNOTE:Thismanualmaycontaininformation formodelnumbersthatarenotcurrentlyapproved forsaleinallgeographies.\\nForacompletelistofmodelnumbersapproved inyourgeography ,consultwithyourlocalsalesrepresentative. Somemodel\\nnumbersmaycontainfewerfeatures;forthosedevices,disregardinformation aboutunavailable features.Referencestonames\\nofnon-quadripolar devicesalsoapplytothecorresponding quadripolar devices.\\nNOTE:AlldevicesexceptforthosewithanLV:LV-1leadconnectionareconsideredMRConditional. Referto\"Magnetic\\nResonance Imaging(MRI)\"onpage22andtheImageReady MRConditional Defibrillation SystemMRITechnical Guideformore\\ninformation.\\nTherapies\\nThesepulsegenerators haveasmall,thin,physiologic shapethatminimizespocketsizeandmayminimize devicemigration.\\nTheyprovideavarietyoftherapies, including:\\n•Ventricular tachyarrhythmia therapy,whichisusedtotreatrhythmsassociated withsuddencardiacdeath(SCD)suchas\\nVTandVF', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 4}), Document(page_content='2•CardiacResynchronization Therapy(CRT),whichtreatsheartfailurebyresynchronizingventricular contractionsthrough\\nbiventricular electricalstimulation\\n•Bradycardiapacing,including adaptiveratepacing,todetectandtreatbradyarrhythmias andtoprovidecardiacrate\\nsupportafterdefibrillation therapy\\nCardioversion/defibrillation therapiesinclude:\\n•Arangeoflow-andhigh-energy shocksusingabiphasicwaveform\\n•Thechoiceofmultipleshockvectors:\\n–Distalshockelectrode toproximalshockelectrode andpulsegenerator case(TRIADelectrode system)\\n–Distalshockelectrode toproximalshockelectrode (RVCoiltoRACoil)\\n–Distalshockelectrode topulsegenerator case(RVCoiltoCan)\\nLeads\\nThepulsegenerator hasindependently programmable outputsandacceptsoneormoreofthefollowing leads,depending on\\nthemodel:\\n•OneIS-11atriallead\\n•OneLV-1unipolarorbipolarleftventricular lead\\n•OneIS-1unipolarorbipolarleftventricular lead\\n•OneIS42quadripolar leftventricular lead\\n•OneDF-1/IS-13cardioversion/defibrillation lead\\n1.IS-1referstotheinternational standardISO5841-3:2013.\\n2.IS4referstotheinternational standardISO27186:2010.\\n3.DF-1referstotheinternational standardISO11318:2002.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 5}), Document(page_content=\"3•OneDF4-LLHH orDF4-LLHO4multipolar connector cardioversion/defibrillation lead\\nLeadswitheitheraGDT-LLHH/LLHO orDF4-LLHH/LLHO labelareequivalent andarecompatible withadevicecontaining either\\naGDT-LLHH orDF4-LLHH port.\\nThepulsegenerator andtheleadsconstitute theimplantable portionofthepulsegenerator system.\\nNOTE:UseofBostonScientificMRConditional leadsisrequiredforanimplanted systemtobeconsideredMRConditional.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnical Guideformodelnumbersofpulsegenerators,\\nleads,accessories,andothersystemcomponents neededtosatisfytheConditions ofUse.\\nProgramming System\\nThesepulsegenerators canonlybeusedwiththeModel3300LATITUDE ProgrammingSystem.TheLATITUDE Programming\\nSystemistheexternalportionofthepulsegenerator system.\\nNOTE:The2868softwareapplication onthemodel3120LATITUDE programmingsystemisoutdated andshouldnotbeused\\nwiththepulsegenerators. Forassistance, call+1.651.582.4000 (worldwide) orcontactyourlocalBostonScientificrepresentative.\\nThe3300LATITUDE ProgrammingSystemincludes:\\n•Model3300Programmer\\n•Model3868SoftwareApplication\\n•Model6395AccessoryTelemetry Wand\\nYoucanusetheprogrammingsystemtodothefollowing:\\n•Interrogate thepulsegenerator\\n•Programthepulsegenerator toprovideavarietyoftherapyoptions\\n•Accessthepulsegenerator's diagnostic features\\n4.DF4referstotheinternational standardISO27186:2010.\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 6}), Document(page_content=\"4•Performnoninvasive diagnostic testing\\n•Accesstherapyhistorydata\\n•Storea12secondtraceoftheECG/EGM displayfromanyscreen\\n•Accessaninteractive Demonstration ModeorPatientDataModewithoutthepresenceofapulsegenerator\\n•Printpatientdataincluding pulsegenerator therapyoptionsandtherapyhistorydata\\n•Savepatientdata\\nYoucanprogramthepulsegenerator usingtwomethods: automatically usingIndications-Based Programming(IBP)or\\nmanually.\\nRELATEDINFORMATION\\nRefertothelead'sinstruction manualforimplantinformation, generalwarnings andprecautions, indications, contraindications,\\nandtechnicalspecifications. Readthismaterialcarefullyforimplantprocedureinstructions specifictothechosenlead\\nconfigurations.\\nRefertothePRMsystemOperator's ManualorZOOMWirelessTransmitterReferenceGuideforspecificinformation aboutthe\\nPRMorZOOMWirelessTransmitter suchassetup,maintenance, andhandling.\\nRefertothesepulsegenerators’ ReferenceGuideforadditional referenceinformation suchasusingthePRMsoftware,\\ntachyarrhythmia detection andtherapy,pacingtherapy,sensing,anddiagnostics.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnical Guideforinformation aboutMRIscanning.\\nRefertotheHeartLogic Technical Guideforinformation abouttheHeartLogic HeartFailureDiagnostic Service.\\nLATITUDE NXTisaremotemonitoring systemthatprovidespulsegenerator dataforclinicians. Allpulsegenerators described in\\nthismanualaredesigned tobeLATITUDE NXTenabled;availability variesbyregion.\\n•Physicians/Clinicians—LATITUDE NXTenablesyoutoperiodically monitorbothpatientanddevicestatusremotelyand\\nautomatically .TheLATITUDE NXTsystemprovidespatientdatathatcanbeusedaspartoftheclinicalevaluation ofthe\\npatient.\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 7}), Document(page_content='5•Patients—A keycomponent ofthesystemistheLATITUDE Communicator ,aneasy-to-use, in-homemonitoring device.\\nTheCommunicator automatically readsimplanted devicedatafromacompatible BostonScientificpulsegenerator at\\ntimesscheduled bythephysician. TheCommunicator sendsthisdatatotheLATITUDE NXTsecureserver.TheLATITUDE\\nNXTserverdisplaysthepatientdataontheLATITUDE NXTWebsite,whichisreadilyaccessibleovertheInternetto\\nauthorized physicians andclinicians.\\nRefertotheLATITUDE NXTClinicianManualformoreinformation.\\nINTENDED AUDIENCE\\nThisliteratureisintendedforusebyprofessionals trainedorexperience dindeviceimplantand/orfollow-up procedures.\\nINDICATIONS ANDUSAGE\\nTheseBostonScientificCardiacResynchronization TherapyDefibrillators (CRT-Ds)areindicated forpatientswithheartfailure\\nwhoreceivestableoptimalpharmacologic therapy(OPT)forheartfailureandwhomeetanyoneofthefollowing classifications:\\n•Moderate tosevereheartfailure(NYHAClassIII-IV)withEF≤35%andQRSduration≥120ms\\n•Leftbundlebranchblock(LBBB)withQRSduration≥130ms,EF≤30%,andmild(NYHAClassII)ischemicornonischemic\\nheartfailureorasymptomatic (NYHAClassI)ischemicheartfailure\\nCONTRAINDICATIONS\\nTherearenocontraindications forthisdevice.\\nWARNINGS\\nGeneral\\n•Labelingknowledge. Readthismanualthoroughly beforeimplantation toavoiddamagetothepulsegenerator and/or\\nlead.Suchdamagecanresultinpatientinjuryordeath.\\n•Forsinglepatient/singleprocedureuseonly.Donotreuse,reprocess,orresterilize.Reuse,reprocessing, or\\nresterilization maycompromisethestructural integrityofthedeviceand/orleadtodevicefailurewhich,inturn,mayresult', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 8}), Document(page_content=\"6inpatientinjury,illness,ordeath.Reuse,reprocessing,orresterilization mayalsocreateariskofcontamination ofthe\\ndeviceand/orcausepatientinfectionorcross-infection, including, butnotlimitedto,thetransmission ofinfectious\\ndisease(s) fromonepatienttoanother.Contamination ofthedevicemayleadtoinjury,illness,ordeathofthepatient.\\n•Backupdefibrillation protection. Alwayshaveexternaldefibrillation equipment availableduringimplantand\\nelectrophysiologic testing.Ifnotterminated inatimelyfashion,aninducedventricular tachyarrhythmia canresultinthe\\npatient'sdeath.\\n•Resuscitation availability .Ensurethatanexternaldefibrillator andmedicalpersonnel skilledinCPRarepresentduring\\npost-implantdevicetestingshouldthepatientrequireexternalrescue.\\n•Patchleads.Donotusedefibrillation patchleadswiththepulsegenerator system,orinjurytothepatientmayoccur.\\n•Separatepulsegenerator. Donotusethispulsegenerator withanotherpulsegenerator.Thiscombination couldcause\\npulsegenerator interaction, resultinginpatientinjuryoralackoftherapydelivery.\\nHandling\\n•Avoidshockduringhandling. Programthepulsegenerator TachyMode(s)toOffduringimplant,explant,orpostmortem\\nprocedurestoavoidinadvertent highvoltageshocks.\\n•Donotkinkleads.Donotkink,twist,orbraidtheleadwithotherleadsasdoingsocouldcauseleadinsulation abrasion\\ndamageorconductordamage.\\n•HandlingtheleadwithoutConnector Tool.ForleadsthatrequiretheuseofaConnector Tool,usecautionhandlingthe\\nleadterminalwhentheConnector Toolisnotpresentonthelead.Donotdirectlycontacttheleadterminalwithany\\nsurgicalinstruments orelectricalconnections suchasPSA(alligator) clips,ECGconnections, forceps,hemostats, and\\nclamps.Thiscoulddamagetheleadterminal,possiblycompromisingthesealingintegrityandresultinlossoftherapyor\\ninappropriate therapy,suchasashortwithintheheader.\\n•Handlingtheterminalwhiletunneling. DonotcontactanyotherportionoftheDF4–LLHH orDF4–LLHO leadterminal,\\notherthantheterminalpin,evenwhentheleadcapisinplace.\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 9}), Document(page_content='7DonotcontactanyotherportionoftheIS4–LLLLleadterminal,otherthantheterminalpin,evenwhentheleadcapisin\\nplace.\\n•Appropriateleadconnections. Whenimplanting asystemwhichusesbothaDF4-LLHH/LLHO andIS4-LLLLlead,ensure\\nthattheleadsareinsertedandsecuredintheappropriat eports.Insertingaleadintoanincorrectportwillresultin\\nunanticipated devicebehavior(potentially leavingthepatientwithouteffectivetherapy).\\nProgramming andDeviceOperations\\n•Atrialtrackingmodes.Donotuseatrialtrackingmodesinpatientswithchronicrefractoryatrialtachyarrhythmias.\\nTrackingofatrialarrhythmias couldresultinventricular tachyarrhythmias.\\n•Atrial-only modes.Donotuseatrial-only modesinpatientswithheartfailurebecausesuchmodesdonotprovideCRT.\\n•Ventricular sensing.Leftventricular leaddislodgement toapositionneartheatriacanresultinatrialoversensing and\\nleftventricular pacinginhibition.\\n•SlowVT.Physicians shouldusemedicaldiscretion whenimplanting thisdeviceinpatientswhopresentwithslowVT.\\nProgramming therapyforslowmonomorphic VTmayprecludeCRTdeliveryatfasterratesiftheseratesareinthe\\ntachyarrhythmia zones.\\nPost-Implant\\n•Protectedenvironments. Advisepatientstoseekmedicalguidance beforeenteringenvironments thatcouldadversely\\naffecttheoperation oftheactiveimplantable medicaldevice,including areasprotected byawarningnoticethatprevents\\nentrybypatientswhohaveapulsegenerator.\\n•MagneticResonance Imaging(MRI)exposure. AlldevicesexceptforthosewithanLV:LV-1leadconnectionare\\nconsideredMRConditional. Forthesedevices,unlessalloftheMRIConditions ofUsearemet,MRIscanningofthepatient\\ndoesnotmeetMRConditional requirements fortheimplanted system.Significant harmtoordeathofthepatientand/or\\ndamagetotheimplanted systemmayresult.Donotexposepatientswithnon-MRConditional devicestoMRIscanning.\\nStrongmagnetic fieldsmaydamagethepulsegenerator and/orleadsystem,possiblyresultingininjurytoordeathofthe\\npatient.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 10}), Document(page_content='8Forpotentialadverseeventsapplicable whentheConditions ofUsearemetornotmet,refertotheImageReady MR\\nConditional Defibrillation SystemMRITechnical Guide.Foradditional warnings, precautions, andConditions ofUse,refer\\nto\"Magnetic Resonance Imaging(MRI)\"onpage22.\\n•Diathermy .Donotsubjectapatientwithanimplanted pulsegenerator and/orleadtodiathermy sincediathermy may\\ncausefibrillation, burningofthemyocardium, andirreversibledamagetothepulsegenerator becauseofinduced\\ncurrents.\\n•EnsurePTMisenabled. Ifdesired,ensurethatPatientTriggered Monitorisenabledpriortosendingthepatienthomeby\\nconfirming theMagnetResponse isprogrammedtoStoreEGM.Ifthefeatureisinadvertently leftintheInhibitTherapy\\nsetting,thepatientcouldpotentially disabletachyarrhythmia detection andtherapy.\\n•MagnetResponse settoInhibitTherapy.OncethePatientTriggered Monitorfeaturehasbeentriggered bythemagnet\\nandanEGMhasbeenstored,orafter60dayshaveelapsedfromthedaythatStoreEGMwasenabled,theMagnet\\nResponse programmingautomatically willbesettoInhibitTherapy.Whenthishappens, thepatientshouldnotapplythe\\nmagnetbecausetachyarrhythmia therapycouldbeinhibited.\\nPRECAUTIONS\\nClinicalConsiderations\\n•Pacemaker-mediated tachycardia (PMT).Programmingminimum PVARPlessthanretrogradeV–Aconduction may\\nincreasethelikelihood ofaPMT.\\n•MVSensormodes.ThesafetyandefficacyoftheMVSensormodeshavenotbeenclinicallyestablished inpatientswith\\nabdominal implantsites.\\n•MVSensormodeperformance. MVSensorperformance maybeadversely affectedundertransientconditions suchas\\npneumothorax, pericardial effusion,orpleuraleffusion.ConsiderprogrammingtheMVSensorOffuntiltheseconditions\\nareresolved.\\n•Adaptive-rate modes.Adaptive-rate modesbasedcompletelyorinpartonMVmightbeinappropriateforpatientswho\\ncanachieverespiratorycyclesshorterthanonesecond(greaterthan60breathsperminute).Higherrespiration rates', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 11}), Document(page_content='9attenuate theimpedance signal,whichdiminishes theMVrateresponse(i.e.,thepacingratewilldroptowardthe\\nprogrammedLRL).\\nAdaptive-ra temodesbasedcompletely orinpartonMVshouldnotbeusedforpatientswith:\\n•Aseparatepacemaker\\n•Aleadotherthanabipolartransvenous lead—MV measurement hasonlybeentestedwithabipolartransvenous\\nlead\\n•Amechanical ventilator—use oftheventilator mightresultinaninappropriate MVSensor-drivenrate\\n•RateAdaptivePacinginHeartFailurePatients. TheclinicalbenefitofRateAdaptivePacinginheartfailurepatientshas\\nnotbeenstudied.RateAdaptivePacingshouldbeusedwithmedicaldiscretion ifthepatientdevelopsanindication such\\naschronotrop icincompetenc e.Patientswithheartfailuremayhavehemodynamic compromiseatrapidsensor-driven\\nrates,andthephysician maywishtoprogramlessaggressive rateadaptiveparameters inaccordancewithpatient\\ncondition.Heartfailure-relatedrespiratorychangesinpatient’sminuteventilation (MV)mayinappropriately increase\\npacedratetotheupperrate(MSR),forinstanceduringheartfailureatrest.Ifthisoccurs,physicians mayconsiderturning\\noffrateresponsive pacingormodifying theRateAdaptivePacingsettings.RateAdaptivePacingmaybehelpfulforheart\\nfailurepatientswithcoexistingbradyarrhythmic conditions.\\nSterilization andStorage\\n•Ifpackageisdamaged. Theblistertraysandcontentsaresterilizedwithethyleneoxidegasbeforefinalpackaging.\\nWhenthepulsegenerator and/orleadisreceived,itissterileprovidedthecontainer isintact.Ifthepackaging iswet,\\npunctured,opened,orotherwise damaged, returnthepulsegenerator and/orleadtoBostonScientific.\\n•Ifdeviceisdropped.Donotimplantadevicewhichhasbeendroppedwhileoutsideofitsintactshelfpackage.Donot\\nimplantadevicewhichhasbeendroppedfromaheightofmorethan24inches(61cm)whilewithinitsintactshelf\\npackage.Sterility,integrity,and/orfunctioncannotbeguaranteedundertheseconditions, andthedeviceshouldbe\\nreturnedtoBostonScientificforinspection.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 12}), Document(page_content=\"10•Storagetemperature andequilibration. Recommended storagetemperatur esare0°C–50°C (32°F–122°F). Allowthe\\ndevicetoreachapropertemperature beforeusingtelemetry communication capabilities, programming,orimplanting the\\ndevicebecausetemperatureextremesmayaffectinitialdevicefunction.\\n•Devicestorage.Storethepulsegenerator inacleanareaawayfrommagnets, kitscontaining magnets, andsourcesof\\nEMItoavoiddevicedamage.\\n•Usebydate.Implantthepulsegenerator and/orleadbeforeorontheUSEBYdateonthepackagelabelbecausethis\\ndatereflectsavalidated shelflife.Forexample, ifthedateisJanuary1,donotimplantonorafterJanuary2.\\nImplantation\\n•Expectedbenefits. Determine whethertheexpecteddevicebenefitsprovidedbyprogrammable optionsoutweigh the\\npossibility ofmorerapidbatterydepletion.\\n•Evaluatepatientforsurgery.Theremaybeadditional factorsregardingthepatient'soverallhealthandmedical\\ncondition that,whilenotrelatedtodevicefunctionorpurpose,couldrenderthepatientapoorcandidate forimplantation\\nofthissystem.Cardiachealthadvocacy groupsmayhavepublished guidelines thatmaybehelpfulinconducting this\\nevaluation.\\n•Leadcompatibility .Priortoimplantation, confirmthelead-to-pulse generator compatibility .Usingincompatible leads\\nandpulsegenerators candamagetheconnector and/orresultinpotentialadverseconsequenc es,suchasundersensing of\\ncardiacactivityorfailuretodelivernecessary therapy.\\n•Telemetry wand.Makesureasteriletelemetry wandisavailableshouldlossofZIPtelemetry occur.Verifythatthewand\\ncaneasilybeconnectedtotheprogrammerandiswithinreachofthepulsegenerator.\\n•Line-powered equipment. Exerciseextremecautioniftestingleadsusingline-powere dequipment becauseleakage\\ncurrentexceeding10µAcaninduceventricular fibrillation. Ensurethatanyline-powere dequipment iswithin\\nspecifications.\\n•Replacement device.Implanting areplacement deviceinasubcutaneous pocketthatpreviously housedalargerdevice\\nmayresultinpocketairentrapment, migration, erosion,orinsufficient grounding betweenthedeviceandtissue.Irrigating\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 13}), Document(page_content='11thepocketwithsterilesalinesolutiondecreases thepossibility ofpocketairentrapment andinsufficient grounding.\\nSuturingthedeviceinplacereducesthepossibility ofmigration anderosion.\\n•Donotbendtheleadnearthelead-header interface. Inserttheleadterminalstraightintotheleadport.Donotbend\\ntheleadnearthelead-header interface.Improper insertioncancauseinsulation orconnector damage.\\n•Absenceofalead.Theabsenceofaleadorpluginaleadportmayaffectdeviceperformance andpotentially leavethe\\npatientwithouteffectivetherapy.Ifaleadisnotused,verifythattheplugandlabeledheaderportmatch(i.e.,IS-1,DF-1,\\nLV-1,IS4,orDF4).Fullyinserttheplugintheunusedportandthentightenthesetscrewontotheplug.Verifyappropriate\\ndevicefunctionusingtheprogrammer.\\n•Afunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriate sensingandpacinginall\\nchambers, regardlessofprogrammedconfiguration.ThisincludesCRTdevicesprogrammedtoAAI(R)orLV-Only\\npacing.\\n•Lackofafunctional RVleadmayresultinundersensing, and/oroversensing andleavethepatientwithouteffective\\ntherapy.\\n•Electrodeconnections. Donotinsertaleadintothepulsegenerator connectorwithouttakingthefollowing precautions\\ntoensureproperleadinsertion:\\n•Insertthetorquewrenchintothepreslitdepression ofthesealplugbeforeinsertingtheleadintotheport,to\\nreleaseanytrappedfluidorair.\\n•Visuallyverifythatthesetscrewissufficiently retractedtoallowinsertion. Usethetorquewrenchtoloosenthe\\nsetscrewifnecessary.\\n•Fullyinserteachleadintoitsleadportandthentightenthesetscrewontotheterminalpin.\\n•Defibrillation leadimpedance. Iftotalshockingleadimpedance duringimplantislessthan20Ω,verifytheproximalcoil\\nisnotincontactwiththepulsegenerator surface.Ameasurement oflessthan20Ωisanindication ofashortsomewhere\\ninthesystem.Ifrepeatedmeasurements showthetotalshockingleadimpedance islessthan20Ω,theleadand/orpulse\\ngenerator mayneedtobereplaced.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 14}), Document(page_content=\"12•Shuntingenergy.Donotallowanyobjectthatiselectrically conductivetocomeintocontactwiththeleadordevice\\nduringinduction becauseitmayshuntenergy,resultinginlessenergygettingtothepatient,andmaydamagethe\\nimplanted system.\\n•Donotsuturedirectlyoverlead.Donotsuturedirectlyovertheleadbody,asthismaycausestructural damage.Usethe\\nsuturesleevetosecuretheleadproximaltothevenousentrysitetopreventleadmovement.\\n•MVSensor.DonotprogramtheMVSensortoOnuntilafterthepulsegenerator hasbeenimplanted andsystemintegrity\\nhasbeentestedandverified.\\n•Programming MVSensorforrespiratory disorders orabnormal breathing. Forpatientswithrespiratory disorders or\\nabnormal breathing patterns,thephysician shouldusemedicaljudgment whenprogrammingtheMVSensortoOn.To\\nmitigateinappropriatesensor-drivenrates,thephysician mayevaluatetherateresponseandconsideralowerResponse\\nFactor.\\n•Diaphragmatic stimulation. Patientsshouldbetestedfordiaphragmatic stimulation bypacingtheLVleadthroughthe\\npulsegenerator at7.5Vandadjusting theleadconfigurationsandleadpositionasnecessary.PSAtestingathigher\\noutputs(e.g.,10.0V)mayalsobeconsideredtobettercharacteriz estimulation margins.Theprobability ofdiaphragmatic\\nstimulation increases whenapacingsystemincludesanLVleadbecauseofthislead'sproximity tothephrenicnerve.\\nDeviceProgramming\\n•Devicecommunication. Useonlythedesignated programmerandsoftwareapplication tocommunicate withthispulse\\ngenerator.\\n•STATPACEsettings. Whenapulsegenerator isprogrammedtoSTATPACEsettings,itwillcontinuetopaceatthehigh-\\nenergySTATPACEvaluesifitisnotreprogrammed.TheuseofSTATPACEparameters willlikelydecreasedevicelongevity.\\n•Biventricular pacingtherapy.ProgrammingthedevicetoprovideRV-onlypacingisnotintendedforthetreatmentof\\nheartfailure.TheclinicaleffectsofRV-onlypacingforthetreatment ofheartfailurehavenotbeenestablished.\\n•Pacingandsensingmargins.ConsiderleadmaturationinyourchoiceofPacingAmplitude, pacingPulseWidth,and\\nSensitivity settings.\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 15}), Document(page_content='13•AnacutePacingThreshold greaterthan1.5VorachronicPacingThreshold greaterthan3Vcanresultinlossof\\ncapturebecausethresholds mayincreaseovertime.\\n•AnR-WaveAmplitude lessthan5mVoraP-WaveAmplitude lessthan2mVcanresultinundersensing because\\nthesensedamplitude maydecreaseafterimplantation.\\n•PacingLeadImpedance shouldbegreaterthantheprogrammedLowImpedance Limitandlessthanthe\\nprogrammedHighImpedance Limit.\\n•Properprogramming oftheleadconfiguration. IftheLeadConfigurat ionisprogrammedtoBipolarwhenaunipolar\\nleadisimplanted, pacingwillnotoccur.\\n•Properprogramming oftheshockvector.IftheShockVectorisprogrammedtoRVcoil>>RAc oilandtheleaddoesnot\\nhaveanRAcoil,shockingwillnotoccur.\\n•Programming forsupraventricular tachyarrhythmias (SVTs).Determine ifthedeviceandprogrammable optionsare\\nappropriat eforpatientswithSVTsbecauseSVTscaninitiateunwanted devicetherapy.\\n•AVDelay.Toensureahighpercentageofbiventricular pacing,theprogrammedAVDelaysettingmustbelessthanthe\\npatient’sintrinsicPRinterval.\\n•Adaptive-rate pacing.Rateadaptivepacingshouldbeusedwithcareinpatientswhoareunabletotolerateincreased\\npacingrates.\\n•Ventricular refractory periods(VRPs)inadaptive-rate pacing.Adaptive-ra tepacingisnotlimitedbyrefractoryperiods.\\nAlongrefractoryperiodprogrammedincombinationwithahighMSRcanresultinasynchronous pacingduringrefractory\\nperiodssincethecombinationcancauseaverysmallsensingwindowornoneatall.UseDynamicAVDelayorDynamic\\nPVARPtooptimizesensingwindows. IfyouareprogrammingafixedAVDelay,considerthesensingoutcomes.\\n•AtrialTachyResponse (ATR).ATRshouldbeprogramm edtoOnifthepatienthasahistoryofatrialtachyarrhythmias.\\nThedeliveryofCRTiscompromisedbecauseAVsynchrony isdisrupted iftheATRmodeswitchoccurs.\\n•Threshold test.DuringmanualLVThreshold andQuickCapturetests,RVBackupPacingisunavailable.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 16}), Document(page_content=\"14•RVS-LVSDelaytesting.Ensurethepatientisclinicallycapableoftolerating lowrateRVBackupPacingandlackofLV\\npacingduringanRVS-LVSDelaytest.\\n•Shockwaveform polarity.ForIS-1/DF-1leads,neverchangetheshockwaveform polaritybyphysically switching thelead\\nanodesandcathodesinthepulsegenerator header—usetheprogramm ablePolarityfeature.Devicedamageor\\nnonconversion ofthearrhythmia post-operatively mayresultifthepolarityisswitchedphysically.\\n•TachyModetoOff.Topreventinappropriate shocks,ensurethatthepulsegenerator's TachyModeisprogrammedtoOff\\nwhennotinuseandbeforehandlingthedevice.Fortachyarrhythmia detection andtherapy,verifythattheTachyModeis\\nprogrammedtoMonitor+Therapy.\\n•Atrialoversensing. Takecaretoensurethatartifactsfromtheventricles arenotpresentontheatrialchannel,oratrial\\noversensing mayresult.Ifventricular artifactsarepresentintheatrialchannel,theatrialleadmayneedtoberepositioned\\ntominimize itsinteraction.\\n•ATRentrycount.ExercisecarewhenprogrammingtheEntryCounttolowvaluesinconjunction withashortATR\\nDuration. Thiscombination allowsmodeswitching withveryfewfastatrialbeats.Forexample, iftheEntryCountwas\\nprogrammedto2andtheATRDurationto0,ATRmodeswitching couldoccuron2fastatrialintervals. Intheseinstances,\\nashortseriesofpremature atrialeventscouldcausethedevicetomodeswitch.\\n•ATRexitcount.ExercisecarewhenprogrammingtheExitCounttolowvalues.Forexample,iftheExitCountwas\\nprogrammedto2,afewcyclesofatrialundersensing couldcausetermination ofmodeswitching.\\n•Properprogramming withoutanatriallead.Ifanatrialleadisnotimplanted (portispluggedinstead),oranatriallead\\nisabandoned butremainsconnected totheheader,deviceprogrammingshouldbeconsistent withthenumberandtype\\nofleadsactuallyinuse.\\n•Atrialsensingprogrammed toOff.WhenatrialsensingisprogrammedtoOffinaDDI(R)orDDD(R)mode,anyatrial\\npacingthatoccurswillbeasynchronous. Additionally ,featuresthatrequireatrialsensingmaynotfunctionasexpected.\\n•Cross-chamber artifacts. Sensitivity adjustments associated withSmartBlankingmaynotbesufficient toinhibitdetection\\nofcross-chamber artifactsifthecross-chamber artifactsaretoolarge.Considerotherfactorsthatimpactthesize/\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 17}), Document(page_content='15amplitude ofcross-chamber artifactsincluding lead-placement, pacingoutput,programmedSensitivity settings,shock\\noutput,andtimesincelastdelivered shock.\\n•SignalArtifactMonitorProgramming Considerations. Formaximum sensitivity indetecting andpreventing potential\\nsignalartifact-generatedoversensing, itisrecommended thattheSignalArtifactMonitor(SAM)isprogrammedOnany\\ntimetheMV/Respir atorySensorisprogrammedtoOnorPassive.TurningtheSignalArtifactMonitorOffmayputthe\\npatientatincreased riskofoversensing, unlesstheMV/Respiratory SensorisalsoprogrammedOff.\\n•TurningtheSignalArtifactMonitorOff.TurningtheSignalArtifactMonitorOffmayputthepatientatincreased riskof\\noversensing, unlesstheMV/Respiratory SensorisalsoprogrammedtoOff.\\n•Leftventricular leadconfiguration. ProperprogrammingoftheLVcoronaryvenousLeadConfigurat ionisessentialfor\\nproperLVleadfunction.ProgramtheLeadConfiguration inaccordancewiththenumberofelectrodes ontheLVlead;\\notherwise, erraticLVsensing,lossofLVpacing,orineffective LVpacingmightoccur.\\n•LeftVentricular ProtectionPeriod(LVPP).UseofalongLVPPreducesthemaximum LVpacingrateandmayinhibitCRT\\nathigherpacingrates.\\n•MVRecalibration. ToobtainanaccurateMVbaselinefollowing anysurgicalprocedureinvolving thepulsegenerator or\\nleads,anew,manualcalibration shouldbeperformed. Leadmaturation, airentrapment inthepocket,pulsegenerator\\nmotionduetoinadequate suturing,externaldefibrillation orcardioversion, orotherpatientcomplications(e.g.,\\npneumothor ax)requireanewMVbaselineforappropriate MVbehavior.\\n•Sensingadjustment. Following anysensingrangeadjustment oranymodification ofthesensinglead,alwaysverify\\nappropriat esensing.ProgrammingSensitivity tothehighestvalue(lowestsensitivity) mayresultindelayeddetection or\\nundersensing ofcardiacactivity.Likewise,programmingtothelowestvalue(highestsensitivity) mayresultinoversensing\\nofnon-cardiac signals.\\n•Patientsheartonescomingfromtheirdevice.Patientsshouldbeadvisedtocontacttheirphysician immediately ifthey\\nheartonescomingfromtheirdevice.\\n•UseofPatientTriggered Monitor. UsecarewhenusingPatientTriggered Monitor,becausethefollowing conditions will\\nexistwhileitisenabled:', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 18}), Document(page_content='16•Allothermagnetfeatures,including inhibiting therapy,aredisabled. TheMagnet/Beeper featurewillnotindicate\\nmagnetposition.\\n•Devicelongevity isimpacted. Tohelpreducethelongevity impact,PTMonlyallowsstorageofoneepisode,and\\nPTMisautomatically disabledafter60daysifdatastoragewasnevertriggered.\\n•OncetheEGMisstored(or60dayselapses),PTMisdisabledandthedeviceMagnetResponse automatically willbe\\nsettoInhibitTherapy.However,thepulsegenerator willnotinhibittherapyuntilthemagnetisremovedfor3\\nsecondsandplacedonthedeviceagain.\\nEnvironmental andMedicalTherapyHazards\\n•Avoidelectromagnetic interference (EMI).AdvisepatientstoavoidsourcesofEMIbecauseEMImaycausethepulse\\ngenerator todeliverinappropriate therapyorinhibitappropriate therapy.\\nMovingawayfromthesourceoftheEMIorturningoffthesourceusuallyallowsthepulsegenerator toreturntonormal\\noperation.\\nExamples ofpotentialEMIsourcesare:\\n•Electricalpowersources,arcweldingorresistanceweldingequipment, androboticjacks\\n•Highvoltagepowerdistribution lines\\n•Electricalsmeltingfurnaces\\n•LargeRFtransmitters suchasradar\\n•Radiotransmitters, including thoseusedtocontroltoys\\n•Electronic surveillance (antitheft) devices\\n•Analternator onacarthatisrunning\\n•Medicaltreatments anddiagnostic testsinwhichanelectricalcurrentispassedthroughthebody,suchasTENS,\\nelectrocautery ,electrolysis/thermolysis, electrodiagnostic testing,electromyogra phy,ornerveconduction studies', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 19}), Document(page_content='17•Anyexternally applieddevicethatusesanautomatic leaddetection alarmsystem(e.g.,anEKGmachine)\\n•WirelessECG.WirelessECGissusceptibletoRFinterferenc e,andmayhaveanintermittent orlostsignal.Ifinterferenc eis\\npresent,especially duringdiagnostic testing,considerusingasurfaceECGinstead.\\nHospitalandMedicalEnvironments\\n•Mechanical ventilators. ProgramtheMV/Respir atorySensortoOffduringmechanical ventilation. Otherwise, the\\nfollowing mayoccur:\\n•Inappropriate MVSensor-drivenrate\\n•Misleading respiration-based trending\\n•Conducted electricalcurrent.Anymedicalequipment, treatment, therapy,ordiagnostic testthatintroduceselectrical\\ncurrentintothepatienthasthepotentialtointerferewithpulsegenerator function.\\n•Externalpatientmonitors(e.g.,respiratorymonitors, surfaceECGmonitors, hemodynamic monitors) maycause:\\n–Inappropriate MVSensor-driven rate(uptomaximum sensor-drivenrate)\\n–Misleading respiration-based trending\\n•Medicaltherapies, treatments, anddiagnostic teststhatuseconductedelectricalcurrent(e.g.,TENS,electrocautery ,\\nelectrolysis/thermolysis, electrodiagnostic testing,electromy ography,ornerveconduction studies)mayinterfere\\nwithordamagethepulsegenerator.ProgramthedevicetoElectrocauteryProtection Modepriortothetreatment,\\nandmonitordeviceperformance duringthetreatment. Afterthetreatment,verifypulsegenerator function(\"Post-\\nTherapyPulseGenerator FollowUp\"onpage21).\\nToresolvesuspected interactions withRespiratory Sensor-baseddiagnostics, deactivate thepulsegenerator\\'s Respiratory\\nSensorbyprogrammingittoOff.\\n•Internaldefibrillation. Donotuseinternaldefibrillation paddlesorcatheters unlessthepulsegenerator isdisconnected\\nfromtheleadsbecausetheleadsmayshuntenergy.Thiscouldresultininjurytothepatientanddamagetothe\\nimplanted system.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 20}), Document(page_content='18•Externaldefibrillation. Itcantakeupto15secondsforsensingtorecoverafteranexternalshockisdelivered. Innon-\\nemergency situations, forpacemakerdependent patients,considerprogrammingthepulsegenerator toanasynchronous\\npacingmodeandprogrammingtheMV/Respiratory SensortoOffpriortoperforming externalcardioversion or\\ndefibrillation.\\nAvoidplacingapad(orpaddle)directlyoveranysubcutaneous leads.\\nExternaldefibrillation orcardioversioncandamagethepulsegenerator.Tohelppreventdamagetothepulsegenerator,\\nconsiderthefollowing:\\n•Avoidplacingapad(orpaddle)directlyoverthepulsegenerator.Positionthepads(orpaddles)asfarfromthe\\npulsegenerator aspossible.\\n•Positionthepads(orpaddles)inaposterior-anteriororientation whenthedeviceisimplanted intherightpectoral\\nregionorananterior-apexorientation whenthedeviceisimplanted intheleftpectoralregion.\\n•Setenergyoutputofexternaldefibrillation equipment aslowasclinicallyacceptable.\\nFollowing externalcardioversion ordefibrillation, verifypulsegenerator function(\"Post-TherapyPulseGenerator Follow\\nUp\"onpage21).\\n•Lithotripsy .Extracorporealshockwavelithotripsy (ESWL)maycauseelectromagnetic interferenc ewithordamagetothe\\npulsegenerator.IfESWLismedically necessary,considerthefollowing tominimize thepotentialforencountering\\ninteraction:\\n•FocustheESWLbeamatleast15cm(6in)awayfromthepulsegenerator.\\n•Depending onthepacingneedsofthepatient,programtheBradyModetoOfforanon-rate-r esponsive VVImode.\\n•ProgramtheTachyModetoOfftopreventinappropriate shocks.\\n•Ultrasound energy.Therapeutic ultrasound (e.g.,lithotripsy) energymaydamagethepulsegenerator.Iftherapeutic\\nultrasound energymustbeused,avoidfocusingnearthepulsegenerator site.Diagnostic ultrasound (e.g.,\\nechocardiogra phy)isnotknowntobeharmfultothepulsegenerator.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 21}), Document(page_content='19•Electricalinterference. Electricalinterferenceor“noise”fromdevicessuchaselectrocautery andmonitoring equipment\\nmayinterferewithestablishing ormaintaining telemetry forinterrogating orprogrammingthedevice.Inthepresenceof\\nsuchinterferenc e,movetheprogrammerawayfromelectricaldevices,andensurethatthewandcordandcablesarenot\\ncrossingoneanother.Iftelemetry iscancelled asaresultofinterferenc e,thedeviceshouldbere-interrogatedpriorto\\nevaluating information frompulsegenerator memory.\\n•Radiofrequency (RF)interference. RFsignalsfromdevicesthatoperateatfrequencies nearthatofthepulsegenerator\\nmayinterruptZIPtelemetry whileinterrogating orprogrammingthepulsegenerator.ThisRFinterferenc ecanbereduced\\nbyincreasing thedistancebetweentheinterfering deviceandthePRMandpulsegenerator.\\n•Centrallineguidewire insertion. Usecautionwheninsertingguidewires forplacement ofothertypesofcentralvenous\\ncathetersystemssuchasPIClinesorHickmancatheters inlocationswherepulsegenerator leadsmaybeencounter ed.\\nInsertionofsuchguidewires intoveinscontaining leadscouldresultintheleadsbeingdamaged ordislodged.\\nHomeandOccupational Environments\\n•Homeappliances. Homeappliances thatareingoodworkingorderandproperlygrounded donotusuallyproduce\\nenoughEMItointerferewithpulsegenerator operation. Therehavebeenreportsofpulsegenerator disturbances caused\\nbyelectrichandtoolsorelectricrazorsuseddirectlyoverthepulsegenerator implantsite.\\n•Magneticfields.Advisepatientsthatextended exposuretostrong(greaterthan10gaussor1mTesla)magnetic fields\\nmaytriggerthemagnetfeature.Examples ofmagnetic sourcesinclude:\\n•Industrial transforme rsandmotors\\n•MRIscanners\\nNOTE:ThemagnetfeatureisdisabledwhenthedeviceisinMRIProtection Mode.Referto\"Magnetic Resonance\\nImaging(MRI)\"onpage22andtheImageReady MRConditional Defibrillation SystemMRITechnical Guideformore\\ninformation.\\n•Largestereospeakers\\n•Telephone receiversifheldwithin1.27cm(0.5inches)ofthepulsegenerator', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 22}), Document(page_content=\"20•Magnetic wandssuchasthoseusedforairportsecurityandintheBingogame\\n•ElectronicArticleSurveillance (EAS)andsecuritysystems. Advisepatientshowtoavoidimpacttocardiacdevice\\nfunctionduetoantitheftandsecuritygates,tagdeactivators, ortagreadersthatincluderadiofrequency identification\\n(RFID)equipment. Thesesystemsmaybefoundattheentrancesandexitsofstores,atcheckoutcounters, inpublic\\nlibraries,andinpoint-of-entryaccesscontrolsystems.Patientsshouldavoidlingeringnearorleaningagainstantitheft\\nandsecuritygatesandtagreaders.Inaddition,patientsshouldavoidleaningagainstcheckoutcounter-mounted and\\nhandheld tagdeactivation systems.Anti-theft gates,securitygates,andentrycontrolsystemsareunlikelytoaffectcardiac\\ndevicefunctionwhenpatientswalkthroughthematanormalpace.Ifthepatientisnearanelectronic antitheft, security,\\norentrycontrolsystemandexperiencessymptoms, theyshouldpromptlymoveawayfromnearbyequipment andinform\\ntheirdoctor.\\n•Cellularphones.Advisepatientstoholdcellularphonestotheearoppositethesideoftheimplanted device.Patients\\nshouldnotcarryacellularphonethatisturnedoninabreastpocketoronabeltwithin15cm(6inches)oftheimplanted\\ndevicesincesomecellularphonesmaycausethepulsegenerator todeliverinappropriate therapyorinhibitappropriate\\ntherapy.\\nFollow-up Testing\\n•Conversion testing.SuccessfulVForVTconversion duringarrhythmia conversion testingisnoassurancethatconversion\\nwilloccurpost-operatively .Beawarethatchangesinthepatient'scondition, drugregimen,andotherfactorsmaychange\\ntheDFT,whichmayresultinnonconversion ofthearrhythmia post-operatively .\\n•Pacingthreshold testing.Ifthepatient'sconditionordrugregimenhaschangedordeviceparameters havebeen\\nreprogrammed, considerperforming apacingthresholdtesttoconfirmadequate marginsforpacecapture.\\n•Follow-up considerations forpatientsleavingthecountry.Pulsegenerator follow-up considerationsshouldbemade\\ninadvanceforpatientswhoplantotravelorrelocatepost-implanttoacountryotherthanthecountryinwhichtheir\\ndevicewasimplanted. Regulatory approvalstatusfordevicesandassociated programmersoftwareconfigurationsvaries\\nbycountry;certaincountries maynothaveapprovalorcapability tofollowspecificproducts.\\nContactBostonScientific, usingtheinformation onthebackcover,forhelpindetermining feasibility ofdevicefollow-up in\\nthepatient'sdestination country.\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 23}), Document(page_content='21ExplantandDisposal\\n•Incineration. Besurethatthepulsegenerator isremovedbeforecremation. Cremation andincineration temperatur es\\nmightcausethepulsegenerator toexplode.\\n•Devicehandling. Beforeexplanting, cleaning,orshippingthedevice,complete thefollowing actionstoprevent\\nunwanted shocks,overwriting ofimportant therapyhistorydata,andaudibletones:\\n•Programthepulsegenerator TachyandBradyModestoOff.\\n•ProgramtheMagnetResponse featuretoOff.\\n•ProgramtheBeepwhenExplantisIndicated featuretoOff.\\n•ProgramtheBeepWhenOut-of-Range featuretoOff.\\n•Handlingattimeofdisposal. Cleananddisinfectthedeviceusingstandardbiohazard handlingtechniques sinceall\\nexplantedcomponents areconsideredbiohazardous.\\nSUPPLEMENTAL PRECAUTIONARY INFORMATION\\nPost-TherapyPulseGenerator FollowUp\\nFollowing anysurgeryormedicalprocedurewiththepotentialtoaffectpulsegenerator function,youshouldperforma\\nthorough follow-up, whichmayincludethefollowing:\\n•Interrogating thepulsegenerator withaprogrammer\\n•Reviewing clinicaleventsandfaultcodes\\n•Reviewing theArrhythmia Logbook, including storedelectrograms(EGMs)\\n•Reviewing real-timeEGMs\\n•Testingtheleads(threshold, amplitude, andimpedance)\\n•Performing amanualcapacitorre-formation', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 24}), Document(page_content='22•Reviewing MVSensor-baseddiagnostics, MVSensorperformance, andperforming amanualMVSensorcalibration if\\ndesired\\n•Reviewing RespiratorySensor-baseddiagnostics\\n•Verifyingbatterystatus\\n•Programminganypermanent bradyparametertoanewvalueandthenreprogrammingitbacktothedesiredvalue\\n•ProgrammingtheTachyModetoanewvalueandthenreprogramming itbacktothedesiredvalue\\n•Savingallpatientdata\\n•Verifyingtheappropriate finalprogrammingpriortoallowingthepatienttoleavetheclinic\\nMagneticResonance Imaging(MRI)\\nMRIProtection ModeisavailableinalldevicesexceptforthosewithanLV:LV-1leadconnection.\\nThefollowing Warnings andPrecautions, andConditions ofUseareapplicable toMRIscanningofpatientsimplanted withan\\nImageReady MRConditional Defibrillation System.RefertotheImageReady MRConditional Defibrillation SystemMRITechnical\\nGuideatwww.bostonscientific- elabeling.com foracomprehensivelistofWarnings andPrecautions, andConditions ofUsethat\\nareapplicable toMRIscanningofpatientsimplanted withanImageReady MRConditional Defibrillation System.\\nMRConditional Defibrillation SystemWarnings andPrecautions\\nWARNING: AlldevicesexceptforthosewithanLV:LV-1leadconnection areconsideredMRConditional. Forthesedevices,\\nunlessalloftheMRIConditions ofUsearemet,MRIscanningofthepatientdoesnotmeetMRConditional requirementsforthe\\nimplanted system.Significant harmtoordeathofthepatientand/ordamagetotheimplanted systemmayresult.Donot\\nexposepatientswithnon-MRConditional devicestoMRIscanning. Strongmagnetic fieldsmaydamagethepulsegenerator\\nand/orleadsystem,possiblyresultingininjurytoordeathofthepatient.\\nForpotentialadverseeventsapplicable whentheConditions ofUsearemetornotmet,refertotheImageReady MRConditional\\nDefibrillation SystemMRITechnical Guide.Foradditional warnings, precautions, andConditions ofUse,referto\"Magnetic\\nResonanceImaging(MRI)\"onpage22.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 25}), Document(page_content='23WARNING: MRIscanningafterExplantstatushasbeenreachedmayleadtopremature batterydepletion, ashortened device\\nreplacementwindow,orsuddenlossoftherapy.Afterperforming anMRIscanonadevicethathasreachedExplantstatus,\\nverifypulsegenerator function(\"Post-TherapyPulseGenerator FollowUp\"onpage21)andscheduledevicereplacement.\\nWARNING: Determine thebeepertypebeforeanMRIscan.TheArmature Beepermaynolongerbeusablefollowing anMRI\\nscan.Comingincontactwiththestrongmagnetic fieldofanMRIscannermaycauseapermanent lossoftheArmature Beeper\\nvolume.Thiscannotberecovered,evenafterleavingtheMRIscanenvironment andexitingMRIProtection Mode.Forthe\\nArmature Beeper,beforeanMRIscanisperformed, aphysician andpatientshouldweighthebenefitoftheMRIscanagainst\\ntheriskoflosingtheBeeper;aftertheMRIscan,performBeeperevaluation testtodetermine iftheBeeperisusable.Ifthe\\nBeeperisnotusable,itisstronglyrecommended thatpatientsarefollowedonLATITUDE NXTafteranMRIscaniftheyarenot\\nalready.Otherwise, anin-clinicfollow-up scheduleofeverythreemonthsisstronglyrecommended tomonitordevice\\nperformance.\\nWARNING: DuringMRIProtection Mode,thepatientwillnotreceiveTachycardia therapy(including ATPanddefibrillation),\\nand,ifBradyModeisprogrammedtoOff,willnotreceiveBradycardiapacing(including backuppacing)andCardiac\\nResynchronization Therapy.Thereforethepatientmustbecontinuously monitored fortheentiredurationinwhichthesystemis\\ninMRIProtection Mode,including duringthescan.\\nWARNING: IftheMRIProtection Time-out valueisprogrammedtoOff,thepatientwillnotreceiveTachycardia therapy,and\\nthepacingoptionsarelimitedtoOfforAsynchronous untilthepulsegenerator isprogrammedoutofMRIProtection Modeand\\nbacktonormaloperation.\\nWARNING: DuringMRIProtection Mode,Tachycardia therapyissuspended. Thesystemwillnotdetectventricular\\narrhythmias andthepatientwillnotreceiveATPorshockdefibrillation therapyuntilthepulsegenerator isprogrammedbackto\\nnormaloperation. Onlyscanthepatientifjudgedtobeclinicallycapableoftolerating noTachycardia protection fortheentire\\ndurationinwhichthepulsegenerator isinMRIProtection Mode.\\nWARNING: Theriskofarrhythmia maybeincreased withasynchronous pacing(AOO,VOO,DOO).Whenprogramming\\nasynchronous pacingduringMRIProtection Mode,selectapacingratethatavoidscompetitivepacingandminimize thetimein\\nMRIProtection Mode.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 26}), Document(page_content='24WARNING: Intherareeventthatnon-recoverableorrepeatfaultconditions occurwhilethedeviceisprogramm edinMRI\\nProtectionMode,thesubsequent devicebehaviorwillbedetermined bytheMRIProtection BradyModesetting.\\n•IfMRIBradyModeissettoOff,thedevicewillenterSafetyMode(permanent VVIunipolarpacingandtachycardia\\ntherapyenabled).\\n•IfMRIBradyModeissettoasynchronous pacing(AOO,VOO,DOO),bothbradycardiatherapyandtachycardiatherapy\\nwillbepermanently disabled.\\nWARNING: TheProgrammerisMRUnsafeandmustremainoutsidetheMRIsiteZoneIII(andhigher)asdefinedbythe\\nAmerican CollegeofRadiology Guidance Document onMRSafePractices5.Undernocircumstanc esshouldtheProgrammerbe\\nbroughtintotheMRIscannerroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nWARNING: Implantofthesystemcannotbeperformed inanMRIsiteZoneIII(andhigher)asdefinedbytheAmerican\\nCollegeofRadiology Guidance Document onMRSafePractices5.Someoftheaccessoriespackaged withpulsegenerators and\\nleads,including thetorquewrenchandstyletwires,arenotMRConditional andshouldnotbebroughtintotheMRIscanner\\nroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nCAUTION: Thephysician choosingMRIProtection Modeparameter valueswillneedtoexerciseprofessional judgment to\\ndetermine anindividual patient’sabilitytotoleratethedevicesettingsrequiredforMRConditional scanning, inconjunction with\\nthephysicalconditionsrequiredduringascan(forexample,prolonged timeinasupineposition).\\nCAUTION: Thepresenceoftheimplanted defibrillation systemmaycauseMRIimageartifacts.\\nNOTE:Otherimplanted devicesorpatientconditions maycauseapatienttobeineligible foranMRIscan,independent ofthe\\nstatusofthepatient’sImageReady MRConditional Defibrillation System.\\nMRConditions ofUse\\nThefollowing subsetoftheMRIConditions ofUsepertainstoimplantation andmustbemetinorderforapatientwithan\\nImageReady Defibrillation SystemtoundergoanMRIscan.AdherencetotheConditions ofUsemustbeverifiedpriortoeach\\n5.KanalE,Barkovich AJ,BellC,etal.ACRguidance document onMRsafepractices:2013.J.Magn.Reson.Imaging2013;37:501-530.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 27}), Document(page_content='25scantoensurethatthemostuptodateinformation hasbeenusedtoassessthepatient’seligibility andreadiness foranMR\\nConditional scan.RefertotheImageReady MRConditional Defibrillation SystemMRITechnical Guideatwww.bostonscientific -\\nelabeling.com foracomprehensive listofWarnings andPrecautions, andConditions ofUsethatareapplicable toMRIscanning\\nofpatientsimplanted withanImageReady MRConditional Defibrillation System.\\nCardiology\\n1.Patientisimplanted withanImageReady MRConditional Defibrillation System\\n2.Nootheractiveorabandoned implanted devices,components, oraccessoriespresentsuchasleadadaptors, extenders,\\nleads,orpulsegenerators\\n3.Patientisjudgedtobeclinicallycapableoftolerating noTachycardia protection fortheentiredurationinwhichthepulse\\ngenerator isinMRIProtection Mode\\n4.Pulsegenerator implantlocationrestricted toleftorrightpectoralregion\\n5.Atleastsix(6)weekshaveelapsedsinceimplantation and/oranyleadrevisionorsurgicalmodification oftheMR\\nConditional Defibrillation System\\n6.Noevidenceofafracturedleadorcompromisedpulsegenerator-leadsystemintegrity\\nTranscutaneous ElectricalNerveStimulation (TENS)\\nCAUTION: TENSinvolvespassingelectricalcurrentthroughthebody,andmayinterferewithpulsegenerator function.IfTENS\\nismedically necessary,evaluatetheTENStherapysettingsforcompatibility withthepulsegenerator.Thefollowing guidelines\\nmayreducethelikelihood ofinteraction:\\n•PlacetheTENSelectrodes asclosetogetherandasfarawayfromthepulsegenerator andleadsaspossible.\\n•Usethelowestclinically-appropriate TENSenergyoutput.\\n•Considercardiacmonitoring duringTENSuse,especially forpacemaker-dependent patients.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 28}), Document(page_content='26Additional stepscanbetakentohelpreduceinterferenc eduringin-clinicuseofTENS:\\n•Ifinterferenceissuspected duringin-clinicuse,turnofftheTENSunit.\\n•DonotchangeTENSsettingsuntilyouhaveverifiedthatthenewsettingsdonotinterferewithpulsegenerator function.\\nIfTENSismedically necessary outsidetheclinicalsetting(at-homeuse),providepatientswiththefollowing instructions:\\n•DonotchangetheTENSsettingsorelectrode positions unlessinstructed todoso.\\n•EndeachTENSsessionbyturningofftheunitbeforeremoving theelectrodes.\\n•IfthepatientreceivesashockduringTENSuse,oriftheyexperience symptoms oflightheadedness, dizziness, orlossof\\nconsciousness, theyshouldturnofftheTENSunitandcontacttheirphysician.\\nFollowthesestepstousethePRMtoevaluatepulsegenerator functionduringTENSuse:\\n1.Programthepulsegenerator TachyModetoMonitorOnly.\\n2.Observereal-timeEGMsatprescribed TENSoutputsettings,notingwhenappropriate sensingorinterferenc eoccurs.\\nNOTE:Patienttriggered monitoring maybeusedasanadditional methodtoconfirmdevicefunctionduringTENSuse.\\n3.Whenfinished,turnofftheTENSunitandreprogramtheTachyModetoMonitor+Therapy.\\nYoushouldalsoperformathorough follow-up evaluation ofthepulsegenerator following TENS,toensurethatdevicefunction\\nhasnotbeencompromised(\"Post-TherapyPulseGenerator FollowUp\"onpage21).\\nForadditional information, contactBostonScientificusingtheinformation onthebackcover.\\nElectrocauteryandRadioFrequency (RF)Ablation\\nCAUTION: ElectrocauteryandRFablationmayinduceventricular arrhythmias and/orfibrillation, andmaycauseasynchronous\\npacing,inhibition ofpacing,inappropriate shocks,and/orareduction inpulsegenerator pacingoutputpossiblyleadingtoloss\\nofcapture.RFablationmayalsocauseventricular pacinguptotheMTRand/orchangesinpacingthresholds. Additionally ,\\nexercisecautionwhenperforming anyothertypeofcardiacablationprocedureinpatientswithimplanted devices.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 29}), Document(page_content='27Ifelectrocautery orRFablationismedically necessary,observethefollowing tominimize risktothepatientanddevice:\\n•Depending onthepacingneedsofthepatient,programtheTachyModetoElectrocautery Protection ModeorOff.\\n•Havetemporary pacingandexternaldefibrillation equipment available.\\n•Avoiddirectcontactbetweentheelectrocautery equipment orablationcatheters andthepulsegenerator andleads.RF\\nablationclosetotheleadelectrode maydamagethelead-tissue interface.\\n•Keepthepathoftheelectricalcurrentasfarawayaspossiblefromthepulsegenerator andleads.\\n•IfRFablationand/orelectrocautery isperformed ontissuenearthedeviceorleads,monitorpre-andpost-\\nmeasurements forsensingandpacingthresholds andimpedances todetermine theintegrityandstabilityofthesystem.\\n•Forelectrocautery ,useabipolarelectrocautery systemwherepossibleanduseshort,intermittent, andirregularburstsat\\nthelowestfeasibleenergylevels.\\n•RFablationequipment maycausetelemetry interferenc ebetweenthepulsegenerator andPRM.Ifdeviceprogramming\\nchangesarenecessary duringanRFablationprocedure,turnofftheRFablationequipment beforeinterrogation.\\nWhentheprocedureisfinished,canceltheElectrocautery Protection ModeorprogramTachyModetoMonitor+Therapyin\\nordertoreactivate thepreviously programmedtherapymodes.\\nIonizingRadiation\\nCAUTION: Itisnotpossibletospecifyasaferadiationdosageorguarantee properpulsegenerator functionfollowing\\nexposuretoionizingradiation. Multiplefactorscollectively determine theimpactofradiationtherapyonanimplanted pulse\\ngenerator,including proximity ofthepulsegenerator totheradiationbeam,typeandenergyleveloftheradiationbeam,dose\\nrate,totaldosedelivered overthelifeofthepulsegenerator,andshielding ofthepulsegenerator.Theimpactofionizing\\nradiationwillalsovaryfromonepulsegenerator toanotherandmayrangefromnochangesinfunctiontoalossofpacingand\\ndefibrillation therapy.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 30}), Document(page_content='28Sourcesofionizingradiationvarysignificantly intheirpotentialimpactonanimplanted pulsegenerator.Severaltherapeutic\\nradiationsourcesarecapableofinterfering withordamaging animplanted pulsegenerator,including thoseusedforthe\\ntreatmentofcancer,suchasradioactive cobalt,linearaccelerators,radioactive seeds,andbetatrons.\\nPriortoacourseoftherapeutic radiationtreatment, thepatient\\'sradiationoncologist andcardiologist orelectrophysiologist\\nshouldconsiderallpatientmanagement options,including increased follow-up anddevicereplacement.Otherconsiderations\\ninclude:\\n•Maximizing shielding ofthepulsegenerator withinthetreatment field\\n•Determining theappropriate levelofpatientmonitoring duringtreatment\\nEvaluatepulsegenerator operation duringandfollowing thecourseofradiationtreatment toexerciseasmuchdevice\\nfunctionality aspossible(\"Post-TherapyPulseGenerator FollowUp\"onpage21).Theextent,timing,andfrequency ofthis\\nevaluation relativetotheradiationtherapyregimenaredependent uponcurrentpatienthealth,andtherefore shouldbe\\ndetermined bytheattending cardiologist orelectrophysiologist.\\nManypulsegenerator diagnostics areperformed automatically onceperhour,sopulsegenerator evaluation shouldnotbe\\nconcludeduntilpulsegenerator diagnostics havebeenupdatedandreviewed (atleastonehourafterradiationexposure).The\\neffectsofradiationexposureontheimplanted pulsegenerator mayremainundetected untilsometimefollowing exposure.For\\nthisreason,continuetomonitorpulsegenerator functioncloselyandusecautionwhenprogrammingafeatureintheweeksor\\nmonthsfollowing radiationtherapy.\\nElevatedPressures\\nTheInternational Standards Organization (ISO)hasnotapproved astandardiz edpressuretestforimplantable pulsegenerators\\nthatexperience hyperbaric oxygentherapy(HBOT)orSCUBAdiving.However,BostonScientificdeveloped atestprotocolto\\nevaluatedeviceperformance uponexposuretoelevatedatmospheric pressures.Thefollowing summary ofpressuretesting\\nshouldnotbeviewedasandisnotanendorsement ofHBOTorSCUBAdiving.\\nCAUTION: ElevatedpressuresduetoHBOTorSCUBAdivingmaydamagethepulsegenerator.Duringlaboratory testing,all\\npulsegenerators inthetestsamplefunctioned asdesigned whenexposedtomorethan1000cyclesatapressureupto5.0', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 31}), Document(page_content=\"29ATA.Laboratory testingdidnotcharacteriz etheimpactofelevatedpressureonpulsegenerator performance orphysiological\\nresponsewhileimplanted inahumanbody.\\nPressureforeachtestcyclebeganatambient/r oompressure,increased toahighpressurelevel,andthenreturnedtoambient\\npressure.Although dwelltime(theamountoftimeunderelevatedpressure)mayhaveanimpactonhumanphysiology ,testing\\nindicated itdidnotimpactpulsegenerator performance. Pressurevalueequivalencies areprovidedbelow(Table1Pressure\\nValueEquivalencies onpage29).\\nTable1.PressureValueEquivalencies\\nPressurevalueequivalencies\\nAtmospheres Absolute 5.0ATA\\nSeawaterdeptha40m(130ft)\\nPressure,absolute 72.8psia\\nPressure,gaugeb58.1psig\\nBar 5.0\\nkPaAbsolute 500\\na.Allpressureswerederivedassuming seawaterdensityof1030kg/m3.\\nb.Pressureasreadonagaugeordial(psia=psig+14.7psi).\\nPriortoSCUBAdivingorstartinganHBOTprogram,thepatient'sattending cardiologis torelectrophysiologist shouldbe\\nconsulted tofullyunderstand thepotentialconsequenc esrelativetothepatient'sspecifichealthcondition. ADiveMedicine\\nSpecialist mayalsobeconsulted priortoSCUBAdiving.\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 32}), Document(page_content='30Morefrequentdevicefollow-up maybewarranted inconjunctionwithHBOTorSCUBAdiving.Evaluatepulsegenerator\\noperationfollowing highpressureexposure(\"Post-TherapyPulseGeneratorFollowUp\"onpage21).Theextent,timing,and\\nfrequencyofthisevaluation relativetothehighpressureexposurearedependent uponcurrentpatienthealth,andshouldbe\\ndetermined bytheattending cardiologist orelectrophysiologist.\\nIfyouhaveadditional questions, orwouldlikemoredetailregardingthetestprotocolortestresultsspecifictoHBOTorSCUBA\\ndiving,contactBostonScientificusingtheinformation onthebackcover.\\nPOTENTIALADVERSEEVENTS\\nBasedontheliteratureandonpulsegenerator and/orleadimplantexperience, thefollowing alphabetical listincludesthe\\npossibleadverseeventsassociated withimplantation ofproductsdescribed inthisliterature:\\n•Airembolism\\n•Allergicreaction\\n•Bleeding\\n•Bradycardia\\n•Cardiactamponade\\n•Chronicnervedamage\\n•Component failure\\n•Conductor coilfracture\\n•Death\\n•Electrolyte imbalance/dehydr ation\\n•Elevatedthresholds\\n•Erosion\\n•Excessive fibrotictissuegrowth\\n•Extracardiacstimulation (muscle/nerve stimulation)', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 33}), Document(page_content='31•Failuretoconvertaninducedarrhythmia\\n•Fluidaccumulation\\n•Foreignbodyrejectionphenomena\\n•Formation ofhematomas orseromas\\n•Heartblock\\n•Inabilitytodefibrillate orpace\\n•Inappropriate therapy(e.g.,shocksandantitachycardia pacing[ATP]whereapplicable, pacing)\\n•Incisional pain\\n•Incomplete leadconnectionwithpulsegenerator\\n•Infectionincluding endocarditis\\n•Insulating myocardium duringdefibrillation withinternalorexternalpaddles\\n•Leaddislodgment\\n•Leadfracture\\n•Leadinsulation breakage orabrasion\\n•Leadperforation\\n•Leadtipdeformation and/orbreakage\\n•Localtissuereaction\\n•Lossofcapture\\n•Myocardial infarction (MI)\\n•Myocardial necrosis\\n•Myocardial trauma(e.g.,tissuedamage,valvedamage)\\n•Myopotential sensing\\n•Oversensing/undersensing', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 34}), Document(page_content='32•Pacemaker-mediated tachycardia (PMT)\\n•Pericardial rub,effusion\\n•Pneumothorax\\n•Pulsegenerator migration\\n•Shuntingcurrentduringdefibrillation withinternalorexternalpaddles\\n•Syncope\\n•Tachyarrhythmias, whichincludeaccelerationofarrhythmias andearly,recurrentatrialfibrillation\\n•Thrombosis/thr omboemboli\\n•Valvedamage\\n•Vasovagal response\\n•Venousocclusion\\n•Venoustrauma(e.g.,perforation, dissection, erosion)\\n•Worsening heartfailure\\nForalistofpotentialadverseeventsassociated withMRIscanning, refertotheImageReady MRConditional Defibrillation\\nSystemMRITechnical Guide.\\nPatientsmaydeveloppsychological intoleranc etoapulsegenerator systemandmayexperiencethefollowing:\\n•Dependency\\n•Depression\\n•Fearofprematurebatterydepletion\\n•Fearofshockingwhileconscious\\n•Fearthatshockingcapability maybelost\\n•Imagined shocking\\n•Fearofdevicemalfunction', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 35}), Document(page_content='33Additionally ,potentialadverseeventsassociated withtheimplantation ofacoronaryvenousleadsysteminclude:\\n•Allergicreactiontocontrastmedia\\n•Breakage/failure ofimplantinstruments\\n•Prolonged exposuretofluoroscopicradiation\\n•Renalfailurefromcontrastmediausedtovisualizecoronaryveins\\nMECHANICAL SPECIFICATIONS\\nAllmodelshaveacaseelectrode surfaceareaof6192mm².Usablebatterycapacityis1.9Ahandresidualusablebattery\\ncapacityatExplantis0.15Ah.Mechanical specifications specifictoeachmodelarelistedbelow.\\nTable2.Mechanical Specifications -RESONATE HFCRT-Ds\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nG524 5.37x8.18x0.99 73.6 32.5 RA:IS-1;RV:\\nDF4;LV:IS-1Yes\\nG525 5.37x8.08x0.99 72.8 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS-1Yes\\nG526 5.37x8.08x0.99 72.9 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:LV-1No\\nG528 5.37x8.08x0.99 73.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 36}), Document(page_content='34Table2.Mechanical Specifications -RESONATE HFCRT-Ds(continued)\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nG537 5.37x8.18x0.99 73.8 32.5 RA:IS-1;RV:\\nDF4;LV:IS4Yes\\nG547 5.37x8.18x0.99 73.8 32.5 RA:IS-1;RV:\\nDF4;LV:IS4Yes\\nG548 5.37x8.08x0.99 73.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nTable3.Mechanical Specifications -RESONATE CRT-Ds\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nG424 5.37x8.18x0.99 73.6 32.5 RA:IS-1;RV:\\nDF4;LV:IS-1Yes\\nG425 5.37x8.08x0.99 72.8 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS-1Yes\\nG426 5.37x8.08x0.99 72.9 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:LV-1No', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 37}), Document(page_content='35Table3.Mechanical Specifications -RESONATE CRT-Ds(continued)\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nG428 5.37x8.08x0.99 73.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nG437 5.37x8.18x0.99 73.8 32.5 RA:IS-1;RV:\\nDF4;LV:IS4Yes\\nG447 5.37x8.18x0.99 73.8 32.5 RA:IS-1;RV:\\nDF4;LV:IS4Yes\\nG448 5.37x8.08x0.99 73.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nTable4.Mechanical Specifications -VIGILANTCRT-Ds\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nG224 5.37x8.18x0.99 73.6 32.5 RA:IS-1;RV:\\nDF4;LV:IS-1Yes\\nG225 5.37x8.08x0.99 72.8 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS-1Yes', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 38}), Document(page_content='36Table4.Mechanical Specifications -VIGILANTCRT-Ds(continued)\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nG228 5.37x8.08x0.99 73.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nG237 5.37x8.18x0.99 73.8 32.5 RA:IS-1;RV:\\nDF4;LV:IS4Yes\\nG247 5.37x8.18x0.99 73.8 32.5 RA:IS-1;RV:\\nDF4;LV:IS4Yes\\nG248 5.37x8.08x0.99 73.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nTable5.Mechanical Specifications -MOMENTUM CRT-Ds\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume(cm3)Connector TypeMRConditional\\nG124 5.37x8.18x0.99 73.6 32.5 RA:IS-1;RV:\\nDF4;LV:IS-1Yes\\nG125 5.37x8.08x\\n0.9972.8 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS-1Yes', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 39}), Document(page_content='37Table5.Mechanical Specifications -MOMENTUM CRT-Ds(continued)\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume(cm3)Connector TypeMRConditional\\nG126 5.37x8.08x\\n0.9972.9 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:LV-1No\\nG128 5.37x8.08x\\n0.9973.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nG138 5.37x8.08x\\n0.9973.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nMaterialspecifications areshownbelow:\\n•Case:hermetically sealedtitanium\\n•Header:implantation-grade polymer\\n•PowerSupply:lithium-manganese dioxidecell;BostonScientificENDURALIFE; 401988\\nITEMSINCLUDED INPACKAGE\\nThefollowing itemsareincludedwiththepulsegenerator:\\n•Onetorquewrench\\n•Productliterature\\nNOTE:Accessories(e.g.,wrenches) areintendedforone-time useonly.Theyshouldnotberesterilizedorreused.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 40}), Document(page_content='38WARNING: Implantofthesystemcannotbeperformed inanMRIsiteZoneIII(andhigher)asdefinedbytheAmerican\\nCollegeofRadiology Guidance Document onMRSafePractices6.Someoftheaccessoriespackaged withpulsegenerators and\\nleads,including thetorquewrenchandstyletwires,arenotMRConditional andshouldnotbebroughtintotheMRIscanner\\nroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nSYMBOLSONPACKAGING\\nThefollowing symbolsmaybeusedonpackaging andlabeling:\\nTable6.Symbolsonpackaging\\nSymbol Description\\nReferenceNumber\\nContents\\nPulsegenerator\\nTorquewrench\\nLiteratureenclosed\\n6.KanalE,Barkovich AJ,BellC,etal.ACRguidance document onMRsafepractices:2013.J.Magn.Reson.Imaging2013;37:501-530.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 41}), Document(page_content='39Table6.Symbolsonpackaging (continued)\\nSymbol Description\\nSerialNumber\\nUseBy\\nLotNumber\\nDateofManufacture\\nNon-Ionizing Electromagnetic Radiation\\nSterilized usingethyleneoxide.\\nSTERILIZE2\\nDoNotResterilize\\nSingleuse.Donotre-use.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 42}), Document(page_content='40Table6.Symbolsonpackaging (continued)\\nSymbol Description\\nDonotuseifpackageisdamaged.\\nDangerous Voltage\\nConsultinstructions foruseonthiswebsite:www.\\nbostonscientific -elabeling.com\\nTemperatur elimitation.\\nPlacetelemetry wandhere', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 43}), Document(page_content='41Table6.Symbolsonpackaging (continued)\\nSymbol Description\\n,\\nOpenHere\\nManufacturer\\nMRConditional\\nCRT-DRA,RV,LV\\nICDRA,RV\\nICDRV\\nUncoated device', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 44}), Document(page_content='42Table6.Symbolsonpackaging (continued)\\nSymbol Description\\nRFTelemetry\\nDoublesterilebarriersystem\\nCHARACTERISTICS ASSHIPPED\\nRefertothetableforpulsegenerator settingsatshipment (Table7Characteristics asshippedonpage42).\\nTable7.Characteristics asshipped\\nParameter Setting\\nTachyMode Storage\\nTachyTherapyavailable ATP,Shock\\nPacingMode Storage\\nPacingTherapyavailable DDDR\\nSensor Accelerometer', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 45}), Document(page_content='43Table7.Characteristics asshipped(continued)\\nParameter Setting\\nSensor Blend(AccelandMV)(MOMENTUM andRESONATE HFmodels)\\nPace/Sense Configuration RA:BI/BI\\nPace/Sense Configuration RV:BI/BI\\nPace/Sense Configuration LV:Off\\nPace/Sense Configuration LV:BI/BI(Quadripolar Models)\\nThepulsegenerator isshippedinapower-savingStoragemodetoextenditsshelflife.InStoragemode,allfeaturesare\\ninactiveexcept:\\n•Telemetry support,whichallowsinterrogation andprogramming\\n•Real-time clock\\n•Commanded capacitorre-formation\\n•STATSHOCKandSTATPACEcommands\\nThedeviceleavesStoragemodewhenoneofthefollowing actionsoccurs;however,programmingotherparameters willnot\\naffecttheStoragemode:\\n•STATSHOCKorSTATPACEiscommanded\\n•TachyModeisprogramm edto:\\n•Off', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 46}), Document(page_content='44•MonitorOnly\\n•Monitor+Therapy\\nOnceyouhaveprogramm edthepulsegenerator outofStoragemode,thedevicecannotbereprogrammedtothatmode.\\nX-RAYIDENTIFIER\\nThepulsegenerator hasanidentifierthatisvisibleonanx-rayorfluoroscopicimage.Thisidentifierprovidesnoninvasive\\nconfirmationofthemanufacturer andconsistsofthefollowing:\\n•Theletters,BSC,toidentifyBostonScientificasthemanufacturer .\\n•Thenumber,140,toidentifythepulsegenerators.\\nThex-rayidentifierisembedded intheheaderofthedevice.Foraleftsidepectoralimplant,theidentifierwillbevisiblebyx-\\nrayorfluorographyattheapproximate locationshown(Figure1X-rayidentifieronpage44).\\n1\\n2\\n3\\n[1]X-RayIdentifier[2]Header[3]PulseGeneratorCase\\nFigure1.X-rayidentifier', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 47}), Document(page_content=\"45Forinformation onidentifying thedeviceviatheProgrammer,refertotheProgrammerOperator's Manual.\\nThepulsegenerator modelnumberandserialnumberareaccessiblefromtheProgrammerSummary screenoncethepulse\\ngenerator isinterrogated. Additional information suchasdateofmanufacture canbeobtainedbycontactingBostonScientific\\nandproviding themodelnumberandserialnumber.\\nFEDERALCOMMUNICATIONS COMMISSION (FCC)\\nThisdevicecomplieswithTitle47,Part15oftheFCCrules.Operationissubjecttothefollowing twoconditions:\\n•Thisdevicemaynotcauseharmfulinterferenc e,and\\n•Thisdevicemustacceptanyinterferenc ereceived,including interferenc ethatmaycauseundesired operation.\\nForpulsegenerators operating withatransmitfrequency of402to405MHz:thistransmitter isauthorizedbyruleunderthe\\nMedicalDeviceRadiocommunication Service(inpart95oftheFCCRules)andmustnotcauseharmfulinterferenc etostations\\noperating inthe400.150–406.000 MHzbandintheMeteorological Aids(i.e.,transmitters andreceiversusedtocommunicate\\nweatherdata),theMeteorological Satellite,ortheEarthExploration SatelliteServicesandmustacceptinterferenc ethatmaybe\\ncausedbysuchstations,including interferenc ethatmaycauseundesired operation. Thistransmitter shallbeusedonlyin\\naccordancewiththeFCCRulesgoverning theMedicalDeviceRadiocomm unication Service.Analoganddigitalvoice\\ncommunications areprohibited. Although thistransmitterhasbeenapproved bytheFederalCommunications Commission,\\nthereisnoguarantee thatitwillnotreceiveinterferenc eorthatanyparticular transmission fromthistransmitter willbefree\\nfrominterference.\\nCAUTION: Changesormodifications notexpresslyapproved byBostonScientificcouldvoidtheuser'sauthoritytooperatethe\\nequipment.\\nRESONATE HF,RESONATE, VIGILANT, andMOMENTUM devicesoperateinthe402–405MHzbandusingFSKmodulation with\\nradiatedpowerconforming totheapplicable 25μWlimit.TheFCCIDisESCCRMG17912. Wandedtelemetry operatesat57kHz\\nandusesQPSKmodulation.\\nPULSEGENERATOR LONGEVITY\\nBasedonsimulated studies,itisanticipated thatthesepulsegenerators haveaveragelongevity toexplantasshownbelow.\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 48}), Document(page_content='46RefertothePRMSummary andBatteryDetailSummary screensforanestimateofpulsegenerator longevity specifictothe\\nimplanted device.\\nThelongevity expectations, whichaccountfortheenergyusedduringmanufacture andstorage,applyattheconditions shown\\ninthetablesalongwiththefollowing:\\n•Assumes70ppmLRL;DDDRmode;100%biventricular pacing;15%atriumpacingand0.4mspacingPulseWidth(RA,\\nRV,LV);sensorsOn,HeartFailureSensorSuiteOn.\\nThefollowing longevity tablesandconditions ofuseapplytoRESONATE HF,RESONATE, VIGILANT, andMOMENTUM\\ndevices.\\nProjectedlongevity iscalculated assuming 2maximum energychargingcyclesperyear,including automatic capacitorre-forms\\nandtherapeutic shocks.Thesecalculations alsoassume3-channel EGMOnsetisonandthatthepulsegenerator spends3\\nmonthsinStoragemodeduringshippingandstorage.\\nPaceSafeOnforRAATandRVATprovidesanoutputof2Xthethreshold withaminimum outputof2.0V.\\nPaceSafeOnforLVATprovidesa1.0Vsafetymarginabovethethreshold withaminimum outputof1.0V.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 49}), Document(page_content='47Table8.Pulsegenerator lifeexpectancy estimation (implanttoexplant)withENDURALIFE battery\\nAllModelsa\\nPacing Longevity (years)\\nVentricular\\nChambersRA/RV LVLVbd500Ωwith\\nLATITUDEb700Ωwith\\nLATITUDEb700ΩNo\\nLATITUDE, MV/RS,\\norHFSSc\\nBiV 2.0V 2.0VOff 11.3 11.9 13.0\\nBiV 2.0V 3.0VOff 10.2 10.9 11.9\\nBiV 2.0V 3.5VOff 9.5 10.4 11.2\\nBiV 2.5V 3.0VOff 9.7 10.5 11.3\\nBiV 2.5V 3.5VOff 9.1 10.0 10.8\\nBiV 3.5V 3.5VOff 8.1 9.0 9.7\\nBiVMSP 2.0V 2.0V2.0V 10.3 10.9 11.9\\nBiVMSP 2.5V 3.0V3.0V 8.2 9.1 9.7\\nBiVMSP 2.5V 3.5V3.5V 7.4 8.3 8.9\\nLV-Only 2.0V/Off2.0VOff 12.9 13.2 14.7', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 50}), Document(page_content='48Table8.Pulsegenerator lifeexpectancy estimation (implanttoexplant)withENDURALIFE battery(continued)\\nAllModelsa\\nPacing Longevity (years)\\nVentricular\\nChambersRA/RV LVLVbd500Ωwith\\nLATITUDEb700Ωwith\\nLATITUDEb700ΩNo\\nLATITUDE, MV/RS,\\norHFSSc\\nLV-Only 2.5V/Off3.0VOff 11.3 12.0 13.2\\nLV-Only 2.5V/Off 3.5VOff 10.6 11.3 12.4\\nLV-OnlyMSP 2.0V/Off2.0V2.0V 11.5 12.1 13.3\\nLV-OnlyMSP 2.5V/Off3.0V3.0V 9.3 10.2 11.0\\nLV-OnlyMSP 2.5V/Off 3.5V3.5V 8.3 9.3 10.0\\na.AssumesZIPtelemetry usefor2hoursatimplantandfor40minutesannuallyforin-clinicfollow-up checks.\\nb.AssumesstandarduseoftheLATITUDE Communicator asfollows:DailyDeviceCheckon,quarterlyscheduled remotefollowups,andother\\ntypicalinterrogations.\\nc.AssumesLATITUDE Communicator isnotused,MinuteVentilation (MV)/Respiratory SensorisOff,andHeartFailureSensorSuiteisOff.\\nd.AppliestomodelswithMultiSitePacing(MSP).\\nNOTE:Theenergyconsumption inthelongevity tableisbasedupontheoretical electricalprinciples andverifiedviabench\\ntestingonly.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 51}), Document(page_content='49Thepulsegenerator longevity mayincreasewithadecreaseinanyofthefollowing:\\n•Pacingrate\\n•Pacingpulseamplitude(s)\\n•Pacingpulsewidth(s)\\n•Percentageofpacedtosensedevents\\n•Chargingfrequency\\nLongevity isalsoaffectedinthefollowing circumstanc es:7\\n•Adecreaseinpacingimpedance mayreducelongevity.\\n•WhentheMV/Respiratory SensorisprogrammedOffforthelifeofthedevice,longevity isincreased byapproximately 4\\nmonths.\\n•WhenPatientTriggered MonitorisprogrammedtoOnfor60days,longevity isreducedbyapproximately 3days.\\n•WhentheLATITUDE Communicator isnotusedforthelifeofthedevice,longevity isincreasedbyapproximately 4\\nmonths.\\n•Onehourofadditional ZIPwandless telemetry reduceslongevity byapproximately 7days.\\n•Fivepatient-initiated LATITUDE Communicator interrogations perweekforayearreduceslongevity byapproximately 31\\ndays.\\n•Anadditional maximum-energy shockreduceslongevity byapproximate ly16days.\\n•SixhoursinMRIProtection Modereduceslongevity byapproximately 3days.\\n•Anadditional 6monthsinStoragemodepriortoimplantwillreducelongevity by45days.\\n•WhentheHeartFailureSensorSuiteisprogrammedtoOffforthelifeofthedevice,longevity isincreased by\\napproximately 1month.\\n7.Assumesimplanted settingsof70ppmLRL;DDDRmode;15%atriumpacing;100%biventricular pacing;0.4mspacingPulseWidth;500Ω\\npacingImpedance; 2.5VpacingpulseAmplitude (RA,RV);3.0VpacingpulseAmplitude (LV).', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 52}), Document(page_content=\"50•AHeartLogic subscription withdailyalertchecksandweeklyinterrogations willdecreaselongevity byapproximately 2\\nmonthswhenusedforthelifeofthedevice.\\n•Dailyinterrogations torefreshHeartLogic following analertfor30dayseachyearwilldecreaselongevity byanadditional\\n1month.\\n•WhentheSignalArtifactMonitorisprogrammedOnforthelifeofthedevice,longevity isreducedbyapproximate ly2\\nmonths.\\nDevicelongevity mayalsobeaffectedby:\\n•Tolerancesofelectronic components\\n•Variations inprogramm edparameters\\n•Variations inusageasaresultofpatientcondition\\nWARRANTY INFORMATION\\nAlimitedwarrantycertificate forthepulsegenerator isavailableatwww.bostonscientific.com. Foracopy,contactBoston\\nScientificusingtheinformation onthebackcover.\\nPRODUCTRELIABILITY\\nItisBostonScientific's intenttoprovideimplantable devicesofhighqualityandreliability.However,thesedevicesmayexhibit\\nmalfunctions thatmayresultinlostorcompromisedabilitytodelivertherapy.Thesemalfunctions mayincludethefollowing:\\n•Prematurebatterydepletion\\n•Sensingorpacingissues\\n•Inabilitytoshock\\n•Errorcodes\\n•Lossoftelemetry\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 53}), Document(page_content=\"51RefertoBostonScientific's CRMProductPerformance Reportonwww.bostonscientific.com formoreinformation aboutdevice\\nperformance, including thetypesandratesofmalfunctions thatthesedeviceshaveexperienced historically .Whilehistorical\\ndatamaynotbepredictive offuturedeviceperformance, suchdatacanprovideimportant contextforunderstanding theoverall\\nreliability ofthesetypesofproducts.\\nSometimes devicemalfunctions resultintheissuanceofproductadvisories. BostonScientificdetermines theneedtoissue\\nproductadvisories basedontheestimated malfunction rateandtheclinicalimplication ofthemalfunction. WhenBoston\\nScientificcommunicates productadvisoryinformation, thedecisionwhethertoreplaceadeviceshouldtakeintoaccountthe\\nrisksofthemalfunction, therisksofthereplacementprocedure,andtheperformance todateofthereplacementdevice.\\nPATIENTCOUNSELING INFORMATION\\nThefollowing topicsshouldbediscussed withthepatientpriortodischarge:\\n•Externaldefibrillation—the patientshouldcontacttheirphysician tohavetheirpulsegenerator systemevaluated ifthey\\nreceiveexternaldefibrillation\\n•Beepingtones—the patientshouldcontacttheirphysician immediately iftheyheartonescomingfromtheirpulse\\ngenerator\\n•Signsandsymptoms ofinfection\\n•Symptoms thatshouldbereported(e.g.,sustained high-rate pacingrequiring reprogramming)\\n•Protected environments—the patientshouldseekmedicalguidance beforeenteringareasprotected byawarningnotice\\nthatpreventsentrybypatientswhohaveapulsegenerator\\n•MRIscanning—the physician following thepatient'sdevicemustbeconsultedtodetermine eligibility foranMRIscan.\\nBeforeanMRIprocedureisperformed, aphysician andpatientshouldweighthebenefitoftheMRprocedureagainstthe\\nriskoflosingtheBeeper.\\nWARNING: Determine thebeepertypebeforeanMRIscan.TheArmature Beepermaynolongerbeusablefollowing anMRI\\nscan.Comingincontactwiththestrongmagnetic fieldofanMRIscannermaycauseapermanent lossoftheArmature Beeper\\nvolume.Thiscannotberecovered,evenafterleavingtheMRIscanenvironment andexitingMRIProtection Mode.Forthe\\nArmature Beeper,beforeanMRIscanisperformed, aphysician andpatientshouldweighthebenefitoftheMRIscanagainst\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 54}), Document(page_content='52theriskoflosingtheBeeper;aftertheMRIscan,performBeeperevaluation testtodetermine iftheBeeperisusable.Ifthe\\nBeeperisnotusable,itisstronglyrecommended thatpatientsarefollowedonLATITUDE NXTafteranMRIscaniftheyarenot\\nalready.Otherwise, anin-clinicfollow-up scheduleofeverythreemonthsisstronglyrecommended tomonitordevice\\nperformance.\\n•AvoidingpotentialsourcesofEMIinhome,work,andmedicalenvironments\\n•Personsadministering CPR—thepresenceofvoltage(tingling) onthepatient\\'sbodysurfacemaybeexperienced when\\nthepulsegenerator deliversashock\\n•Reliability oftheirpulsegenerator (\"Product Reliability\" onpage50)\\n•Activityrestrictions (ifapplicable)\\n•Minimum heartrate(lowerratelimitofthepulsegenerator)\\n•Frequency offollowup\\n•Travelorrelocation—follow-up arrangementsshouldbemadeinadvanceifthepatientisleavingthecountryofimplant\\n•PatientIDcard—the patientshouldbeadvisedtocarrytheirpatientIDcardatalltimes(atemporary patientIDcardis\\nprovidedwiththedevice,andapermanent IDcardwillbesenttothepatient4to6weeksaftertheimplantformis\\nreceivedbyBostonScientific)\\nNOTE:PatientsshouldpresenttheirpatientIDcardbeforeenteringprotected environments suchasforMRI\\nscanning.\\nPatientHandbook\\nThePatientHandbook isprovidedforeachdevice.\\nItisrecommended thatyoudiscusstheinformation inthePatientHandbook withconcernedindividuals bothbeforeandafter\\nimplantation sotheyarefullyfamiliarwithpulsegenerator operation.\\nInaddition,forpatientswithanImageReady MRConditional Defibrillation System,anImageReady MRConditional Defibrillation\\nSystemMRIPatientGuideisavailable.\\nForadditional copies,contactBostonScientificusingtheinformation onthebackcover.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 55}), Document(page_content='53LEADCONNECTIONS\\nLeadconnections areillustrated below.\\nCAUTION: Priortoimplantation, confirmthelead-to-pulse generator compatibility .Usingincompatibleleadsandpulse\\ngenerators candamagetheconnector and/orresultinpotentialadverseconsequenc es,suchasundersensing ofcardiacactivity\\norfailuretodelivernecessary therapy.\\nWhendeactivating alead,ensuretheleadisfullyinsulated andelectricalnonactivebyusingleadcaps.Whendeactivating a\\nleadport,verifythattheplugandlabeledheaderportmatch.Verifywithaprogrammertheappropriate devicefunctionand\\nnewlyestablished configuration.Theabsenceofaleadorportplugmayaffectdeviceperformance andpotentially leavethe\\npatientwithouteffectivetherapy.\\nNOTE:UseofBostonScientificMRConditional leadsisrequiredforanimplanted systemtobeconsideredMRConditional.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnical Guideformodelnumbersofpulsegenerators,\\nleads,accessories,andothersystemcomponents neededtosatisfytheConditions ofUse.\\nCAUTION: IftheLeadConfiguration isprogrammedtoBipolarwhenaunipolarleadisimplanted, pacingwillnotoccur.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 56}), Document(page_content='54\\n6\\n4\\n5\\n7\\nIS-1 \\nBI\\nDF4-LLHH\\nRV\\nR\\nA\\nIS4-LLLL\\nLV\\n32\\n1[1]RA:White[2]LV:Green[3]RV:Red[4]RA(-)[5]LV(-)[6]SutureHoles[7]RV(-)\\nFigure2.Leadconnectionsandsetscrewlocations, RA:IS-1,RV:DF4-LLHH, LV:IS4-LLLL', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 57}), Document(page_content='55\\n11\\n6\\n7\\n10\\n8\\n9\\nIS-1 \\nBI\\nLV\\nRV\\n–\\n+\\nRA\\nDF-1\\nDF-1\\nIS-1 \\nBI\\n1\\n2\\n3\\n45\\nLV-1 \\nUNI/BI[1]Defib(-):Red[2]Defib(+):Blue[3]RA:White[4]LV:Green[5]RV:White[6]Defib(+)[7]Defib(-)[8]RA(-)[9]RV(-)[10]LV\\n(-)[11]SutureHole\\nFigure3.Leadconnections andsetscrewlocations, RA:IS-1,RV:IS-1/DF-1,LV:LV-1', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 58}), Document(page_content='56\\n6\\n4\\n5\\n7IS-1 \\nBI\\nDF4-LLHH\\nRV\\nRA\\nLV\\nIS-1 \\nUNI/BI\\n1\\n2\\n3[1]RA:White[2]LV:Green[3]RV:Red[4]RA(-)[5]LV(-)[6]SutureHoles[7]RV(-)\\nFigure4.Leadconnections andsetscrewlocations, RA:IS-1,RV:DF4-LLHH, LV:IS-1', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 59}), Document(page_content='57\\n11\\n6\\n7\\n10\\n8\\n9\\nIS-1 \\nB\\nI\\nIS4-LLLL\\nLV\\nR\\nV\\n–\\n+\\nRA\\nDF-1\\nDF-1\\nIS-1 \\nB\\nI\\n1\\n2\\n3\\n45[1]Defib(-):Red[2]Defib(+):Blue[3]RA:White[4]LV:Green[5]RV:White[6]Defib(+)[7]Defib(-)[8]RA(-)[9]RV(-)[10]LV\\n(-)[11]SutureHole\\nFigure5.Leadconnections andsetscrewlocations, RA:IS-1,RV:IS-1/DF-1,LV:IS4-LLLL', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 60}), Document(page_content='58\\n11\\n6\\n7\\n10\\n8\\n9\\nIS-1 \\nBI\\nLV\\nRV\\n–\\n+\\nRA\\nDF-1\\nDF-1\\nIS-1 \\nBI\\nIS-1 \\nUNI/BI1\\n2\\n3\\n45[1]Defib(-):Red[2]Defib(+):Blue[3]RA:White[4]LV:Green[5]RV:White[6]Defib(+)[7]Defib(-)[8]RA(-)[9]RV(-)[10]LV\\n(-)[11]SutureHole\\nFigure6.Leadconnections andsetscrewlocations, RA:IS-1,RV:IS-1/DF-1,LV:IS-1\\nNOTE:Thepulsegenerator caseisusedasadefibrillating electrode unlessthepulsegenerator hasbeenprogrammedtothe\\nDistalCoiltoProximalCoil(or“ColdCan”)ShockVector.\\nIMPLANTING THEPULSEGENERATOR\\nImplantthepulsegenerator byperforming thefollowing stepsinthesequence provided. Somepatientsmayrequirepacing\\ntherapiesimmediately uponconnecting theleadstothepulsegenerator.Insuchcases,considerprogrammingthepulse\\ngenerator beforeorinparallelwithimplanting theleadsystemandformingtheimplantation pocket.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 61}), Document(page_content='59WARNING: Implantofthesystemcannotbeperformed inanMRIsiteZoneIII(andhigher)asdefinedbytheAmerican\\nCollegeofRadiology Guidance Document onMRSafePractices8.Someoftheaccessoriespackaged withpulsegenerators and\\nleads,including thetorquewrenchandstyletwires,arenotMRConditional andshouldnotbebroughtintotheMRIscanner\\nroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nStepA:CheckEquipment\\nItisrecommended thatinstrumentation forcardiacmonitoring, defibrillation, andleadsignalmeasurement shouldbeavailable\\nduringtheimplantprocedure.ThisincludesthePRMsystemwithitsrelatedaccessoriesandthesoftwareapplication. Before\\nbeginning theimplantation procedure,becomecompletelyfamiliarwiththeoperation ofalltheequipment andtheinformation\\nintherespective operator\\'s anduser\\'smanuals. Verifytheoperational statusofallequipment thatmaybeusedduringthe\\nprocedure.Incaseofaccidental damageorcontamination, thefollowing shouldbeavailable:\\n•Sterileduplicates ofallimplantable items\\n•Sterilewand\\n•SterilePSAcables\\n•Torqueandnon-torque wrenches\\nDuringtheimplantation procedure,alwayshaveastandardexternaldefibrillator withexternalpadsorpaddlesavailableforuse\\nduringdefibrillation threshold testing.\\nStepB:InterrogateandCheckthePulseGenerator\\nThePRMcommunicates withthepulsegenerator usingatelemetry wand.Afterinitiatingcommunication withthewand,the\\nPRMcanusewandless ZIPtelemetry (two-way RFcommunication) tointerfacewithRFcapablepulsegenerators. Telemetry is\\nrequiredtodirectcommands fromthePRMsystem,modifydeviceparameter settingsandconductdiagnostics tests.\\nForadditional technicalspecifications regardingtelemetry function,referto\"FederalCommunications Commission (FCC)\"on\\npage45.\\n8.KanalE,Barkovich AJ,BellC,etal.ACRguidance document onMRsafepractices:2013.J.Magn.Reson.Imaging2013;37:501-530.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 62}), Document(page_content=\"60Tomaintainsterility,testthepulsegenerator asdescribed belowbeforeopeningthesterileblistertray.Thepulsegenerator\\nshouldbeatroomtemperatur etoensureaccuratelymeasured parameters.\\n1.Interrogate thepulsegenerator usingthePRM.Verifythatthepulsegenerator's TachyModeisprogrammedtoStorage.\\nIfotherwise, contactBostonScientificusingtheinformation onthebackcover.\\nTobeginaZIPtelemetry session,verifythattheZOOMWirelessTransmitter isconnected tothePRMviatheUSBcable\\nandthatthegreenlightontopofthetransmitter isilluminated. Toinitiatecommunication withalldevices,positionthe\\nwandoverthePGandusethePRMtoInterrogate thepulsegenerator.Keepthetelemetry wandinpositionuntileithera\\nmessageappears,indicating thatthetelemetry wandmayberemovedfromproximity ofthepulsegenerator,ortheZIP\\ntelemetry lightilluminates onthePRMsystem.SelecttheEndSessionbuttontoquitatelemetry sessionandreturnto\\nthestartupscreen.Radiofrequency interferenc emaytemporarily disruptZIPtelemetry communication. Increasing the\\ndistancefromthesourceofinterfering signalsorrepositioning theZOOMWirelessTransmitter mayimproveZIP\\ntelemetry performance. IfZIPtelemetry performance isnotsatisfactory ,theoptionofusingwandedtelemetry is\\navailable.\\n2.Performamanualcapacitorre-formation.\\n3.Reviewthepulsegenerator's currentbatterystatus.Countersshouldbeatzero.Ifthepulsegenerator batterystatusis\\nnotatfullcapacity,donotimplantthepulsegenerator.ContactBostonScientificusingtheinformation onthebackcover.\\nStepC:ImplanttheLeadSystem\\nThepulsegenerator requiresaleadsystemforsensing,pacing,anddelivering shocks.Thepulsegenerator canuseitscaseasa\\ndefibrillating electrode.\\nAfunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriate sensingandpacinginallchambers,\\nregardless ofprogrammedconfiguration,inconjunction withalltherapyrequiredleads.\\nSelectionofleadconfigurationandspecificsurgicalproceduresisamatterofprofessional judgment. Thefollowing leadsare\\navailableforusewiththepulsegenerator depending onthedevicemodel.\\n•Bipolarendocardial cardioversion/defibrillation andpacingleadsystem\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 63}), Document(page_content=\"61•Ventricular endocardial bipolarlead\\n•Atrialbipolarlead\\n•Unipolarorbipolarleftventricular lead\\n•Superiorvenacavaleadcoupledwithaventricular patchlead\\n•Quadripolar leftventricular lead\\nNOTE:Ifacoronaryvenousleadcannotbeusedandthephysician's medicaljudgment indicatesthatalimitedleft\\nthoracotomyisjustifiedtoplaceanepicardial lead,theuseofeitherasutureable,steroid-eluting pace/senseepicardial leador\\nsutureless epicardial pace/sense leadisrecommended.\\nNOTE:UseofBostonScientificMRConditional leadsisrequiredforanimplanted systemtobeconsideredMRConditional.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnical Guideformodelnumbersofpulsegenerators,\\nleads,accessories,andothersystemcomponents neededtosatisfytheConditions ofUse,andforwarnings andprecautions\\nregardingMRIscanning.\\nCAUTION: Theabsenceofaleadorpluginaleadportmayaffectdeviceperformance andpotentially leavethepatient\\nwithouteffectivetherapy.Ifaleadisnotused,verifythattheplugandlabeledheaderportmatch(i.e.,IS-1,DF-1,LV-1,IS4,or\\nDF4).Fullyinserttheplugintheunusedportandthentightenthesetscrewontotheplug.Verifyappropriate devicefunction\\nusingtheprogrammer.\\n•Afunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriate sensingandpacinginall\\nchambers, regardlessofprogrammedconfiguration.ThisincludesCRTdevicesprogrammedtoAAI(R)orLV-Onlypacing.\\n•Lackofafunctional RVleadmayresultinundersensing, and/oroversensing andleavethepatientwithouteffective\\ntherapy.\\nCAUTION: Donotsuturedirectlyovertheleadbody,asthismaycausestructural damage.Usethesuturesleevetosecure\\ntheleadproximaltothevenousentrysitetopreventleadmovement.\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 64}), Document(page_content='62Whichever leadconfigurationisusedforbothpacing/sensing anddefibrillating, severalconsiderationsandcautionsshouldbe\\nheeded.Factorssuchascardiomegaly ordrugtherapymaynecessitate repositioning ofthedefibrillating leadsorsubstituting\\noneleadforanothertofacilitatearrhythmia conversion. Insomeinstances, noleadconfigurationmaybefoundthatprovides\\nreliablearrhythmia termination atenergylevelsavailablefromthepulsegenerator.Implantation ofthepulsegenerator isnot\\nrecommended inthesecases.\\nImplanttheleadsviathesurgicalapproach chosen.\\nNOTE:Shouldleadperformance changesoccurwhichcannotberesolvedwithprogramming,theleadmayneedtobe\\nreplacedifnoadapterisavailable.\\nNOTE:Useofadaptersisinconsistent withtheConditions ofUserequiredforMRConditional status.RefertotheImageReady\\nMRConditional Defibrillation SystemMRITechnical Guideforwarnings, precautions, andotherinformation aboutMRIscanning.\\nStepD:TakeBaselineMeasurements\\nOncetheleadsareimplanted, takebaselinemeasurements. Evaluatetheleadsignals.Ifperforming apulsegenerator\\nreplacement procedure,existingleadsshouldbereevaluated, (e.g.,signalamplitudes, pacingthresholds,andimpedance). The\\nuseofradiographymayhelpensureleadpositionandintegrity.Iftestingresultsareunsatisfactory ,leadsystemrepositioning or\\nreplacement mayberequired.\\n•Connectthepace/senselead(s)toapacingsystemanalyzer(PSA).\\nWARNING: ForleadsthatrequiretheuseofaConnector Tool,usecautionhandlingtheleadterminalwhentheConnector\\nToolisnotpresentonthelead.Donotdirectlycontacttheleadterminalwithanysurgicalinstruments orelectricalconnections\\nsuchasPSA(alligator) clips,ECGconnections,forceps,hemostats, andclamps.Thiscoulddamagetheleadterminal,possibly\\ncompromisingthesealingintegrityandresultinlossoftherapyorinappropriate therapy,suchasashortwithintheheader.\\n•Pace/sense leadmeasurements, measuredapproximate ly10minutesafterinitialplacement (acute)orduringa\\nreplacementprocedure(chronic), arelistedbelow.Valuesotherthanwhataresuggested inthetablemaybeclinically\\nacceptableifappropriate sensingcanbedocumented withthecurrentlyprogrammedvalues.Considerreprogramming', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 65}), Document(page_content='63thesensitivity parameter ifinappropriate sensingisobserved. Notethatthepulsegenerator measurements maynot\\nexactlycorrelatetothePSAmeasurements duetosignalfiltering.\\nTable9.Leadmeasurements\\nPace/senselead(acute) Pace/senselead(chronic)Shockinglead(acuteand\\nchronic)\\nR-WaveAmplitudeab>5mV >5mV >1.0mV\\nP-WaveAmplitudeab>1.5mV >1.5mV\\nR-WaveDurationbcd<100ms <100ms\\nPacingThreshold (right\\nventricle)<1.5Vendocardial\\n<2.0Vepicardial<3.0Vendocardial\\n<3.5Vepicardial\\nPacingThreshold (left\\nventricle)<2.5Vcoronaryvenous\\n<2.0Vepicardial<3.5Vcoronaryvenous\\n<3.5Vepicardial\\nPacingThreshold (atrium) <1.5Vendocardial <3.0Vendocardial\\nLeadimpedance (at5.0V\\nand0.5msatrium)e>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 66}), Document(page_content=\"64Table9.Leadmeasurements (continued)\\nPace/senselead(acute) Pace/senselead(chronic)Shockinglead(acuteand\\nchronic)\\nLeadimpedance (at5.0V\\nand0.5msrightventricle)e>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>20Ω\\n<programmedHigh\\nImpedance Limit(125–200\\nΩ)\\nLeadimpedance (at5.0V\\nand0.5msleftventricle)>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg\\na.Amplitudes lessthan2mVcauseinaccurate ratecountinginthechronicstate,andresultininabilitytosenseatachyarrhythmia orthe\\nmisinterpretation ofanormalrhythmasabnormal.\\nb.LowerR-waveamplitudes andlongerdurationmaybeassociated withplacement inischemicorscarredtissues.Sincesignalqualitymay\\ndeteriorate chronically ,effortsshouldbemadetomeettheabovecriteriabyrepositioning theleadstoobtainsignalswiththelargestpossible\\namplitude andshortestduration.\\nc.Durations longerthan135ms(thepulsegenerator's refractoryperiod)mayresultininaccuratecardiacratedetermination, inabilitytosensea\\ntachyarrhythmia, orinthemisinterpretation ofanormalrhythmasabnormal.\\nd.Thismeasurement isnotinclusiveofcurrentofinjury.\\ne.Changesinthedefibrillation electrode surfacearea,suchaschanging fromatriadconfigurationtoasinglecoilconfiguration,canaffectthe\\nimpedance measurements. Baselinedefibrillation impedance measurements shouldfallwithintherecommended valuesindicated inthetable.\\nf.TheLowImpedance Limitisprogrammable between200–500Ω.\\ng.TheHighImpedance Limitisprogrammable between2000–3000 Ω.\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 67}), Document(page_content=\"65Iftheleadintegrityisinquestion, standardleadtroubleshooting testsshouldbeusedtoassesstheleadsystemintegrity.\\nTroubleshooting testsinclude,butarenotlimitedto,thefollowing:\\n•Electrogramanalysiswithpocketmanipulation\\n•X-rayorfluoroscopicimagereview\\n•Additional maximum-energy shocks\\n•ProgrammingtheShockLeadVector\\n•WirelessECG\\n•Invasivevisualinspection\\nStepE:FormtheImplantation Pocket\\nUsingstandardoperating procedurestoprepareanimplantation pocket,choosethepositionofthepocketbasedonthe\\nimplanted leadconfigurationandthepatient'sbodyhabitus.Givingconsiderationtopatientanatomyandpulsegenerator size\\nandmotion,gentlycoilanyexcessleadandplaceadjacenttothepulsegenerator.Itisimportant toplacetheleadintothe\\npocketinamannerthatminimizes leadtension,twisting,sharpangles,and/orpressure.Pulsegenerators aretypically\\nimplanted subcutaneously inordertominimize tissuetraumaandfacilitateexplant.However,deeperimplantation (e.g.,\\nsubpectoral) mayhelpavoiderosionorextrusion insomepatients.\\nIfanabdominal implantissuitable,itisrecommended thatimplantation occurontheleftabdominal side.\\nNOTE:Anabdominal implantsiteisinconsistent withtheConditions ofUseforMRConditional MRIscanning. Refertothe\\nImageReady MRConditional Defibrillation SystemMRITechnical Guideforwarnings, precautions andotherinformation about\\nMRIscanning.\\nIfitisnecessary totunnelthelead,considerthefollowing:\\nWARNING: ForleadsthatrequiretheuseofaConnector Tool,usecautionhandlingtheleadterminalwhentheConnector\\nToolisnotpresentonthelead.Donotdirectlycontacttheleadterminalwithanysurgicalinstruments orelectricalconnections\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 68}), Document(page_content='66suchasPSA(alligator) clips,ECGconnections,forceps,hemostats, andclamps.Thiscoulddamagetheleadterminal,possibly\\ncompromisingthesealingintegrityandresultinlossoftherapyorinappropriate therapy,suchasashortwithintheheader.\\nWARNING: DonotcontactanyotherportionoftheDF4–LLHH orDF4–LLHO leadterminal,otherthantheterminalpin,even\\nwhentheleadcapisinplace.\\nDonotcontactanyotherportionoftheIS4–LLLLleadterminal,otherthantheterminalpin,evenwhentheleadcapisinplace.\\n•Ifacompatibletunnelerisnotused,captheleadterminalpins.APenrosedrain,largechesttube,ortunneling toolmay\\nbeusedtotunneltheleads.\\n•ForDF4-LLHH orDF4-LLHO leads,ifacompatible tunneling tipand/ortunnelerkitisnotused,captheleadterminaland\\ngriponlytheterminalpinwithahemostat orequivalent.\\n•ForIS4-LLLLleads,ifacompatibletunneling tipand/ortunnelerkitisnotused,captheleadterminalandgriponlythe\\nterminalpinwithahemostat orequivalent.\\n•Gentlytunneltheleadssubcutaneously totheimplantation pocket,ifnecessary.\\n•Reevaluate allleadsignalstodetermine ifanyoftheleadshavebeendamaged duringthetunneling procedure.\\nIftheleadsarenotconnected toapulsegenerator atthetimeofleadimplantation, theymustbecappedbeforeclosingthe\\nincision.\\nStepF:ConnecttheLeadstothePulseGenerator\\nToconnectleadstothepulsegenerator,useonlythetoolsprovidedinthepulsegenerator steriletrayoraccessorykit.Failure\\ntousethesuppliedtorquewrenchmayresultindamagetothesetscrews, sealplugs,orconnector threads.Donotimplantthe\\npulsegenerator ifthesealplugsappeartobedamaged. Retainthetoolsuntilalltestingproceduresarecomplete andthepulse\\ngenerator isimplanted.\\nNOTE:Somepatientsmayrequirepacingtherapies immediately uponconnectingtheleadstothepulsegenerator.Insuch\\ncases,considerprogrammingthepulsegenerator beforecontinuing.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 69}), Document(page_content='67Leadsshouldbeconnected tothepulsegenerator inthefollowing sequence (forpulsegenerator headerandsetscrewlocation\\nillustrations, referto\"LeadConnections\" onpage53):\\n1.Rightventricle. ConnecttheRVleadfirstbecauseitisrequiredtoestablishRV-based timingcyclesthatyield\\nappropriate sensingandpacinginallchambers, regardless oftheprogrammedconfiguration.\\n•InmodelswithanIS-1RVleadport,insertandsecuretheterminalpinofanIS-1RVpace/sense lead.\\n•InmodelswithaDF4-LLHH RVleadport,insertandsecuretheterminalpinofaDF4-LLHH orDF4-LLHO lead.\\n2.Rightatrium.\\n•InmodelswithanIS-1RAleadport,insertandsecuretheterminalpinofanIS-1atrialpace/sense lead.\\n3.Leftventricle.\\n•InmodelswithanIS-1LVleadport,insertandsecuretheterminalpinofanIS-1coronaryvenouspace/sense lead.\\n•InmodelswithanLV-1LVleadport,insertandsecuretheterminalpinofanLV-1coronaryvenouspace/sense\\nlead.\\n•InmodelswithaIS4-LLLLLVleadport,insertandsecuretheterminalpinofaIS4-LLLLlead.\\nWARNING: Whenimplanting asystemwhichusesbothaDF4-LLHH/LLHO andIS4-LLLLlead,ensurethattheleadsare\\ninsertedandsecuredintheappropriat eports.Insertingaleadintoanincorrectportwillresultinunanticipated devicebehavior\\n(potentially leavingthepatientwithouteffectivetherapy).\\n4.Defibrillation lead.\\n•InmodelswithDF-1leadports,firstinsertandsecurethedefibrillation leadanode(+,proximal) intothe(+)DF-1\\nleadport.Theninsertandsecuretheleadcathode(–,distal)intothe(–)DF-1leadport.\\nCAUTION: ForIS-1/DF-1leads,neverchangetheshockwaveform polaritybyphysically switching theleadanodesand\\ncathodesinthepulsegenerator header—use theprogrammable Polarityfeature.Devicedamageornonconversion ofthe\\narrhythmia post-operatively mayresultifthepolarityisswitchedphysically.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 70}), Document(page_content='68Connecteachleadtothepulsegenerator byfollowing thesesteps(foradditional information aboutthetorquewrench,referto\\n\"BidirectionalTorqueWrench\"onpage82):\\n1.Checkforthepresenceofanybloodorotherbodyfluidsintheleadportsonthepulsegenerator header.Iffluid\\ninadvertently enterstheports,cleanthemthoroughly withsterilewater.\\n2.Ifapplicable, removeanddiscardthetipprotection beforeusingthetorquewrench.\\n3.Gentlyinsertthetorquewrenchbladeintothesetscrewbypassingitthroughthepreslit,centerdepression oftheseal\\nplugata90°angle(Figure7Insertingthetorquewrenchonpage69).Thiswillopenupthesealplug,relievingany\\npotentialpressurebuild-upfromtheleadportbyproviding apathwaytoreleasetrappedfluidorair.\\nNOTE:Failuretoproperlyinsertthetorquewrenchinthepreslitdepression ofthesealplugmayresultindamageto\\nthepluganditssealingproperties.\\nCAUTION: Donotinsertaleadintothepulsegenerator connector withouttakingthefollowing precautionstoensure\\nproperleadinsertion:\\n•Insertthetorquewrenchintothepreslitdepression ofthesealplugbeforeinsertingtheleadintotheport,to\\nreleaseanytrappedfluidorair.\\n•Visuallyverifythatthesetscrewissufficiently retractedtoallowinsertion. Usethetorquewrenchtoloosenthe\\nsetscrewifnecessary.\\n•Fullyinserteachleadintoitsleadportandthentightenthesetscrewontotheterminalpin.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 71}), Document(page_content='69\\nFigure7.Insertingthetorquewrench\\n4.Withthetorquewrenchinplace,fullyinserttheleadterminalintotheleadport.Theleadterminalpinshouldbeclearly\\nvisiblebeyondtheconnector blockwhenviewedthroughthesideofthepulsegenerator header.Placepressureonthe\\nleadtomaintainitspositionandensurethatitremainsfullyinsertedintheleadport.\\nCAUTION: Inserttheleadterminalstraightintotheleadport.Donotbendtheleadnearthelead-header interface.\\nImproper insertioncancauseinsulation orconnectordamage.\\nNOTE:Ifnecessary,lubricatetheentireleadterminal(areashowninFigure8DF4LeadTerminalonpage69)sparingly\\nwithsterilewaterorsterilemineraloiltomakeinsertioneasier.\\nFigure8.DF4LeadTerminal', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 72}), Document(page_content='70\\nFigure9.IS4LeadTerminal\\nNOTE:ForIS-1leads,becertainthattheterminalpinvisiblyextendsbeyondtheconnector blockatleast1mm.\\nNOTE:ForDF4-LLHH orDF4-LLHO leads,theterminalpinmustbeinsertedbeyondthesetscrewblocktoenablea\\nproperconnection. Visualization oftheterminalpininsertionindicatorbeyondthesetscrewblockmaybeusedtoconfirm\\nthattheterminalpinisfullyinsertedintotheleadport.\\nNOTE:ForIS4-LLLLleads,theterminalpinmustbeinsertedbeyondthesetscrewblocktoenableaproperconnection.\\nVisualization oftheterminalpininsertionindicatorbeyondthesetscrewblockmaybeusedtoconfirmthattheterminal\\npinisfullyinsertedintotheleadport.\\n5.Applygentledownward pressureonthetorquewrenchuntilthebladeisfullyengagedwithinthesetscrewcavity,taking\\ncaretoavoiddamagetothesealplug.Tightenthesetscrewbyslowlyturningthetorquewrenchclockwise, untilit\\nratchetsonce.Thetorquewrenchispresettoapplytheproperamountofforcetothecaptivesetscrew; additional\\nrotationandforceisunnecessary .\\n6.Removethetorquewrench.\\n7.Applygentletractiontotheleadtoensureasecureconnection.\\n8.Iftheleadterminalisnotsecure,attempttoreseatthesetscrew.Reinsertthetorquewrenchasdescribed above,and\\nloosenthesetscrewbyslowlyturningthewrenchcounterclockwise, untiltheleadisloose.Thenrepeatthesequence\\nabove.\\n9.Ifaleadportisnotused,insertaplugintotheunusedportandtightenthesetscrew.\\nCAUTION: Theabsenceofaleadorpluginaleadportmayaffectdeviceperformance andpotentially leavethe\\npatientwithouteffectivetherapy.Ifaleadisnotused,verifythattheplugandlabeledheaderportmatch(i.e.,IS-1,DF-1,\\nLV-1,IS4,orDF4).Fullyinserttheplugintheunusedportandthentightenthesetscrewontotheplug.Verifyappropriate\\ndevicefunctionusingtheprogrammer.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 73}), Document(page_content=\"71•Afunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriate sensingandpacingin\\nallchambers, regardless ofprogrammedconfiguration.ThisincludesCRTdevicesprogramm edtoAAI(R)orLV-\\nOnlypacing.\\n•Lackofafunctional RVleadmayresultinundersensing, and/oroversensing andleavethepatientwithout\\neffectivetherapy.\\nStepG:EvaluateLeadSignals\\n1.Takethepulsegenerator outofpower-savingStoragemodebyprogrammingtheTachyModetoOff.\\nCAUTION: Topreventinappropriate shocks,ensurethatthepulsegenerator's TachyModeisprogrammedtoOffwhennot\\ninuseandbeforehandlingthedevice.Fortachyarrhythmia detection andtherapy,verifythattheTachyModeisprogrammedto\\nMonitor+Therapy.\\n2.Insertthepulsegenerator intotheimplantation pocket.\\n3.Evaluatethepace/senseanddefibrillation leadsignalsbyviewingthereal-timeEGMsandmarkers.Thesignalfromthe\\nimplanted defibrillation leadsshouldbecontinuous andwithoutartifact,similartoabody-surface ECG.Adiscontinuous\\nsignalmayindicateapoorconnection, leadfractureorotherwise damaged lead,oraninsulation breakthatwould\\nnecessitate leadreplacement.Inadequate signalsmayresultinfailureofthepulsegenerator systemtodetectan\\narrhythmia, inabilitytodeliverprogrammedtherapy,orunnecessary deliveryoftherapy.Leadmeasurements should\\nreflectthoseabove(Table9Leadmeasurements onpage63).\\nCAUTION: Takecaretoensurethatartifactsfromtheventricles arenotpresentontheatrialchannel,oratrialoversensing\\nmayresult.Ifventricular artifactsarepresentintheatrialchannel,theatrialleadmayneedtoberepositioned tominimize its\\ninteraction.\\n4.Evaluateallleadimpedances.\\nCAUTION: Iftotalshockingleadimpedance duringimplantislessthan20Ω,verifytheproximalcoilisnotincontactwith\\nthepulsegenerator surface.Ameasurement oflessthan20Ωisanindication ofashortsomewhere inthesystem.Ifrepeated\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 74}), Document(page_content=\"72measurementsshowthetotalshockingleadimpedance islessthan20Ω,theleadand/orpulsegenerator mayneedtobe\\nreplaced.\\nCAUTION: Patientsshouldbetestedfordiaphragmatic stimulation bypacingtheLVleadthroughthepulsegenerator at\\n7.5Vandadjusting theleadconfigurationsandleadpositionasnecessary.PSAtestingathigheroutputs(e.g.,10.0V)mayalso\\nbeconsideredtobettercharacteriz estimulation margins.Theprobability ofdiaphragmatic stimulation increases whenapacing\\nsystemincludesanLVleadbecauseofthislead'sproximity tothephrenicnerve.\\nTheHighImpedance Limitisnominally setto2000Ω,andisprogrammable between2000and3000Ωin250Ωincrements.\\nTheLowImpedance Limitisnominally setto200Ω,andisprogrammable between200and500Ωin50Ωincrements.\\nConsiderthefollowing factorswhenchoosingavaluefortheimpedance limits:\\n•Forchronicleads,historicalimpedance measurements forthelead,aswellasotherelectricalperformance indicators such\\nasstabilityovertime\\n•Fornewlyimplanted leads,thestartingmeasured impedance value\\nNOTE:Depending onleadmaturation effects,duringfollow-up testingthephysician maychoosetoreprogramthe\\nimpedanc elimits.\\n•Pacingdependenc eofthepatient\\n•Recommended impedanc erangeforthelead(s)beingused,ifavailable\\nTheShockLowImpedance Limitisfixedat20Ω.TheShockHighImpedance Limitisnominally setto125Ω,andis\\nprogrammable between125and200Ωin25Ωincrements. Considerthefollowing factorswhenchoosingavaluefortheHigh\\nImpedanc eLimits:\\n•Forchronicleads,historicalimpedance measurements forthelead,aswellasotherelectricalperformance indicators such\\nasstabilityovertime\\n•Fornewlyimplanted leads,thestartingmeasured impedance value\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 75}), Document(page_content=\"73NOTE:Depending onleadmaturation effects,duringfollow-up testingthephysician maychoosetoreprogramtheHigh\\nImpedance Limits.\\n•Recommended impedance rangeforthelead(s)beingused,ifavailable\\n•Theimpedance valueofahighormaximum energyshockimpedance test\\nShockingleadimpedance readingsbetween20ΩandtheprogrammedHighImpedance Limitareconsideredin-range. Ifabrupt\\norlargeimpedance fluctuations orout-of-range conditions areobserved, considerthefollowing:\\n•Verifytheconfiguration—ensure theprogrammedShockVectormatchestheconfigurationoftheimplanted lead(e.g.,\\nuseRVCoiltoCanwithasingle-coil lead).\\n•Verifytheconnection—ensur etheshockinglead'sterminalpinsareplacedinthecorrectleadportsandverifyasecure\\nleadconnection.\\n•Verifythecontact—ensur ethedeviceisinsideawetimplantpocketsincethepulsegenerator caseservesasanactive\\nelectrode intheV-TRIADconfiguration.Avoidpocketmanipulation duringthetest.\\n•Turnoffsourcesofexternalnoise(e.g.,electrocautery equipment, monitors).\\n•Useothertroubleshooting tools,asneeded,tofurtherassessleadsystemintegrity,including electrogramanalysis,X-ray\\norfluoroscopicimagereview,orinternalvisualinspection.\\nNOTE:Becausethisdeviceusesasubthreshold testpulsetoconductshockleadimpedance measurements, itcanbedifficult\\ntomeasureresponses totestsignalswhenelectricalinterferenc eor“noise”(e.g.,electrocautery orexternalmonitoring\\nequipment attacheddirectlytothepatient)ispresentduringthetest.Thismayresultinimpedance measurement variations,\\nparticularly atimplant.Intheabsenceofsuchelectricalinterferenc e,shockleadimpedance readingswillbemorestable.\\nStepH:ProgramthePulseGenerator\\n1.ChecktheProgrammerClockandsetandsynchroniz ethepulsegenerator asnecessary sothatthepropertimeappears\\nonprintedreportsandPRMstripchartrecordings.\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 76}), Document(page_content='742.ItmaybeusefultoprogramtheBeepDuringCapacitor ChargefeaturetoOnduringconversion testingandimplantation\\ntohelprecognizewhenthepulsegenerator ischargingtodeliverashock.\\n3.Performamanualcapacitorre-formationifnotalreadyperformed.\\n4.Programthepulsegenerator appropriat elyifaleadport(s)isnotused.\\n5.Programthepulsegenerator todesiredparameters appropriate forthepatientforconversion testing.\\nConsiderthefollowing whenprogrammingthepulsegenerator:\\n•Theminimum 2Xvoltageor3Xpulsewidthsafetymarginisrecommended foreachchamberbasedonthecapture\\nthresholds, whichshouldprovideanadequate safetymarginandhelppreservebatterylongevity.\\n•WhenSmartBlankingisused,itispossiblethatpolarization artifactsfollowing atrialpacingmaybedetectedasR-waves\\nandinhibitventricular pacing(aftertachytherapyorhigh-output ventricular pacing).Ifthepatientispacemaker-\\ndependent, testforpropersensingaftershocktherapy.Ifoversensing isoccurring post-shock,bepreparedtousethe\\nSTATPACEcommand.\\n•Programmingalongerblankingperiodmayincreasethelikelihood ofundersensing R-waves.\\n•Programmingashorterblankingperiodmayincreasethelikelihood forventricular oversensing ofanatrialpacedevent.\\n•Toreducetheriskofventricular undersensing duetoV-BlankafterA-Pace(whenadual-chamber pacingmodewithRate\\nSmoothing orRateAdaptivePacingisnecessary):\\n–ReducetheLRL\\n–ShortentheAVDelayoruseDynamicAVDelayandreducetheminimum DynamicAVDelaysetting\\n–IncreasetheDownRateSmoothing percentagetothelargestpossiblevalue\\n–DecreasetheRecoveryTimeforRateAdaptivePacingmodes\\n–ReducetheMTRorMPRifDownRateSmoothing ison', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 77}), Document(page_content='75–ReducetheMSRifthepacingmodeisrateadaptive\\n•WhenreprogrammingtheRhythmMatch Thresholdvalue,considerthefollowing:\\n–Reviewthemeasured RhythmMatch valuesforpreviousepisodesofVTandSVT(inducedorspontaneous)\\n–Toincreasethelikelihood ofappropriate treatment ofVT,theRhythmMatch Threshold shouldbeprogrammed\\nabovethemeasured RhythmMatch valuesofanyVTs\\n–Toincreasethelikelihood ofappropriate inhibition oftherapyforSVT,theRhythmMatch Threshold shouldbe\\nprogrammedbelowthemeasured RhythmMatch valuesofanySVTs\\n–Ingeneral,thesensitivity ofVTdetection declineswithlowerprogrammedRhythmMatch Threshold values,\\nthereforeformaximum sensitivity toVT,thehighestappropriate RhythmMatch Threshold valueshouldbe\\nprogrammed.\\n–Measured RhythmMatch valuesmayalsobeusefulforprogrammingotherRhythmIDparameters including Atrial\\nTachyarrhythmia Discrimination, AFibRateThreshold,andStability\\n•WhenprogrammingMTR,considerthepatient’scondition, age,generalhealth,sinusnodefunction,andthatahighMTR\\nmaybeinappropriateforpatientswhoexperience anginaorothersymptoms ofmyocardial ischemiaathigherrates.\\n•WhenprogrammingMSR,considerthepatient’scondition, age,generalhealthandthatadaptive-rat epacingathigher\\nratesmaybeinappropriate forpatientswhoexperienceanginaorothersymptoms ofmyocardial ischemiaatthese\\nhigherrates.Anappropriate MSRshouldbeselectedbasedonanassessment ofthehighestpacingratethatthepatient\\ncantoleratewell.\\n•Forheartfailurepatientswithsecond-andthird-degr eeAVblock,programminglongAtrialRefractory periodsin\\ncombination withcertainAVDelayperiodscancause2:1blocktooccurabruptlyattheprogrammedMTR.\\n•Certainconditions maycausethetemporary lossofCRTorAVsynchrony duetoWenckebach-lik ebehavior,andheart\\nfailurepatientsmaybecomesymptomatic ifCRTiscompromised.Considerpatientcondition whenprogrammingfeatures\\nsuchasMTR,AFR,RateSmoothing, andfeaturesthatswitchtoVVIorVVI-likebehavior.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 78}), Document(page_content=\"76•PriortoprogrammingRVATon,considerperforming aCommanded Ventricular Automatic ThresholdMeasurement to\\nverifythatthefeaturefunctions asexpected.\\n•Inpacemaker-dependent patients,usecarewhenconsidering settingNoiseResponse toInhibitPacingaspacingwillnot\\noccurinthepresenceofnoise.\\n•Toresolvesuspected impedance-based interactions withtheMV/Respiratory Sensor,programthesensortoOff.\\nCAUTION: Topreventinappropriateshocks,ensurethatthepulsegenerator's TachyModeisprogrammedtoOffwhennot\\ninuseandbeforehandlingthedevice.Fortachyarrhythmia detection andtherapy,verifythattheTachyModeisprogrammedto\\nMonitor+Therapy.\\nStepI:TestforAbilitytoConvertVentricular Fibrillation andInducibleArrhythmias\\nAfterobtaining acceptablesignalsfromtheimplanted leads,thephysician maychoosetoperformVTandVFconversion testing\\ntodetermine (1)iftheconfigurationandpositionoftheimplanted leadsareappropriate forthepatientand(2)ifthepulse\\ngenerator’ sprogrammedshockenergyormaximum-shock energywillbesufficient toconvertarrhythmias reliablyand(3)if\\nAGCanddetection enhancementsareprogrammedappropriately todetectVF/VT.Aconversion testconsistsofinducingthe\\narrhythmia andthenattempting toconvertthearrhythmia withapreselected energylevel.\\nDemonstr atingconversion ofventricular fibrillation issuggested beforeimplanting apulsegenerator becauseashockdelivered\\nduringventricular tachycardia hasthepotentialtoacceleratethearrhythmia. Intraoperativetestingmaybeminimizedby\\nperforming onlyVFtestingattimeofimplantandperforming VTtestingpost-operatively intheelectrophysiology labpriorto\\nthepatient’sdischarge.\\nIftheconversion isunsuccessful,thepatientshouldberescuedusinganappropriate externaldefibrillator .Aspartoftheoverall\\nclinicalevaluation duringconversion testingandevaluation ofspontaneous episodesduringfollowup,ensurethereisnodelay\\norinterruption intachyarrhythmia detection andtherapydelivery.Performadditional evaluation ifanydiversion ofcharging\\ncyclesorshockdeliveryisobserved.\\nIfconversion testingisperformed, thepermanently programmedparameters maybethesameasthoseusedduringtesting,or\\ntheymaybemodifiedtodifferentvalues.Thedevicecanbeprogrammedwiththeintendedfinalparameter settingsforallVT/\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 79}), Document(page_content=\"77VF(multiplezones),orwithasinglezoneVFsettingwitharatethreshold belowthatofanyknownarrhythmia. Whenno\\nconversion testingisperformed inpatientswithprimaryprevention indications, aphysician shouldconsiderthathighdetection\\nratescanlimittheabilityofthedevicetoaccuratelydetectandtreatpolymorphic tachyarrhythmias. Itisimportant toevaluate\\nthedevice'sstoreddiagnostic dataandEGMs,including theintervalplot,afterconversion testing(referto“Tachyarrhythmia\\nProgrammingConsiderations” below).Programmingfinalratethresholds forVT/VFtohighervalues,orlesssensitiveAGC\\nsettings,thanthetestedparameters mayresultinunder-detection oflaterspontaneous tachyarrhythmias.\\nWARNING: Alwayshaveexternaldefibrillation equipment availableduringimplantandelectrophysiologic testing.Ifnot\\nterminated inatimelyfashion,aninducedventricular tachyarrhythmia canresultinthepatient'sdeath.\\nNOTE:Ifopenchestsurgeryisperformed andachestretractorisused,removeitbeforeconversion testingtobestsimulate\\ntheambulatory conditions inwhichthepulsegenerator willoperateandtoavoidpotentialshuntingofenergy.\\nInducethePatient’sArrhythmia\\nAnarrhythmia canbeinducedbyusingtheinduction featuresofthepulsegenerator.\\nAllowthepatient’sbloodpressureandelectrophysiologic statustoreturntobaselinebetweenarrhythmia inductions, whether\\nsuccessfulorunsuccessful.Theminimum timebetweenconversion testsshouldbebasedontheclinical(hemodynamic and\\nmetabolic) stabilityofthepatientandthephysician’s discretion.\\nDuringeacharrhythmia induction, notetheheartratetodetermine theappropriate ratethreshold values.Ventricular cycle\\nlengthsthatoccurclosetobutbelowthelowestprogrammedratethreshold valuemaybedetectedasnormalsinusrhythm.To\\nprovidesufficient opportunity fordetection, theratethreshold value(s)shouldbeprogramm edatleast10bpmbelowtherate\\nofthearrhythmia(s) intendedtobetreated.\\nPerformtheInduction\\n1.Verifythepulsegenerator isintheimplantation pocket.Temporarily closethepocketenoughtoensurethatthepulse\\ngenerator willremaininpositionduringconversion testing.Makesurethepulsegenerator hasgoodcontactwith\\nsurrounding tissue;flushthepocketwithsalinesolution,ifnecessary,toavoidadrypocket.\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 80}), Document(page_content='78CAUTION: Donotallowanyobjectthatiselectrically conductive tocomeintocontactwiththeleadordeviceduring\\ninduction becauseitmayshuntenergy,resultinginlessenergygettingtothepatient,andmaydamagetheimplanted system.\\n2.Verifymagnetfunctionandtelemetry toensurethepulsegenerator iswithinacceptablerange.\\n3.Programtheappropriat eparameters andchangethepulsegenerator TachyModetoMonitor+Therapy.\\n4.Performtheinduction usingtheprogrammer.\\nTestingEnergyRequirements andThresholds forSuccessfulDefibrillation\\nDefibrillation energyrequirements andthreshold testingforsuccessfuldefibrillation shouldbeperformed atimplant.\\nShocksintendedforVForpolymorphic VTtherapyshouldbeprogrammedwitha10Jsafetymarginabovetheshockenergy\\nlevelthatthephysician determines isrequiredforsuccessfulVFconversion. Insomesituations, analternative safetymargin\\n(abovetheshockenergylevelrequiredforsuccessfulVFconversion) maybedetermined bythephysician tobeadequate.\\nDifferenttestmethodsfordetermining defibrillation thresholds aredescribed inclinicalliteratureandinclude,butarenot\\nlimitedto:\\n•Steppingdowntofailuredefibrillation threshold testingtodetermine theDFTandverifyingthelastsuccessfulenergy\\neitheronce[1x(DFT+)]ortwice[2x(DFT++)].\\n•Selectingthedefibrillation energyrequirementtestingbysubtracting theacceptedsafetymarginfromthedevice\\nmaximum output.\\nDefininganimplantation safetymarginandtherelationship totheprobabilityforsuccessisdescribed inclinicalliterature.Any\\nresultfromasingletestmethodmaybeanexampleofstatistical variation, andaone-time conversion ofarhythmdisturbance\\nataparticular energyleveldoesnotguaranteeorensurethattheenergylevelisreliableforconversion.\\nAsasafetymarginwitha41Jsystem,itisrecommended thattheconversion testbeperformed attheDFTleveltwotimesif\\ntheDFTorselectedenergylevelis31J,oronetimeiftheDFTorselectedenergylevelis21Jwithnofailurestoconvert.\\nAlwayshaveastandardexternaldefibrillator withexternalpadsorpaddlesavailableforuseduringdefibrillation threshold\\ntesting.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 81}), Document(page_content='79Ifimplantation safetymarginandinitialconversion at31Jisunsuccessful,consideracombination ofdifferentmethodsto\\noptimizethedefibrillation fieldandefficacy.Possibilities include,butarenotlimitedto:\\n•Optimizetheleadposition—placetheleadasapicalandseptalaspossibletodirectmostoftheenergytotheleft\\nventricular massasdescribed inclinicalliterature.\\n•Reversepolarity—useelectronic deviceprogrammingoptionstochangepolarity.Donotphysically switchthelead\\nanodesandcathodesinthepulsegenerator header.\\n•ReprogramtheShockLeadVectorconfigurationinthedevice(e.g.,removetheproximalcoilfromaTRIADconfiguration\\ntoasingleshockvectorsuchastheRVCoiltoCanconfiguration).\\n•Addadditional defibrillation coilsorleadstoincreasethedefibrillation surfacearea.\\nNOTE:RefertoTable9Leadmeasurements onpage63foracceptableleadmeasurements afterleadrepositioning or\\nreprogramming.\\nStepJ:Tachyarrhythmia Programming Considerations\\nDetection Zones\\nSelecttheappropriat enumberoftherapyzones(VT-1,VT,VF)totreattheexpectedventricular tachyarrhythmias basedonthe\\ntachyarrhythmia hemodynamic stability,patientindications, andtheindividual patientclinicalcharacteristics. Toprovide\\nsufficient opportunity fordetection, theratethreshold value(s)shouldbeprogrammedatleast10bpmbelowtherateofknown\\narrhythmia(s) intendedtobetreated.\\nNOTE:Thedevicedetection andsubsequent therapymaybedifferentforthesameunderlying tachyarrhythmia depending on\\nthenumberofzonesandprogrammedparameters suchasratethreshold, detection time,anddetection enhancements (if\\napplied).\\nEpisodeStorageReview\\nDevicediagnostics arestoredinthepulsegenerator andareviewableviathePRMorLATITUDE NXT.Diagnostics enablea\\nreviewofdevicedetection andresponsetoinducedandspontaneous tachyarrhythmias. Storedelectrogramsincludeaninterval', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 82}), Document(page_content='80plot.Evaluating theintervalplothelpstoidentifydetectedbeatsincluding thosebelowtheratethreshold. Beatsbelowthe\\nprogrammedratethreshold maydelayorinhibitdevicedetection ofatachyarrhythmia, andconsiderationshouldbegivento\\nreprogramtheratestoimprovedetection. Inspection ofthestoredelectrograms,withuseoftheon-screen calipersforEGM\\namplitude andtimingmeasurement, permitsthephysician tointerpretwhetherthereareventricular beatswhicharenot\\ndetected. Ifthereareunmarked beats,thenanassessment shouldoccurtodetermine ifprogrammingslowerratezoneswould\\nimprovedetection.\\nDetection andAutomatic GainControl(AGC)\\nTherightventricular AGCissettoanominalvalueof0.6mVandcanbeadjustedusingthePRM.Adjustment oftheAGCmay\\nbeconsideredforcaseswithlowamplitude EGMs,delayintimetotherapy,orperthephysician’s discretion inindividual cases.\\nAnyadjustment oftheAGCmustbeevaluated incombinationwiththeprogrammeddetection ratethresholds/z onestoensure\\nappropriat eratedetection oftheexpectedtachyarrhythmia. TheAGCmaynotreachitsprogrammedfloorwhen\\ntachyarrhythmia detection ratesarerapidandthearrhythmia ispolymorphic. Alwaysevaluatetherateofthedetection zones\\nandtheAGCsettingincombination usingtheepisodestorageinformation. Ifaphysician examines theEGMsandbelievesthe\\ndeviceisnotdetecting ventricular beat(s)intheappropriate zone,thenreprogramming detection ratethresholds toslowerrates\\nmayfacilitatetheoveralldetection behavior.Adjusting theAGCwithconversion testingmaybeconsidered.Changesinthe\\npatient’smetabolic state,alongwithprescription drugs,mayaffectthesizeofthewaveform ontheEGM.AGCreprogramming\\nmaynotbenecessary whenmarkersindicatedevicesensingisappropriate, butthesensedintervalsarebelowtheratecriteria.\\nMarkers\\nMarkerssuchasVT-1,VT,andVF,including themeasured cyclelength,arerecordedandassociated withtheprogrammed\\ndetection zones.Thepresenceofmarkersindicatesthatthedevicehasdetectedacertainbeat.Fluctuating tachycardiarates\\nthatarecloseto,orjustbelow,thelowestratethreshold maybemarkedasVS(ventricular sense).Reviewoftheintervalplot\\nprovidesanoverviewoftheprogrammedratethresholds andintervaldistribution duringtheepisodes. Thisinformation enables\\nclinicaladjustment ofdetection parameters perthephysician’s discretion.\\nStepK:ImplantthePulseGenerator\\n1.ProgramtheTachyModetoOff.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 83}), Document(page_content='812.Verifymagnetfunctionandwandedtelemetry toensurethepulsegenerator iswithinacceptablerangetoinitiate\\ninterrogation.\\n3.Ensurethatthepulsegenerator hasgoodcontactwithsurrounding tissueoftheimplantation pocket,andthensutureit\\ninplacetominimize devicemigration (forsutureholelocationillustrations, referto\"LeadConnections\" onpage53).\\nGentlycoilexcessleadandplaceadjacenttothepulsegenerator.Flushthepocketwithsalinesolution,ifnecessary,to\\navoidadrypocket.\\nWARNING: Donotkink,twist,orbraidtheleadwithotherleadsasdoingsocouldcauseleadinsulation abrasion\\ndamageorconductor damage.\\n4.Closetheimplantation pocket.Consideration shouldbegiventoplacetheleadsinamannertopreventcontactwith\\nsuturematerials. Itisrecommended thatabsorbable suturesbeusedforclosureoftissuelayers.\\n5.Complete anyelectrocautery proceduresbeforereactivating thepulsegenerator.\\n6.ProgramtheTachyModetothedesiredsettingandconfirmfinalprogrammedparameters.\\nCAUTION: Following anysensingrangeadjustment oranymodification ofthesensinglead,alwaysverifyappropriate\\nsensing.ProgrammingSensitivity tothehighestvalue(lowestsensitivity) mayresultindelayeddetection or\\nundersensing ofcardiacactivity.Likewise,programmingtothelowestvalue(highestsensitivity) mayresultin\\noversensing ofnon-cardiac signals.\\n7.UsethePRMtoprintoutparameter reportsandsaveallpatientdata.\\nStepL:Complete andReturntheImplantation Form\\nWithintendaysofimplantation, complete theWarrantyValidation andLeadRegistration formandreturntheoriginaltoBoston\\nScientificalongwithacopyofthepatientdatasavedfromthePRM.Thisinformation enablesBostonScientifictoregistereach\\nimplanted pulsegenerator andsetofleads,andprovideclinicaldataontheperformance oftheimplanted system.Keepacopy\\noftheWarrantyValidation andLeadRegistration formandprogrammerprintouts, andtheoriginalpatientdataforthepatient\\'s\\nfile.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 84}), Document(page_content='82Complete thetemporary patientidentification cardandgiveittothepatient.Afterreceivingthevalidation form,Boston\\nScientificsendsthepatientapermanent identification card.\\nBIDIRECTIONAL TORQUEWRENCH\\nAtorquewrench(model6628)isincludedinthesteriletraywiththepulsegenerator,andisdesigned fortightening and\\nloosening #2-56setscrews,capturedsetscrews, andsetscrews onthisandotherBostonScientificpulsegenerators andlead\\naccessoriesthathavesetscrewsthatspinfreelywhenfullyretracted(thesesetscrews typicallyhavewhitesealplugs).\\nThetorquewrenchisbidirectional, ispresettoapplyadequate torquetothesetscrew,andwillratchetwhenthesetscrewis\\nsecure.Theratchetreleasemechanism preventsovertightening thatcouldresultindevicedamage.Tofacilitatetheloosening of\\ntightextendedsetscrews, thiswrenchappliesmoretorqueinthecounterclockwise directionthanintheclockwise direction.\\nNOTE:Asanadditional safeguard, thetipofthetorquewrenchisdesigned tobreakoffifusedtoovertighten beyondpreset\\ntorquelevels.Ifthisoccurs,thebrokentipmustbeextractedfromthesetscrewusingforceps.\\nThistorquewrenchmayalsobeusedforloosening setscrews onotherBostonScientificpulsegenerators andleadaccessories\\nthathavesetscrewsthattightenagainstastopwhenfullyretracted(thesesetscrews typicallyhaveclearsealplugs).However,\\nwhenretractingthesesetscrews, stopturningthetorquewrenchwhenthesetscrewhascomeincontactwiththestop.The\\nadditional counterclockwise torqueofthiswrenchmaycausethesesetscrewstobecomestuckiftightened againstthestop.\\nLoosening StuckSetscrews\\nFollowthesestepstoloosenstucksetscrews:\\n1.Fromaperpendicular position,tiltthetorquewrenchtotheside20ºto30ºfromtheverticalcenteraxisofthesetscrew\\n(Figure10Rotatingthetorquewrenchtoloosenastucksetscrewonpage83).\\n2.Rotatethewrenchclockwise (forretractedsetscrew) orcounterclockwise (forextendedsetscrew) aroundtheaxisthree\\ntimes,suchthatthehandleofthewrenchorbitsthecenterline ofthescrew(Figure10Rotatingthetorquewrenchto\\nloosenastucksetscrewonpage83).Thetorquewrenchhandleshouldnotturnortwistduringthisrotation.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 85}), Document(page_content='833.Asneeded,youmayattemptthisuptofourtimeswithslightlymoreangleeachtime.Ifyoucannotfullyloosenthe\\nsetscrew,usethe#2torquewrenchfromWrenchKitModel6501.\\n4.Oncethesetscrewhasbeenfreed,itmaybeextendedorretractedasappropriate.\\n5.Discardthetorquewrenchuponcompletion ofthisprocedure.\\n20°–30°\\n[1]Clockwise rotationtofreesetscrews stuckintheretractedposition[2]Counterclockwise rotationtofreesetscrews stuckinthe\\nextended position\\nFigure10.Rotatingthetorquewrenchtoloosenastucksetscrew', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 86}), Document(page_content='84FOLLOWUPTESTING\\nItisrecommended thatdevicefunctions beevaluated withperiodicfollow-up testingbytrainedpersonnel. Followupguidance\\nbelowwillenablethorough reviewofdeviceperformance andassociated patienthealthstatusthroughout thelifeofthedevice\\n(refertotheinformation withinthe“ProgramthePulseGenerator” stepin\"Implanting thePulseGenerator\"onpage58).\\nWARNING: Ensurethatanexternaldefibrillator andmedicalpersonnel skilledinCPRarepresentduringpost-implantdevice\\ntestingshouldthepatientrequireexternalrescue.\\nPredischar geFollowUp\\nThefollowing proceduresaretypicallyperformed duringthepredischar gefollowuptestusingPRMtelemetry:\\n1.Interrogate thepulsegenerator andreviewtheSummary screen.\\n2.Verifypacingthresholds,leadimpedance, andamplitude ofintrinsicsignals.\\n3.Reviewcountersandhistograms.\\n4.Whenalltestingiscomplete, performafinalinterrogation andsaveallthepatientdata.\\n5.PrinttheQuickNotesandPatientDatareportstoretaininyourfilesforfuturereference.\\n6.Clearthecountersandhistograms sothatthemostrecentdatawillbedisplayed atthenextfollowupsession.Counters\\nandhistograms canbeclearedbypressingResetontheHistogram screen,TachyCountersscreen,orBradyCounters\\nscreen.\\nRoutineFollowUp\\nYoushouldconductroutinefollowupexaminations onemonthafterthepredischar gecheckandeverythreemonthsthereafter\\ntoevaluatedeviceprogramming,therapyeffectiveness, leadstatus,andbatterystatus.Officevisitsmaybesupplemented by\\nremotemonitoring whereavailable.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 87}), Document(page_content='85NOTE:Becausethedurationofthedevicereplacementtimeristhreemonths(startingwhenExplantstatusisreached), three\\nmonthfollowupfrequency isparticularly important aftertheOneYearRemaining statusisreached.\\nConsiderperforming thefollowing proceduresduringaroutinefollow-up test:\\n1.Interrogate thepulsegenerator andreviewtheSummary screen.\\n2.Verifypacingthresholds, leadimpedance, andamplitude ofintrinsicsignals.\\n3.PrinttheQuickNotesandPatientDatareportstoretaininyourfilesforfuturereference.\\n4.ReviewtheArrhythmia Logbookscreenandforepisodesofinterest,printepisodedetailsandstoredelectrogram\\ninformation.\\n5.Clearthecountersandhistograms sothatthemostrecentepisodedatawillbedisplayed atthenextfollow-up session.\\n6.Verifythatimportant programmedparameter values(e.g.,LowerRateLimit,AVDelay,LVOffset,RateAdaptivePacing,\\noutputAmplitude, PulseWidth,Sensitivity ,Ventricular Zones,Detection Rate)areoptimalforcurrentpatientstatus.Refer\\ntothestepsabove(“TestforAbilitytoConvertVentricular Fibrillation andInducible Arrhythmias” and“Tachyarrhythmia\\nProgrammingConsiderations”) foradditional information onprogrammingtachyarrhythmia detection andtherapy\\n(\"Implanting thePulseGenerator\" onpage58).\\nNOTE:Echo-Doppler studiesmaybeusedtonon-invasively evaluateAVDelayandotherprogrammingoptionspost-implant.\\nCAUTION: SuccessfulVForVTconversion duringarrhythmia conversion testingisnoassurancethatconversion willoccur\\npost-operatively .Beawarethatchangesinthepatient\\'scondition, drugregimen,andotherfactorsmaychangetheDFT,which\\nmayresultinnonconversion ofthearrhythmia post-operatively .\\nEXPLANTATION ANDDISPOSAL\\nWARNING: Donotreuse,reprocess,orresterilize.Reuse,reprocessing, orresterilization maycompromisethestructural\\nintegrityofthedeviceand/orleadtodevicefailurewhich,inturn,mayresultinpatientinjury,illness,ordeath.Reuse,\\nreprocessing, orresterilization mayalsocreateariskofcontamination ofthedeviceand/orcausepatientinfectionorcross-', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 88}), Document(page_content=\"86infection, including, butnotlimitedto,thetransmission ofinfectious disease(s) fromonepatienttoanother.Contamination of\\nthedevicemayleadtoinjury,illness,ordeathofthepatient.\\nNOTE:Returnallexplanted devicestoBostonScientificregardlessofcondition. Examination ofexplanted devicescanprovide\\ninformation forcontinued improvement insystemreliabilityandwarrantyconsiderations.ForaReturned ProductKit,contact\\nBostonScientificusingtheinformation onthebackcover.\\nContactBostonScientificwhenanyofthefollowing occur:\\n•Whenaproductisremovedfromservice.\\n•Intheeventofpatientdeath(regardlessofcause),alongwithanautopsyreport,ifperformed.\\n•Forotherobservation orcomplication reasons.\\nConsiderthefollowing itemswhenexplanting andreturning devices:\\n•Interrogate thepulsegenerator andprintacomprehensivereport.\\n•Deactivate thepulsegenerator beforeexplantation.\\n•Disconnect theleadsfromthepulsegenerator.\\n•Ifleadsareexplanted,attempttoremovethemintact,andreturnthemregardless ofcondition. Donotremoveleads\\nwithhemostats oranyotherclamping toolthatmaydamagetheleads.Resorttotoolsonlyifmanualmanipulation\\ncannotfreethelead.\\n•Wash,butdonotsubmerge, thedevicestoremovebodyfluidsanddebrisusingadisinfectant solution.Donotallow\\nfluidstoenterthepulsegenerator's headerport(s).\\n•UseaBostonScientificReturned ProductKittoproperlypackagethedevices,andsendittoBostonScientific.\\nCAUTION: Cleananddisinfectthedeviceusingstandardbiohazard handlingtechniques sinceallexplantedcomponents are\\nconsideredbiohazardous.\\nNOTE:Discolorationofthepulsegenerator mayhaveoccurredduetoanormalprocessofanodization, andhasnoeffecton\\nthepulsegenerator function.\", metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 89}), Document(page_content='87CAUTION: Besurethatthepulsegenerator isremovedbeforecremation. Cremation andincineration temperaturesmight\\ncausethepulsegenerator toexplode.\\nCAUTION: Beforeexplanting, cleaning,orshippingthedevice,complete thefollowing actionstopreventunwanted shocks,\\noverwriting ofimportant therapyhistorydata,andaudibletones:\\n•Programthepulsegenerator TachyandBradyModestoOff.\\n•ProgramtheMagnetResponse featuretoOff.\\n•ProgramtheBeepwhenExplantisIndicated featuretoOff.\\n•ProgramtheBeepWhenOut-of-Range featuretoOff.\\nAllitemsusedduringexplantation, suchasaccessories,consumables, andsharps,maybecontaminated withinfectious\\nsubstances. Considerthefollowing tominimize theriskofinfection, microbial hazards,orphysicalharm:\\n•Biohazardous wasteshouldbedisposedinabiohazard containerthatislabeledwiththebiological hazardsymboland\\ntakentoadesignated facilityforbiohazardous wasteforpropertreatment inaccordancewithhospital,administrative,\\nand/orlocalgovernment policy.\\n•Biohazardous wasteshouldbetreatedwithanappropriate thermalorchemicalprocess.\\n•Sharpsshouldbedisposedofinasharpsdisposalcontainer.\\nNOTE:Disposalofexplanted devicesissubjecttoapplicable lawsandregulations.\\nNOTE:Untreatedbiohazardous wasteshouldnotbedisposedofinamunicipal wastesystem.', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 90}), Document(page_content='', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 91}), Document(page_content='', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 92}), Document(page_content='Foradditional referenceinformation, gotowww.\\nbostonscientific -elabeling.com.\\nBostonScientificCorporation\\n4100HamlineAvenueNorth\\nSt.Paul,MN55112–5798 USA\\nwww.bostonscientific.com\\n1.800.CARDIAC (227.3422)\\n+1.651.582.4000\\n©2021BostonScientificCorporation oritsaffiliates.\\nAllrightsreserved.\\n51113879-001 ENUS2021-08\\n*51113879-001*', metadata={'source': 'raw_data/_51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 93})]\n"
     ]
    }
   ],
   "source": [
    "path = './raw_data'\n",
    "loader = PyPDFDirectoryLoader(path)\n",
    "documents = loader.load()\n",
    "print(documents)\n",
    "\n",
    "# split the documents in small chunks\n",
    "# Change the chunk_size and chunk_overlap as needed\n",
    "text_splitter = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=1000, chunk_overlap=100)\n",
    "all_splits = text_splitter.split_documents(documents)\n",
    "\n",
    "pages = all_splits\n",
    "\n",
    "# Replace book.pdf with any pdf of your choice\n",
    "# loader = UnstructuredPDFLoader(\"../../raw_data/_51113879-001A_NG4_Tachy_CRT-D_PTM_en_S.pdf\")\n",
    "# pages = loader.load_and_split()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Using embedded DuckDB without persistence: data will be transient\n"
     ]
    }
   ],
   "source": [
    "embeddings = OpenAIEmbeddings(openai_api_key=OPENAI_API_KEY)\n",
    "docsearch = Chroma.from_documents(pages, embeddings).as_retriever()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Here are the dimensions of the defibrillators mentioned in the provided context:\n",
      "\n",
      "RESONATE HFICDs:\n",
      "- D520(VR): 5.37x7.79x0.99 cm\n",
      "- D521(DR): 5.37x7.79x0.99 cm\n",
      "- D532(VR): 5.37x7.36x0.99 cm\n",
      "- D533(DR): 5.37x7.68x0.99 cm\n",
      "\n",
      "RESONATE Extended Longevity (EL)ICDs:\n",
      "- D420(VR): 5.37x7.79x0.99 cm\n",
      "- D421(DR): 5.37x7.79x0.99 cm\n",
      "- D432(VR): 5.37x7.36x0.99 cm\n",
      "- D433(DR): 5.37x7.68x0.99 cm\n",
      "\n",
      "PERCIVAHFICDs:\n",
      "- D500(VR): 5.23x7.14x0.99 cm\n",
      "- D501(DR): 5.23x7.14x0.99 cm\n",
      "- D512(VR): 5.23x6.71x0.99 cm\n",
      "- D513(DR): 5.23x7.03x0.99 cm\n",
      "\n",
      "RESONATE HFCRT-Ds:\n",
      "- G524: 5.37x8.18x0.99 cm\n",
      "- G525: 5.37x8.08x0.99 cm\n",
      "- G526: 5.37x8.08x0.99 cm\n",
      "- G528: 5.37x8.08x0.99 cm\n"
     ]
    }
   ],
   "source": [
    "# Choose any query of your choice\n",
    "query = \"Give me the dimensions of defibrilators?\"\n",
    "# query = \"Give me position of kamasutra\"\n",
    "docs = docsearch.get_relevant_documents(query)\n",
    "# chain = load_qa_chain(OpenAI(temperature=0, openai_api_key=OPENAI_API_KEY), chain_type=\"stuff\")\n",
    "chain = load_qa_chain(ChatOpenAI(\n",
    "    temperature=0, openai_api_key=OPENAI_API_KEY), chain_type=\"stuff\")\n",
    "output = chain.run(input_documents=docs, question=query)\n",
    "print(output)\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "openaitest",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
